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Abstract
Proteins are the main functional components of all cellular processes, and most of them fold into unique
three-dimensional shapes guided by their amino-acid sequence. Discovering the structure of a protein, or
protein complexes, can provide important clues about how they perform their function. However, the
chemical, physical or architectural properties of many proteins impede traditional approaches to structure
determination. Two such proteins, the tumor suppressor p53 and the cholesterol processing enzyme
endothelial lipase, are prime examples of problematic proteins that defy structural investigation via
crystallographic methods. Therefore, new techniques must be developed to gain valuable structural
insights, such as: computationally assisted protein design strategies, more efficient crystal screening, or a
combination of both.
We applied a statistical computationally assisted design strategy to stabilize a p53 variant consisting of
two independently folding domains. The re-engineered variant retained normal DNA-binding activities, and
allowed us to experimentally determine the first structure of a physiologically active multi-domain p53
tetramer bound to a full-length DNA response element. We then demonstrated how computational
methodology can be used to gain functional detail of proteins in the absence of experimentally
determined structures. By creating comparative models of endothelial lipase, we discovered structural
features that describe function and regulation, and gained a better understanding of the mechanisms
conferring substrate specificity.
Additionally, traditional methods for protein structure determination, such as X-ray crystallography, require
relatively large amounts of purified sample in order to screen a sufficient variety of conditions. To improve
this process, we developed a novel method for protein crystal screening using a microfluidics platform.
We show how it is possible to use smaller quantities of protein to screen larger varieties of conditions, in
turn increasing the probability of success in obtaining crystals. Furthermore, in contrast to current
crystallographic approaches, all steps from screening to crystal growth to data collection were performed
within the same reaction chamber, without any manipulation of the crystal, dramatically increasing the
efficiency of both time and sample required to realize the structure. Collectively, these results
demonstrate how advances in computational and experimental approaches can provide structural detail
for proteins in circumstances where traditional methodology fails.
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ABSTRACT
PROBABILISTIC PROTEIN DESIGN, COMPARATIVE MODELING, AND THE
STRUCTURE OF A MULTIDOMAIN P53 OLIGOMER BOUND TO DNA
Thomas John Petty II
Thanos D. Halazonetis & Jeffery G. Saven

Proteins are the main functional components of all cellular processes, and most of
them fold into unique three-dimensional shapes guided by their amino-acid sequence.
Discovering the structure of a protein, or protein complexes, can provide important clues
about how they perform their function. However, the chemical, physical or architectural
properties of many proteins impede traditional approaches to structure determination.
Two such proteins, the tumor suppressor p53 and the cholesterol processing enzyme
endothelial lipase, are prime examples of problematic proteins that defy structural
investigation via crystallographic methods. Therefore, new techniques must be developed
to gain valuable structural insights, such as: computationally assisted protein design
strategies, more efficient crystal screening, or a combination of both.

We applied a statistical computationally assisted design strategy to stabilize a p53
variant consisting of two independently folding domains. The re-engineered variant
retained normal DNA-binding activities, and allowed us to experimentally determine the
first structure of a physiologically active multi-domain p53 tetramer bound to a fulllength DNA response element. We then demonstrated how computational methodology
can be used to gain functional detail of proteins in the absence of experimentally
iv

determined structures. By creating comparative models of endothelial lipase, we
discovered structural features that describe function and regulation, and gained a better
understanding of the mechanisms conferring substrate specificity.

Additionally, traditional methods for protein structure determination, such as Xray crystallography, require relatively large amounts of purified sample in order to screen
a sufficient variety of conditions. To improve this process, we developed a novel method
for protein crystal screening using a microfluidics platform. We show how it is possible
to use smaller quantities of protein to screen larger varieties of conditions, in turn
increasing the probability of success in obtaining crystals. Furthermore, in contrast to
current crystallographic approaches, all steps from screening to crystal growth to data
collection were performed within the same reaction chamber, without any manipulation
of the crystal, dramatically increasing the efficiency of both time and sample required to
realize the structure. Collectively, these results demonstrate how advances in
computational and experimental approaches can provide structural detail for proteins in
circumstances where traditional methodology fails.
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General Introduction
The structural characterization of proteins provides knowledge that can be used to
help deduce a protein's role in human health and disease, as well as aid in drug
development. Traditional approaches to structure determination, such as protein
crystallography and nuclear magnetic resonance [NMR], are dependant upon the
availability of pure, soluble protein. However, many proteins are modified and/or exist in
complexes with other factors in vivo and can become unstable when removed from their
native environment during experimental purification, preventing subsequent structural
analysis.

Structure determination by traditional techniques is a complicated process that
involves producing the protein of interest in large quantities for subsequent purification
and concentration, followed by screening against hundreds of conditions, characterization
of crystals, crystal optimization, leading eventually to the generation of high quality Xray diffraction data. Numerous experimental challenges at each step, coupled to the need
to maintain the protein in soluble form, make structure determination a long and
problematic process. However, various approaches can be used to address these problems
such as: creation of stable variants of the protein of interest, computational analysis and
re-design of the protein, optimization of the crystal growth and screening process, or a
combination of these approaches. In the what follows, advances in each of these topics
are presented.
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Organization and overview of chapters
This dissertation is divided in two parts. Part one (chapters 1-3) describes the first
multi-domain crystal structure of the human tumor suppressor p53, made possible
through selective mutagenesis and computational re-design of the protein. Given that p53
is the most frequently mutated gene in all cancers, that it is implicated in many cellular
processes affecting cell fate, and that the majority of the thesis work was dedicated to this
investigation, the detailed introduction and discussion are centered on the p53-related
discoveries and are presented in the first three chapters.

Part two (chapters 4-7) is focused on describing recent developments in
experimental and computational approaches used in determining protein structures. Each
chapter is a self-contained module reflecting the associated scientific investigation
containing a specific set of hypotheses, methods and corresponding bibliography
sections. The figures and tables, however, are numbered in the context of the entire
dissertation.

Chapter 1
INTRODUCTION: p53 through history, function and structure
The most frequently mutated gene in cancer encodes the tumor suppressor p53.
This transcription factor has the crucial function of responding to cellular stress and
eliciting responses that can change the cell cycle dynamics and initiate DNA damage
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repair, or in situations when the damage is beyond repair, induce more drastic measures
that lead to senescence or cell death.

Thirty years after its discovery in 1979, research continues to reveal novel p53
functions. At the base of all known functions, however, lies the requirement for p53 to
recognize and bind DNA response elements of effector genes, subsequently regulating
their expression, in turn affecting various cellular responses. The vast majority of cancercausing mutations are located in the DNA-binding domain, demonstrating how altered
DNA-binding capabilities lead to tumorigenesis.

The history of p53 is described in chapter one, starting with the discovery and the
initial classification of p53 as an oncogene and how continued research led to the
understanding that p53 is a tumor suppressor. Next, the multitude of well-documented
functions are described, followed by a review of currently understood modes of
regulation. Finally, after a description of the DNA response element sequence, the
available p53-DNA structures are discussed, illustrating the contributions of each
structure to current knowledge, and highlighting why more comprehensive p53-DNA
structures are needed.
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Chapter 2
RESULTS: structure of a multidomain p53 oligomer bound to DNA
The critical function of p53 is the ability to recognize and bind to response
element sequences of effector genes. Although previous p53-DNA structures have
provided some insight into the details of DNA binding, there is still debate concerning
various aspects of the p53-DNA interaction. Here we present the first structures of p53
variants containing both DNA binding and oligomerization domains, made possible
through selective mutagenesis and the computational protein design strategies described
in chapter five.

In the absence of DNA, the p53 variants dimerize through the oligomerization
domains, but the DNA-binding domains do not interact with each other. When incubated
with dsDNA containing the full-length consensus p53 response element, the p53 dimers
form tetramers on the DNA, creating robust protein-protein interfaces that induce a shift
within the DNA. The structure reveals novel base-specific contacts and provides a more
detailed understanding of cooperative binding interactions.

Chapter 3
DISCUSSION: p53 DNA-binding
The tetrameric p53-DNA complex reported here answers key questions regarding
specific aspects of DNA binding. The architecture of the DNA binding and
oligomerization domains is further described, with more discussion on how the DNA
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binding domains come together on the response element to form relatively large proteinprotein interfaces involving conserved surface residues. Furthermore the most frequently
mutated residue of p53 in cancer, Arg248, is discussed in more detail demonstrating how
this residue interacts with invariant bases within the p53 response element sequence.

Chapter 4
Microfluidics, protein crystallization and in situ X-ray diffraction
Protein crystal screening is a rate-limiting step to the discovery of novel protein
structures. Many combinations of salts, buffers and precipitants must be sampled before
discovering the conditions promoting crystal growth, and conditions initially promoting
growth usually require refinement in order to generate diffraction-quality crystals.
Additionally, the limited amounts of purified protein can restrict the screening search
space. Although liquid-handling robots are able to rapidly set up a large number of
screening conditions using small volumes of sample, the choice of crystallographic
method is limited. Furthermore, there are many subsequent time-consuming steps; the
plates must be separately observed and cataloged, and crystals must be harvested or regrown, and finally stabilized and cryo-prepared for X-ray exposure.

We demonstrate an automated approach that can develop intricate custom
screening buffers using fluid combinatorics, accurately distribute protein sample volumes
of 50 to 100 nanoliters, grow crystals, and facilitate the collection of X-ray diffraction
data to solve a structure to 1.5 Å with 100% completeness, all within the same reaction
chamber and without direct manipulation of the crystal. Furthermore, unlike other
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automated screening systems with limited flexibility, the system can replicate various
well-established crystallographic protocols such as microbatch, vapor diffusion, and free
interface diffusion. The methods developed here demonstrate the basis for a selfcontained, cost-effective, high-throughput (hundreds to thousands of unique simultaneous
reactions), crystal screening system that streamlines all aspects of protein crystallization
including data collection.

Chapter 5
Computational protein design: tailoring sequence, structure, and folding
properties
While protein crystallization is an important means for obtaining atomic detail of
macromolecules, often times this approach is not tractable due to protein insolubility or
insufficient quantities of protein after purification, rendering experimental manipulation
(expression, purification, crystallography) difficult or impossible. While the traditional
methodology of sequence selection and mutagenesis can help to stabilize proteins, it
involves a lengthy process of cloning, expression, screening and finally experimental
characterization of the protein variants.

Here we present excerpts from a book chapter that we developed, published by
the Royal Society of Chemistry in 2008, focusing on computational protein methodology.
We present the current state of computational protein design and describe the underlying
theories of these design approaches. Computational protein design strategies have been
successfully used to solubilize trans-membrane proteins, modify substrate specificity of
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enzymes, and to create self assembling polypeptides. We used some of the methods
described in this chapter, namely the statistical computationally assisted design strategy
[SCADS], to stabilize a human tumor suppressor p53 variant that led to determination of
the first X-ray crystal structures of multi-domain p53 dimers and p53 tetramers bound to
DNA.

Chapter 6
The active form of endothelial lipase: a homodimer in a head-to-tail
conformation
Strategies other than probabilistic protein design, such as comparative protein
modeling, can also be implemented to generate theoretical three-dimensional models of
proteins in the absence of X-ray crystal structures. This technique uses the structural
coordinates of a homologous protein as a sequence-structure template, to which the
protein of unknown structure (the target) is then aligned, in order to generate initial
structural models. A final step calculates a set of spatial restraints from the sequence
alignment and three-dimensional template coordinates and applies them to protein
backbone distances and dihedral angles. These restraints then serve as the basis of a
global optimization step, leading to iterative refinement of the positions of atoms from
the residues of the target sequence, resulting in an energy minimized three-dimensional
model of the target protein. In this investigation, the existing pancreatic lipase [PL]
structures served as the basis for modeling endothelial lipase [EL].
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Because endothelial lipase is a pharmacologic target for inhibition as a strategy to
raise HDL cholesterol levels in humans, detailed structural information regarding the
active forms of endothelial lipase could be important to the optimal design of EL
inhibitors. Here we present comparative models of human endothelial lipase that grant
the first structural details of this enzyme and provide evidence that it functions as a
homodimer.

Chapter 7
Functional analysis of positively charged regions of endothelial lipase
The role of endothelial lipase in lipoprotein metabolism and in the development of
atherosclerosis in humans continues to be an important area of study. Based on its ability
to hydrolyze high density lipoprotein [HDL] and its reported association with coronary
artery disease, endothelial lipase is a potential therapeutic target. Understanding key
structural, substrate and surface binding domains can contribute to the efforts to regulate
EL pharmacologically.

The endothelial lipase models presented in chapter six provided the basis to
investigate experimental observations that various regions within endothelial lipase, when
mutated or deleted, alter the activity towards lipid hydrolysis. We demonstrate that four
regions map to the surface and can create motifs of local charge capable of recruiting
factors regulating function. We also describe the implications of one region important for
heparin-binding and another carboxy-terminal region implicated in regulation of the
active EL conformation.
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CHAPTER 1
Introduction: p53 through history, function and structure

History
Discovery of p53
Two experimental investigations, one virologic and the other serologic, led to the
near simultaneous discovery of p53 in 1979 by independent research groups (Fig. 1.1)
(Lane DP & Crawford LV 1979; Linzer DIH & Levine AJ 1979). This early work
probing either murine cells transformed by simian virus 40 [SV40] infection, or
uninfected embryonic carcinoma cells, revealed an increased synthesis or stability of an
approximately 53-54 kilodalton [kDa] cellular protein. A few months after these initial
reports another group confirmed that p53 is a cellular tumor antigen by demonstrating
that animals immunized with non-virally transformed cells produced antibodies to the
same 53 kDa protein. This immunologic study detected an antigen that cross-reacted in
two different cancers and could be linked to transformation, the ability of a cell to
become immortal. The antigen was a protein 53,000 Daltons in size, was subsequently
named p53, and was found to be expressed in a variety of cells transformed either by
tumor viruses, spontaneously by chemicals, or by irradiation (DeLeo et al. 1979).

-9-

Figure 1.1

Highlights in p53 research since 1979. Numerous key discoveries leading to the
classification of p53 as a tumor suppressor, and defining the various structural elements
of this transcription factor, are listed above. The small brown circles in each text box on
the timeline correspond to the number in the reference list in the gray box.
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p53 as an oncogene
The observation that various types of cancers elicited an immune response to p53
prompted similar studies in humans. Numerous reports in the early 1980s revealed that
anti-p53 antibodies were found in a wide variety of human cancer types (Crawford et al.
1982; Caron de Fromentel et al. 1987). The 53 kDa protein gained popularity as a
potential oncogene, given that elevated protein levels were associated with increased cell
proliferation. Multiple groups using different cell types showed that expression of p53
was positively correlated to induction of cell growth (Milner & McCornick 1980; Reich
& Levine 1984; Mercer et al. 1984). However, during this period of discovery and
characterization, the p53 protein detected in the aforementioned studies was believed to
be wild-type.

In one investigation though, a p53 clone was unable to activate transformation,
raising the question as to why this particular p53 clone could not transform cells (Finlay
et al. 1989). Available cDNA clones were compared in attempts to find the reasons for
this difference, and sequences of p53 previously classified as polymorphic were reclassified at the realization that some sequence changes occurred in highly conserved
regions (Fig. 1.2). After careful investigation of the sequences, it was understood that this
particular non-transforming clone was actually wild-type p53, whereas the other clones
previously characterized contained point mutations that enhanced transforming
capabilities (Finlay et al. 1989; Soussi et al. 1990). This discovery led to the design of
experiments introducing wild-type p53 into transformed cells. Subsequently, wild-type
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p53 reduced or suppressed the proliferative effects of various cancer types, and so it was
realized that p53 is indeed a tumor suppressor (Eliyahu et al. 1989; Finlay et al. 1989).

p53 as a tumor suppressor
One of the first reports that p53 might be a tumor suppressor came from the
observation that over 75% of colorectal carcinomas had allelic deletions of the short arm
of chromosome 17 (Baker et al. 1989). The work of Baker et al. demonstrated that the
wild-type p53 alleles were frequently lost or mutated and that the tumor cells no longer
contained any wild-type p53. However, no gross alterations within p53 were discovered.
But by following the hypothesis that p53 might still be somehow affected, a closer
inspection revealed amino acid mutations in a highly conserved region of p53 that
coincided with mutations found in murine cancers (Fig. 1.2).

It is expected then, as a tumor suppressor, organisms harboring germline
mutations in p53 should have a higher susceptibility to cancer. Indeed, transgenic mice
with germline mutations in p53 have an increased likelihood of developing different
types of cancer, with a large proportion of sarcomas (Lavigueur et al. 1989). Similar
results were found in human investigations carried out on patients with Li-Fraumeni
syndrome, a disease characterized by a variety of early-onset cancers. The studies
revealed that there is familial linkage conferring various cancer types, and that there is a
strong correlation of transmission of the mutant p53 allele with the development of
cancer (Malkin et al. 1990; Srivastava et al. 1990).
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Activity & Function: DNA binding
At the time of the initial cloning and characterization of p53, little was known of
its function (Oren et al. 1983). However, low amounts of p53 were also observed in nontransformed cells with an extremely short protein half life, suggesting a potential
regulatory role of p53 (Oren et al. 1981). An initial attempt was made to compare p53 to
other known oncogenes at the time. The closest match was the myc oncogene, since both
proteins accumulate in the nuclei of transformed cells (Donner et al. 1982; Rotter et al.
1983), both bind DNA (Donner et al. 1982), both are involved in cell-cycle control
(Reich & Levine 1984; Kelly et al. 1983; Campisi et al. 1984) and both appear to be
induced at an early stage after mitogenic stimulation of resting cells (Mercer et al. 1982
& 1984; Kelly et al. 1983).

Continued investigation uncovered more details of the structure, function, and
regulation that helped define the role of p53 as one of the guardians of the genome. The
393-residue polypeptide chain of p53 was shown to consist of four domains that confer
functionality as a DNA-binding tetramer, and offer a wide range of regulation (Appendix
II, Fig. a2.3). The marginally stable transactivation domain [TAD] (residues 1-44) is
necessary for transcriptional activation of downstream target genes (Fields et al. 1990;
Raycroft et al. 1990). The Proline-Rich Doman [PRD] (residues 60-100) (Walker &
Levine 1996; Toledo et al. 2007) is indispensible for eliciting apoptosis (Baptiste et al.
2002). The sequence-specific DNA binding activity resides in the structurally compact
DNA-binding domain [DBD] (residues 102-292), is highly conserved across species and
contains 97% of the p53 mutations found in cancers (Steinmeyer et al. 1988). The
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oligomerization domain (residues 325-356) is required for efficient activity in vivo
(Pietenpol et al. 1994) although not required for DNA-binding activity in vitro (Pavletich
et al. 1993). The carboxyterminus contains a basic regulatory domain (residues 353-390)
implicated in nonspecific interactions with DNA, as well as multiple nuclear localization
signals [NLS] (Fig 1.2; Wang et al. 1993; Jeffrey et al. 1995).

In order to ensure rapid responses to a variety of cellular and genotoxic stress, p53
is maintained at low levels in the cell at all times. The constant turnover and degradation
is mediated through interactions with the E3 ubiquitin ligase MDM2 that targets p53 for
proteosomic degradation. During periods of cellular stress, p53 is stabilized through
inhibition of interaction with MDM2 and by a variety of post-translational modifications
that in turn allow p53 to bind sequence specific response elements [RE] to regulate
expression of target genes that affect cell cycle progression, DNA repair and apoptosis
(Appendix II, Fig. a2.3). Once p53 is bound to DNA, gene expression may be further
regulated through the basal transcription factor TFIID (Thut et al. 1995) or through
coactivators such as CBP and p300 (Gu et al. 1997; Espinosa et al. 2001). Therefore p53
regulation can lead to one of four main outcomes consisting of reversible cell cycle
arrest, apoptosis, senescence or differentiation (Vousden et al. 2002).
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Figure 1.2
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Cellular effects of p53 activity
A wide variety of pathways within the cell involve many genes under the
transcriptional control of p53 (Fig. 1.3). Currently p53 is known to regulate DNA repair,
cell cycle, cell growth, cell adhesion, protein catabolism, apoptosis, metabolism, ion
transport and transcription. The following section describes a subset of the many reported
effects in order to demonstrate the functional diversity of p53.

Apoptosis
Apoptosis via p53 occurs through regulation of many genes, some of the more
characterized being: BAX, PUMA, SIVA, FOS, and FAS. BAX [Bcl-2-associated-X
protein] encodes a pro-apoptotic protein that promotes cell death via cytochrome C
release (Oltvai et al. 1993). The transcription level is upregulated when p53 binds to
response elements located in the promoter and intronic regions of BAX (Miyashita et al.
1995; Thornborrow et al. 2002).

PUMA [p53-Upregulated Modulator of Apoptosis] can mediate apoptosis induced
via both nuclear and cytoplasmic p53 (Nakano et al. 2001). Upon activation by p53 in the
nucleus, PUMA binds Bcl-2 and Bcl-XL (Yu et al. 2001 & 2003), relieving their
inhibition of pro-apoptotic protein BAX (Ming et al. 2006). In the cytoplasm, PUMA can
free p53 from Bcl-XL, allowing p53 activation of BAX, thus inducing mitochondrial
permeabilization leading to cell death. There are two p53-binding sites in the promoter
region of PUMA that can be directly bound and transactivated by p53 in vitro (Yu et al.
2001 & 2003).
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Figure 1.3

From

Levine AJ & Oren M. The first 30 years of p53: growing ever more
complex. Nat Rev Cancer. (2009) 9:749-58.
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SIVA [named after the Hindu god of destruction] is yet another pro-apoptotic
protein that shares features with TNFR [Tumor Necrosis Factor Receptor] and FAS,
interacts with CD27 to induce apoptosis in a variety of cell lines (Prasad et al. 1997), and
is a direct transcriptional target of p53 (Fortin et al. 2004). FOS, a constituent of the AP-1
transcription factor complex, and implicated in cell proliferation, differentiation and
apoptosis, is likewise under the regulatory control of p53. The FOS gene is positively
regulated through a p53 response element located within the first intron, and studies show
that in vivo induction of FOS after ionizing radiation is p53 dependent (Elkeles et al.
1999). Likewise, multiple reports confirm that FAS-mediated apoptosis is dependent on
the presence of functional wild-type p53 (Owen-Schaub et al. 1995; Li et al. 2003).

Cell cycle modulation
Cell cycle regulation is affected by p53 through inhibition of cyclin-dependent
kinases or PCNA [Proliferating Cell Nuclear Antigen] that results in G1/S cell cycle
arrest governed by p21 (Gibbs et al. 1997). In response to stress, p53 regulates p21 levels
through the six response elements located in the p21 promoter (Chin et al. 1997; Wei et
al. 2006). Furthermore, p53 can regulate G2/M arrest via GADD45 (Chen et al. 1995;
Chin et al. 1997), and phosphorylated p53 can increase transcription of APC
[Adenomatous Polyposis of the Colon], in turn regulating not only cell cycle, but also
chromosome segregation, mitotic spindle assembly, cell migration, cell adhesion and
apoptosis (Narayan et al. 1997; Jaiswal et al. 2001).
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Cellular senescence, constituent cell cycle arrest, is also dependent upon p53
function. One study demonstrates that when MDM2 activity is abolished by the small
molecule nutlin, the p53-MDM2 interaction is disrupted, in turn stabilizing p53 leading to
the induction of senescence in eight different cancer cell lines. Three days after the start
of nutlin treatment, the cells adopt a senescence-like state, yet upon removal of nutlin, the
cells regain proliferative capability (Huang et al. 2009). These findings suggest that p53
activity is required not only for induction, but also for the maintenance of the senescentlike state in human cancer cells.

DNA damage repair
The nucleotide excision repair [NER] pathway is used to fix UV photoproducts or
to remove large adducts on the DNA throughout the genome. Binding of p53 upregulates
the genes DDB2 (DNA Damage Binding Protein 2) and XPC (Xeroderma Pigmentosum
group C), whose products then recognize the DNA damage and initiate NER (Hwang et
al. 1999; Tang et al. 2000; Tan et al. 2002).

Mismatch repair [MMR], used to recognize and repair insertion, deletion and
misincorperated bases, is likewise under the control of p53 (Chen et al. 2005). Two gene
products involved in MMR, PMS2 [yeast Postmeiotic Segregation increased 2] and
MLH1 [MutL Homolog 1] contain p53 response elements and are upregulated upon p53
binding. The finding of p53 targets in MMR-related genes creates a potential link
between the p53-mediated control of growth arrest and apoptosis. Activated PMS2
stabilizes p73, which is required for p53-dependent apoptosis following DNA damage
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(Flores et al. 2002; Shimodaira et al. 2003). Therefore it is possible that upon DNA
damage, activated p53 arrests cell growth via the p21/WAF pathway, while MLH1 and
PMS2 are induced to begin DNA repair. If the extent of the damage is too great, then the
stabilization of p73 by PMS2 could serve as a trigger for p53-mediated apoptosis.

Homologous recombination [HR] is a mechanism used to repair DNA double
strand breaks via sister chromatid pairing. One protein responsible for strand pairing,
RAD51 [RecA homolog, E. coli] (Sonoda et al. 1999), is down-regulated when p53 binds
the RAD51 promoter (Arias-Lopez et al. 2006). This is consistent with the tumorsuppressing role of p53, as cells with extensive DNA damage require repression of HR
for apoptosis (Collis et al. 2001).

Reactive oxygen species
Evidence exists that p53 regulates the intracellular redox state by monitoring
reactive oxygen species [ROS], in turn protecting against the oxidation of protein, lipids
and DNA (Johnson et al. 1996). Two metalloproteins involved in ROS scavenging, GPx1
[Glutathione Peroxidase-1] and MnSOD [Manganese Superoxide Dismutase], are
upregulated in a p53-dependent manner in doxorubicin-exposed human lymphoblasts
(Tan et al. 1999; Hussain et al. 2004). However, contrary to anti-ROS activities, p53 can
also up-regulate pro-oxidative genes such as PIG-3 [P53 Induced Gene] and POX
[Proline Oxidase] to induce apoptosis via oxidative degradation of mitochondrial
components (Polyak et al. 1997; Maxwell et al. 2008). Thus it is interesting to speculate
that p53 regulates the fate of the cell by eliciting the appropriate response to intracellular
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ROS levels. The p53-dependant upregulation of genes involved in ROS scavenging can
help the cell manage the redox state as long as ROS concentrations are marginal.
However, if ROS concentrations surpass a critical limit, the ROS levels can instead be
supplemented via induction of pro-oxidative genes, in order to push the critically
damaged cell towards apoptosis.

Other effects
The following list provides a sampling of the growing number of cellular
processes potentially affected by p53 activity. The significance, however, of the
contribution of p53 to these processes has yet to be determined.

Cellular autophagy
Autophagy, the lysosomal degradation of cellular organelles, can lead to cell
atrophy or death and could serve as another level of tumor suppression. The mTOR
[Mammalian Target Of Rapamycin] pathway controls autophagy, and recent reports show
that activation of p53 can inhibit mTOR and increase autophagy (Stambolic et al. 2001;
Feng et al. 2005). Another p53-inducible gene involved in metabolism, TIGAR [TP53
Induced Glycolysis and Apoptosis Regulator], can limit autophagy via ROS regulation
(Bensaad et al. 2009)

Cellular metabolism
The regulation of cellular energy levels has a direct effect on ROS production,
and as previously discussed, ROS levels must be controlled to prevent cellular and
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genomic stress. Mitochondrial respiration is controlled in part by SCO2 [Synthesis of
Cytochrome C Oxidase 2], and SCO2 is regulated by p53 (Matoba et al. 2006). Likewise,
p53 can affect glycolysis by upregulating the TIGAR gene, leading to an inhibition of
glycolysis and an overall decrease in intracellular ROS levels (Bensaad et al. 2006; Green
et al. 2006).

MicroRNA
Microarray and bioinformatics experiments estimate that approximately 30% of
all genes are regulated, at least partially, by miRNAs [Micro RNA] (Lim et al. 2005). The
small miRNAs, approximately 20 to 25 nucleotides in length after processing, form
complexes with other proteins and downregulate expression of genes containing
sequences complementary to the miRNA. The miR-34 family of miRNAs is implicated in
regulation of apoptosis, cell cycle arrest and senescence. Recently, two miRNAs from
this family, miR-34a and miR-34b/c, were found to contain p53 response elements and to
be under transcriptional regulation by p53. These p53-regulated miRNAs in turn downregulate expression of genes that modulate cell cycle progression such as CDK4/6, Cyclin
E2, MET and BCL-2 (Bommer et al. 2007; Corney et al. 2007; He et al. 2007). Given that
p53 generally induces expression of target genes through DNA-binding, miRNA
regulation could serve as a complementary mode of control via indirect gene repression.

Indirect effects
Multiple reports demonstrate the ability of p53 to influence gene expression in the
absence of DNA-binding. p53 has been shown to interact with Wilms Tumor 1 [WT1] to
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induce GADD45 expression, (Zhan et al. 1998) and also to interact with the transcription
factor SP1 [Sephacryl and Phosphocellulose Purification 1] to induce transcription of
p21 (Koutsodontis et al. 2001). However, p53 can elicit an apoptotic response even in the
absence of direct DNA-binding. There is evidence that a p53-SP1 complex can bind to
the promoter region and down-regulate expression of MnSOD [Manganese Superoxide
Dismutase], a gene product that protects against cell death (Dhar et al. 2006).

Regulation of p53
The role of p53 as general mediator of cellular responses to genotoxic stress
includes many functions (previously discussed) that lead to a host of different cellular
outcomes. While p53 can control many different pathways, p53 itself is regulated by
many different mechanisms. Although new modes of p53 regulation continue to be
discovered, some well-characterized regulatory mechanisms are discussed in the
following section.

mRNA level
Currently ten variations of p53 are known to exist in human tissues as the result of
alternative splicing, or translation from an alternative promoter or translation start sites
(Appendix II, Fig. a2.2; Yin et al. 2002; Courtois et al. 2002; Bourdon et al. 2005). These
variants contain the DNA-binding domain and maintain DNA-binding capabilities but
differ in the amino and carboxyterminal regulatory domains. Some p53 variants are
differentially expressed in a tissue-specific manner, suggesting expression can be
selectively regulated. Although the significance of these isoforms has yet to be
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determined, there is evidence for differential transcriptional activities among the p53
variations.

Full-length wild-type p53 binds preferentially to MDM2 and p21 response
elements whereas p53β preferentially binds p21 and BAX. Furthermore, p53 and p53β
interact and enhance transcriptional activity at the BAX, but not the p21, promoter
(Bourdon et al. 2005). Increased expression of p53/47 stabilizes p53 in the presence of
MDM2 and alters expression of p53 effector genes (Yin et al. 2002). One other isoform
lacking the N-terminal activation domain, ΔN-p53, has no known role in response to
genotoxic stress but is implicated as a transient negative regulator of p53 during cell
cycle progression (Courtois et al. 2002). Another p53 variant, lacking part of the DNAbinding and oligomerization domains, is present during the intra S-phase cell cycle
checkpoint (Rohaly et al. 2005). These variants could potentially play a role in buffering
the p53 response by modulating the threshold of full-length p53 needed to bind and
regulate effector genes.

Cellular localization
The cellular localization of p53 is likewise critical for timely and effective
regulation of the appropriate stress response. The shuttling of p53 between the nucleus
and the cytoplasm is closely linked to cell cycle (Shaulsky et al. 1990), and the
importation of p53 into the nucleus during the G1/S phase transition can dramatically
impact the effectiveness of p53. The negative consequences of nuclear exclusion of p53
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are demonstrated by the cytoplasmic localization of p53 observed in breast cancers and
neuroblastomas (Moll et al. 1996).

Nuclear export of p53 during S-phase is another mode of regulation and involves
the C-terminal nuclear export signal [NES]. Various models have been proposed that
suggest either ubiquitination or dimeric forms of p53 can expose the NES (residues 340351) that is otherwise masked in tetrameric p53 (Stommel et al. 1999; Nie et al. 2007).
Indeed mutations in this region can deregulate an otherwise fully functional p53. A small
proportion of cancers have mutations in this area of p53 (Fig. 1.2).

Degradation
Under normal non-stress conditions, the cell maintains steady but low levels of
p53 by targeting it for constant proteolytic degradation through ubiquitination via
MDM2. In response to genotoxic stress, however, MDM2 is auto-poly-ubiquitinated and
subsequently degraded, allowing p53 levels to increase (Momand et al. 1992; Haupt et al.
1997). This regulation occurs as a feedback loop, as MDM2 transcription is regulated by
p53 (Fig. 1.3; Barak et al. 1993; Haupt et al. 1997).

The stability of p53 is also modulated by MDMX, a homologue of MDM2, as
well as the ubiquitin ligases PIRH2, COP1 and CHIP. MDMX stabilizes MDM2 through
direct binding, which in turn enhances ubiquitination and subsequent degradation of p53
(Shvarts et al. 1996; Badciong et al. 2002). The ubiquitin-mediated degradation of p53 is
supplemented through the actions of PirH2 (Leng et al. 2003), COP1 (Dornan et al.
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2004), and CHIP (Esser et al. 2005), which are also part of the p53-controlled regulatory
feedback loop. The presence of multiple feedback mechanisms might ensure that the p53
circuit has backup measures in order to prevent uncontrolled or incorrect stress responses.
Furthermore, the constant turnover ensures that functional p53 is available when needed
for immediate action to elicit the appropriate cellular responses, and in the context of a
damaged genome, avoids complete dependence on transcription from a potentially
mutated p53 locus.

Post-translational modifications
The post-translational regulation of p53 occurs mainly through modifications to
the N-terminal transactivation domain [TAD] and C-terminal domain, with the
modifications mostly affecting interactions with p53 negative regulator MDM2. In
response to DNA damage, upstream kinases including ATM, ATR, Chk1, Chk2, CK1,
DNA-PK, DYRK2, ERK1, ERK2, HIPK2, JNK, MAPK can phosphorylate various
serine and threonine residues of p53 (Appendix II, Fig. a2.3; Bode et al. 2004, Olsson et
al. 2007). The modifications can either affect p53 stability, or can reduce or abolish the
effectiveness of protein-protein interactions with p53 and co-activators. MDM2 also
plays a role in regulating post-translational modifications by concealing the TAD of p53
upon binding, thus preventing modifications and interactions with co-activators such as
p300 and CBP (Oliner et al. 1993).

Post-translational modifications specifically adapt p53 responses to the particular
variety of stress. Although the majority of modifications are phosphorylation and
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acetylation, the list also includes mono- and poly-ubiquitination, methylation,
sumoylation, neddylation and proyl-isomerization as means to regulate p53 (Olsson et al.
2007). The varieties of specific p53 modifications are well documented and involve
various sets of residues to elicit particular responses to stress. For example,
phosphorylation of serines 15, 20 and 37 are induced by gamma irradiation, whereas
exposure to UV radiation leads to phosphorylation of the same three residues plus serines
33 and 46. Treatment of cells with doxorubicin, a small DNA-intercalating
chemotherapeutic molecule that inhibits DNA replication, leads to phosphorylation of
serines 6 and 9. At the C-terminus of p53, acetylation is the primary form of
modifications found on a range of lysine residues in response to UV and gamma radiation
(Gu et al. 1997[Cell]; Sakaguchi et al. 1998). As some of these acetylated lysines are also
targets of ubiquitination, the acetylation events could stabilize p53 by preventing
proteasomal degradation (Brooks et al. 2003; Bode et al. 2004).

Autoregulation
The N-terminal proline rich region [PRR] and the C-terminal basic region of p53
are involved in auto-regulatory functions that modulate DNA-binding (Fig 1.2). Deletion
of residues 80 to 93 that contain the PRR enhance the DNA binding activity of p53.
Furthermore, synthetic peptides made from this region are able to activate sequencespecific DNA-binding in vivo (Müller-Tiemann et al. 1998). Through NMR-based
analysis using full-length p53 and various peptides sampling the PRR; complementary
sources of experiment and simulation provide evidence for a stiffened chain extending
away from the core DNA-binding domain. These structural studies suggest the extended,
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relatively rigid conformation of the PRR could facilitate interactions with the SH3
domains of p53 related regulatory kinases (Wells et al. 2008).

Relative to the N-terminal regulatory regions, there is more debate over the
functional significance of the C-terminal basic region. This domain is believed to
maintain p53 in a latent form, and that stress-induced modifications in this region create
an active conformation with high sequence-specific DNA-binding activity. Various
studies support this idea by demonstrating enhanced response element binding when
residues 360-393 are deleted (Hupp et al. 1992), when residues 370 to 378 are masked by
a monoclonal antibody (Halazonetis et al. 1993), when serine 378 is phosphorylated
(Takenaka et al. 1995), and when lysines 373 and 382 are acetylated (Gu et al.
1997[Cell]).

There are conflicting reports, however, that suggest p53 is not a latent form
structure that becomes activated through C-terminal modification and structural changes.
One report shows that there is no noticeable structural change of latent and active forms
of p53 (Ayed et al. 2001), and another report claims that the C-terminal domain is not
inhibitory, but rather that it is required for p53 association with particular target sites
(Espinosa et al. 2001). The ability of the C-terminal region to interact non-specifically
with a variety of DNA forms (Nelson et al. 1994; May et al. 1999) leads to an alternative
model. Given the evidence, it is possible that the C-terminal domain competes with the
DNA-binding domain for interactions with DNA. In the absence of C-terminal
modifications, p53 would be sequestered to non-specific DNA through the C-terminal
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domain, rendering p53 functionally inactive. Modifications to the C-terminus could
abolish the non-specific DNA interactions, thus freeing the DNA-binding domain to bind
specific response elements. Currently more evidence is needed to uncover the functional
implications of the auto-regulatory effects of the C-terminal domain.

Other regulatory interactions
Various reports describe modulation of p53 binding affinity through direct
protein-protein interactions, although the mechanistic details and functional significance
of these interactions are not yet fully understood. Proteins such as ASPP1 and ASPP2
interact with p53 and enhance p53 binding to promoters of pro-apoptotic genes BAX and
PIG-3 (p53 Inducible Gene 3). Accordingly, p53-mediated apoptosis is suppressed when
ASPP1 and ASPP2 are rendered non-functional (Samuels-Lev et al. 2001).

In a mouse cell line lacking the genes for p53 homologs p63 and p73, p53 binding
to pro-apoptotic genes is reduced. Despite the presence of wild-type p53 in these double
null cells, p53 is not able to induce apoptosis in response to DNA damage (Flores et al.
2002). But exactly how these proteins enhance p53 binding to RE remains to be
determined, as yet another observation is that p63, p73, ASPP1 and ASPP2 interact with
p53 through the DNA-binding domain, which is somewhat counter-intuitive.
Furthermore, p53 is also reported to modulate homologous recombination factors in a
transcription-independent manner through direct interactions with hRAD51 and hRAD54
(Linke et al. 2003).
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Cancer: effects of altered p53 function
Because p53 is so often mutated in so many varieties of cancers, intense research
over the past 30 years has helped in the understanding of how these mutations can affect
p53 functionality. Below is a brief discussion of what happens when mutations in p53
affect normal function. Approximately 97% of p53 missense mutations are localized to
the DNA-binding domain and impair DNA binding, thus reducing or attenuating the
transactivation activity (Petitjean et al. 2007). These mutations can be classified into one
of two groups; 1) contact mutations, with minor effects on folding and stability that
impair DNA-binding and 2) mutations affecting structural stability that can lead to
unfolding of the DNA-binding domain (Cho et al. 1994; Yip et al. 2006). Over 60% of
the mutated residues in the DNA-binding domain are either directly involved in binding
DNA, or located close to the protein-DNA interface (Cho et al. 1994).

Loss of function
The active form of p53 is a tetramer of four identical subunits, made of a dimer of
dimers (Jeffrey et al. 1995). Mutations affecting residues involved in DNA binding or
stabilization have a dominant negative effect within the tetramers. These mutations grant
p53 a prolonged half-life relative to wild-type p53, which in turn reduces or abolishes
transcriptional activities (Chan et al. 2004). However the extent of functional defects
depends on the location of the mutation within p53, and can have different consequences
for different effector genes. One such report describes that a mutation at residue Arg175,
the third most common mutation in p53, renders p53 defective in its ability to induce
apoptosis. A p53 variant with a proline at position 175, transfected into rat cells, acted in
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a dominant-negative manner by suppressing the apoptotic ability of endogenous rat p53.
However, the same Arg175Pro variant was able to induce normal cell-cycle arrest in two
human tumor cell lines deficient in wild-type p53 (Rowan et al. 1996).

In a larger study, 2,314 different p53 clones containing point mutations
representing >95% of the tumor-derived p53 amino acid substitutions listed in the IARC
[International Agency for Research on Cancer] database R7 (2002), as well as randomly
chosen mutations, were assessed for in vivo functionality using 8 different p53 effector
gene promoters (Kato et al. 2003). In this yeast-based assay, 905 mutants (~39%)
exhibited normal transactivation capabilities; correspondingly these mutants have not
been reported in tumors. As expected, 361 mutants (~16%) were inactive for all 8
promoters and have been reported at least once in tumors. However, of the remaining
mutants, 635 (~28%) were inactive only for various promoter subsets. This work
highlights the diversity of mutational effects and demonstrates that only subsets of p53
downstream pathways might be affected upon mutation. These results further support the
view that sequence-specific transactivation is the critical function in p53-dependent
tumor suppression.

There is also growing evidence that mutations in the DNA-binding domain could
affect binding to response elements in the effector genes only in a stress-dependant
manner. A study on colon carcinoma cells showed that p53 with mutations in residues
175 and 273 could not elicit the G1/S cell cycle arrest after gamma irradiation, whereas a
mutant at residue 143 functioned normally (Pocard et al. 1996). In contrast, another study
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performed with the same cell line revealed that upon treatment with a mitotic spindle
inhibitor, nocodazole, the 273 mutant could induce G1/S arrest whereas the 143 and 175
mutants could not (Dridi et al. 2003). Taken together, these facts demonstrate how p53
mutations might have different functional consequences that are dependant on the type of
activating stress.

Gain of function
Despite debate over the importance of gain of function [GOF] mutations and their
contribution to tumorigenesis, there is increasing evidence that mutant p53 proteins can
also gain new abilities that promote tumorigenesis. Gain of function mutations typically
work by stabilizing the mutant form of p53 (Natan et al. 2009). Although more work is
needed to better understand how various mutations lead to a gain of function phenotype,
some studies have demonstrated how p53 mutations can cause enhanced cell proliferation
in culture (Zalcenstein et al. 2006), increased tumorgenicity in mice (Lang et al. 2004;
Olive et al. 2004), and enhanced resistance to various anti-cancer drugs (Blandino et al.
1999; Buganim et al. 2006).

One model explains that while mutations in p53 can reduce or abolish recognition
of canonical response elements, certain mutations can give p53 the ability to recognize
and regulate new target genes (O'Farrell et al. 2004). A growing number of reports
provide evidence for this GOF model. For example, TGFβ1 [Transforming Growth
Factor Beta 1] has a critical role in preventing the initiation and progression of cancer by
maintaining cellular homeostasis through regulation of proliferation, differentiation, and
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migration (Croxtall et al. 1992; Massagué 2000; Massagué et al. 2000). Mutant p53
proteins (R175H and R248W), but not wild-type p53, can down regulate TGFβRII
expression, which decreases TGFβ1-regulated functions (Kalo et al. 2007). Likewise ID4
[Inhibitor of DNA Binding 4], implicated in preventing cell proliferation, differentiation
and tumorigenesis, has been identified as a transcriptional target of GOF p53 mutants
R175H, R273H and R280K (Fontemaggi et al. 2009). Another group demonstrated p53
gain of function properties indirectly by showing that the inhibition of GOF p53 mutants
R175H or R273H, via inducible short-hairpin RNA, leads to a delay in tumor formation
and a reduction in tumor vascularization in tumor xenografts (Bossi et al. 2006).

Another GOF model suggests that mutant p53 can acquire new binding properties
and sequester other proteins involved in cell cycle arrest or apoptosis. There is a growing
pool of evidence supporting this sequestration model. In a study testing various p53
mutants (Y220C, R249S, C277Y, R283H, R175H), three mutant p53 proteins (Y220C,
R249S, R283H) can interact directly with close homologs p63 and p73 and inhibit their
transcriptional activity. Furthermore there is a correlation between the efficiency of p53
interactions with p63 and p73, and the ability to down regulate p63 or p73 transcriptional
activity (Gaiddon et al. 2001). Indeed it is interesting to note that p53, once classified as
an oncogene then properly characterized as a tumor-suppressor, can once again be
viewed as an oncogene in certain circumstances.
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p53 mode of action
The fate of the cell in the presence of genotoxic stress depends heavily on the
DNA-binding activity of p53; mutant versions of p53 that loose this tight control can
cause cell cycle deregulation and transformation. Almost all of the p53 functions,
previously discussed, occur as a result of sequence-specific DNA binding and
transactivation, making DNA-binding the critical function in p53-dependent tumor
suppression. Approximately ten years after its discovery, when the biological significance
of DNA-binding was not yet realized, over one thousand mutations in p53 from human
cancers were already identified (Nigro et al. 1989; Hollstein et al. 1991; Wang et al.
1993). Although small in comparison to the current count of 24,785 mutations (tp53
Database Nov 2008), there was enough information to show that most mutations were
targeted to four conserved domains (Fig. 1.2). Additionally, these conserved regions were
located in the core portion (residues 102-292) already shown to contain the DNA binding
activity of p53 (Pavletich et al. 1993; Wang et al. 1993; Halazonetis et al. 1993).

Sequence-specific DNA binding
Although the DNA-binding and transcriptional activation functions of p53 were
realized soon after its discovery, no specific DNA response element had yet been
identified. In a gene activation study, co-transfections of wild-type p53 with a musclespecific creatine kinase [MCK]– chloramphenicol acetyltransferase [CAT] reporter gene
into CV1 cells induced a 40-fold CAT activity over negative controls (Weintraub et al.
1991). Through 5’ deletion mapping, the p53 response element was reduced to a region
between positions -3,300 and -2,800 within the 3,300-bp enhancer situated upstream of
the MCK gene in a variety of tissue culture cell types.
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Additional binding specificity experiments refined the wild-type p53 response
element to a 50-bp region (Zambetti et al. 1992). The same study also reported that
binding and gene activation did not depend on RE orientation. The boundaries of the p53
RE region were subsequently reduced to a 33 bp sequence (Kern et al. 1991). The
consensus p53 RE was then found to be composed of a tandem 10-base pair sequence
motif separated by 0-13 base pairs (El-Diery et al. 1992). Concurrent with p53 binding is
the transcriptional activation of those genes containing p53 binding sites (Raycroft et al.
1990; Bargonetti, et al. 1991; Kern et al. 1992; Farmer et al. 1992), and in these same
studies it was shown that mutant forms of p53 had compromised DNA binding abilities.
The combination of these results defined DNA-binding as a critical activity of p53 in its
tumor suppressing abilities.

p53 response element
The transcriptional activities of p53 come primarily from binding to DNA
response elements located in promoters or first introns of effector genes (Wei et al.
2006). The p53 response element [|◊|] is composed of two 10-base pair halfsites [|] with each half-site separated [◊] by 0 to 13 base pairs. Each half-site
contains two inverted pentameric sequences [] and []. The consensus sequence for
each 10 bp half-site, 5’-RRRCW|WGYYY-3’, highlights the importance of the cytosine
(C) at position 4 and guanine (G) at position 7 (invariable), and the limited variability of
the other positions requiring either adenine or thymine (W), purines (R) or pyrimidines
(Y) as indicated (Fig 3.9d; El-Diery et al. 1992).
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Response element sequence affects p53 binding affinity
The definition of the p53 response element consensus motif has been further
modified as a result of continued investigations of p53 DNA-binding properties on a
larger scale. Recent chromatin immuno-precipitation [ChIP] and microarray analyses
have identified 542 high confidence p53 binding sites that gave more insight into the
specific sequence composition of the consensus p53 RE motif (Wei et al. 2006). Another
recent study measured the effects of every possible single base-pair substitution in the RE
on the affinity of full-length p53 for DNA (Veprintsev et al. 2008). The data generated
made it possible to quantify the effect of response element sequence variation on p53
binding affinity, allowing the prediction of p53 affinity for any potential RE sequence,
thus adding even more information to the p53 RE definition. However, until recently, the
subtle variations of nucleotide distribution within the RE were not yet linked to the
functional outcome of p53 binding (e.g. activation or repression).

Response element sequence affects p53 functional outcome
Recent evidence suggests that certain positions within the response element
sequence can determine the functional outcome of p53 binding. Nearly 18 years after the
initial descriptions of the p53 RE, current data suggest there are potentially two major
types of p53 response elements; described as activator REs and repressor REs. A recent
multi-disciplinary study found distinct patterns of nucleotide frequency distributions
when p53 REs were analyzed in the context of activating or repressing activities. The
results suggest that the p53 RE might actually exist as two functionally distinct types.
While the definition of the canonical activator RE remains the same (half site 5’- 36 -

RRRCW|WGYYY-3’), the consensus repressor RE contains a slightly different
sequence composition such as 5’-RRXCXXGXYX-3’ (Wang et al. 2009).

Structures of p53-DNA complexes
Until now, no X-ray crystal structure of a p53 multimer containing both DNAbinding and oligomerization domains, either unbound or bound to DNA, has been
reported. The flexibility of the 30-residue linker connecting the DBD and oligomerization
domains, coupled with the intrinsic marginal stability of the N- and C-terminal domains,
has impeded crystallographic study for the past three decades. In order to address the
questions of how p53 binds DNA, various groups have used the compactly folding DBD
and various strategies to obtain crystals of the DBD bound to DNA. An overview of
current p53-DNA structures is presented in figure 1.4. Therefore, before discussing the
structure of a multi-domain p53 tetramer bound to DNA, the previously determined p53DNA structures warrant brief review.

Initial structure of p53 DBDs bound to DNA
The hypothesis that DNA binding is critical for the biological activity of p53 was
further supported by the first crystal structure of human p53 bound to DNA (Fig. 1.4a;
Cho et al. 1994). This study was motivated by a need to better understand the growing
list of mutations and how and why they inactivate p53. The structure revealed for the first
time the protein fold topology of the p53 core DNA-binding domain. Proteolytic
digestions of the human p53 protein showed that residues 102-292 constitute an
independently folded, compact structural domain that exists as a monomer in solution
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(Pavletich et al. 1993). The core domain is composed of a sandwich of two antiparallel βsheets, with each sheet composed of either four or five β-strands (Fig. 1.5). The βsandwich serves as a scaffold, while a loop-sheet-helix motif interacts with the DNA
(loop L1 and helix H2). Two additional loops (L2 & L3), stemming from the β-sandwich,
are stabilized by a tetrahedrally coordinated zinc atom (Fig. 1.5).

The major and minor grooves and the phosphate backbone of DNA are contacted
by the DNA-binding motifs of p53. The structure revealed that the regions of the core
domain that contact the DNA are highly conserved and also contain the majority of
cancer related mutation hotspot residues, with 30% targeting loop L3, 25% of the
mutations in the loop-sheet-helix motif (L1-sheet-H2), and 17% of mutations found in the
L2 loop (Levine et al. 1994).

This structural work established the initial understanding of how p53 mutations
observed in tumors could affect sequence-specific DNA binding functions. The atomiclevel description of the DNA binding surfaces of p53 showed how inactivating mutations
in cancer are targeted to this conserved area. Analysis of mutation hotspot residues
provided an understanding for both mutations that could abolish DNA-binding, and also
those that lead to a destabilized DBD core, thus leading to structural defects affecting
wild-type function.

Fifteen years after the discovery of p53, this structural study provided the first
insight into the atomic details of the p53–DNA interaction. However there are many
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aspects that were not completely resolved in this study that have continued to motivate
structural research of p53 and p53-DNA interactions.

Most notable is that although it was already established that p53 binds the RE as a
tetramer in vivo and in vitro, the structure shows only three monomers bound to DNA,
and furthermore only one of the three monomers makes DNA base-specific contacts. As a
transcription factor, interaction with specific DNA nucleotides is critical for recognition
of the sequence contained within the corresponding response element. Most transcription
factors make more than three nucleotide specific contacts, whereas this structure has one
monomer making three nucleotide specific contacts.
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Figure 1.4
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Of the three residues making base-specific interactions with the DNA, the
significance of one of these contacts, K120 of loop L1, remains questionable. This lysine
is not a mutation hotspot residue (although there are a few reported cases of mutations at
this position), yet it is expected that a residue involved in making base-specific contacts
is critical for the DNA binding activities. Therefore although this structure serves as the
groundwork for understanding how p53 binds DNA, many open questions remain.
Among the questions; If K120 is not frequently targeted for mutations, is it involved in
RE recognition? Given that modeling the DBD tetramer leads to steric clashes, do the
protein-DNA interactions presented in this structure reflect the physiological complex?
Furthermore, the authors conclude that DNA binding by p53 did not result in any
significant structural changes to either the core DBD or the DNA. Yet at that time,
biochemical studies using conformation-specific antibodies demonstrated that p53
changes conformation upon DNA binding (Halazonetis et al. 1993).

Structure of a p53 dimer bound to DNA
This study performed by Ho et al. in 2006 employs a crosslinking strategy to
covalently trap the mouse core DNA-binding domain on a response element half-site
(two pentamer repeats). The resulting dimeric structure highlights some of the molecular
details of cooperative DNA binding in a dimeric form (Fig. 1.4c). The surface regions
involved in the dimeric protein-protein (anti-parallel) interface contain some of the
hotspot mutations found in cancer, thus illustrating the functional importance of p53
dimerization during DNA-binding.
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Figure 1.5

From: Cho Y, Gorina S, Jeffrey PD, Pavletich NP. Crystal structure of a
p53 tumor suppressor-DNA complex: understanding tumorigenic
mutations. Science. (1994) 265:346-55.
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The structure shows how the two subunits form an anti-parallel interface
positioned over the DNA minor groove, and that this interface involves loops L2 and L3
that coordinate a zinc atom. When compared to the original trimeric p53-DNA structure
(Fig. 1.4a; Cho et al.1994), many structural similarities are observed. In particular, as in
this first published p53-DNA structure (Cho et al.1994), within loop L2, R277 (residue
R281 of human p53) of helix H2 makes base specific contacts with guanosine 7 in the
DNA major groove and residues A276, R277, and R280 (residues A280, R281, and R283
of human p53) make analogous DNA backbone contacts. In addition, residues S238 and
R245 (residues S241 and R248 of human p53) from the L3 loop make interactions with
the DNA minor groove.

The authors observe that the DNA is bent approximately 20 degrees just below
the p53 dimer interface, arguing that p53 cooperative binding induces DNA bending.
Extrapolation of this observation suggests that DNA binding by a full tetramer, two p53
dimers, could induce the 40 degree bend in DNA observed in solution studies
(Balagurumoorthy et al. 1995 & 2002; Nagaich et al. 1997). However in another
structure released by the same group, a dimer of mouse DBD dimers crosslinked to DNA,
shows no significant bending of the DNA (Fig. 1.4d; Malecka et al. 2009).
While providing more insight into the detail of the anti-parallel interactions, the
structures presented in 2006 and 2009 provide limited detail of parallel tetrameric
interactions. In both structures, the p53 DBD is covalently linked to DNA. Although this
strategy has been used to obtain crystals of other protein-nucleic acid complexes (Huang
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et al. 1998 & 2000), the presence of the crosslink could affect DNA recognition and bias
protein-protein interfaces. The authors claim that because the linker is not visible in the
electron density map of this structure that the chemical tether (a sulfur-bearing threecarbon linker connecting C274 to N4 atom of a cytosine base in the RE) remains flexible,
and accommodates native protein-DNA interactions. However the tether could bias, or
even prevent, intermolecular interactions by fixing p53 into a potentially incorrect
dimeric or tetrameric orientation. The potential effects of this tether on the parallel
interface are discussed later in chapter three. Furthermore, p53-DNA binding is dynamic,
and it is possible that this crosslink trapped the protein in a position “mid-binding” which
may not representative of DNA-bound p53 in vivo.

Furthermore, loop L1 (mouse DBD residues 114-118), shown to make basespecific contact with K120 (mouse K117) is found to be unordered in the 2006 structure.
Conformational variations of loop L1 exist, ranging from and extended loop making base
specific contacts with K120 (Cho et al. 1994), to a retracted helical form in the C.
elegans structure in the absence of DNA (Huyen et al. 2004). The authors conclude that
loop L1 does not make a significant contribution to DNA binding. In the 2009 structure
reporting a dimer of p53 dimers bound to DNA, mouse K117 (human K120) is displaced
from the DNA and positioned at the parallel interface between dimers.

Structure of p53 DBDs bound to different response elements
Many open questions remained after the initial p53–DNA structure was elucidated
in 1994 concerning the specificity, affinity and cooperativity of DNA binding by p53,
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especially concerning the p53 tetramer. At the time, there was no structural information
of a tetramer bound to DNA, nor any structural insight for different DNA response
element targets. To address these topics, four different DNA oligonucleotides containing
a p53 RE half-site were crystallized with the p53 core DBD. Within the structures, two
human p53 dimers bound to DNA assemble in tandem via protein-protein and DNA base
stacking interactions within the crystal, providing the first details of the p53 tetramer
(Fig. 1.4b; Kitayner et al. 2006).

The ability of p53 DBDs to assemble as a tetramer on p53 REs had been
established (Weinberg et al. 2005), providing support for cooperative binding through
protein-protein interactions within the p53 core domain. This structure, released at the
same time as another tetrameric structure with p53 DBDs crosslinked to DNA (Fig. 1.4c
& d; Ho et al. 2006) describes these tetrameric parallel protein-protein interactions. The
symmetric interactions of each dimer bound to DNA are similar to those previously
described by NMR (Dehner et al. 2005; Klein et al. 2001) and mutagenesis studies of the
core domain (Dehner et al. 2005) and full-length p53 (Veprintsev et al. 2006),
strengthening the validity of the observed anti-parallel dimer interface across the DNA.
However, there is more variability observed across the parallel interface made from a
dimer of dimers along two non-continuous p53 half sites (Fig. 3.6a).

In order to gain insight into the differential binding affinities of p53 to the REs,
the authors analyzed four structures containing different RE sequences. Four residues,
R280, K120, A276, and C277 make direct DNA base contacts in each structure. As
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predicted, the specific interactions of K120, A276, and C277 change in each of the
structures when the central base pair of the pentameric quarter site is changed from G/C
to A/T. Quantitative gel mobility shift assays demonstrate differences in affinities of the
p53 DBDs for the various REs in the range of 14 to 50 nM, supporting in vivo DNA
binding behavior. Higher affinity RE sequences correlate with those related to cell cycle
arrest whereas sequences with lower affinity are related to cell apoptosis, as demonstrated
by transcriptional activation studies (Weinberg et al. 2005).

While providing insight into the mechanisms of DNA RE recognition by p53, the
strategies used to obtain p53-DNA crystals introduce a level of uncertainty in the results
presented. The crystals were created by mixing p53 DBDs with RE half-sites, 12-basepair
DNA oligonucleotides, with each dsDNA able to accommodate two p53 DBDs. Although
the crystal packing arranged the p53 dimers in a tetrameric form, the DNA axis is shifted
between dimers and one dimer is rotated about the DNA approximately 45° relative to the
other (Fig 3.6a).

The rotational offset of one DBD to the other, in turn, reduces the protein-protein
interface between dimers. These parallel interfaces are not symmetric, with one parallel
interface burying 118 Å2 of surface area, and the other burying 282 Å2. The interfaces are
the smallest of the p53-DNA structures, compared to the symmetric parallel interfaces of
the tetrameric structure reported here, which involve approximately 550 Å2 each (Fig.
3.8). Furthermore, molecular dynamics simulations of this structure show that this
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parallel interface is quickly lost, showing that the energy minimized state has a parallel
interface angle close to 0° (Pan et al. 2009).

Structure of a multi-domain p53 tetramer bound to a response element
While various p53-DNA structures have been reported over the years, each
contributing to an increased understanding of the atomic details of DNA-binding, there
are still unanswered questions regarding many aspects of the DNA-binding functions of
this tumor suppressor. The marginal stability of p53 makes crystallographic investigation
challenging, requiring the use of short DNA half-sites or crosslinking the protein to the
DNA in order to determine the DNA-bound structure.

In the following chapters, we present the first stabilized p53 variant containing
both DBD and the oligomerization domains, show that the variant is functional in vitro
and in vivo, and solve the X-ray crystal structure of both an unbound p53 dimer and a
DNA-bound p53 tetramer. We demonstrate for the first time how p53 oligomers bind to a
full-length response element and form robust parallel protein-protein interfaces involving
conserved residues. We describe conformational changes in the DBD that accommodate
binding to invariable bases within the RE, and show how loop L1 can serve as a wedge to
facilitate cooperative binding by creating a shift in the response element DNA.
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Abstract
The p53 tumor suppressor is the most frequently inactivated gene in human
cancer. It encodes a transcription factor that contains two independently folding domains,
a core sequence-specific DNA binding domain and a homo-tetramerization domain (1).
Here we describe the structure of a p53 polypeptide containing both these domains on its
own and in complex with DNA. The structure of the complex shows four DNA binding
domains interacting with one another and with DNA. Both the DNA binding domains of
p53 and the DNA undergo conformational changes upon DNA binding. These
conformational changes are asymmetric, even though the p53 DNA binding site is made
of four identical consensus repeats. The DNA corresponding to the center two repeats is
distorted such that its helical axis shifts by more than four angstroms. This results in
widening of the major groove at the center of the p53 binding site, which can thus
accommodate sequence-specific contacts by both loop L1 and helix H2. The geometry of
the DNA corresponding to the outer two repeats resembles better B-form DNA; this
results in loop L1 of one subunit adopting a recessed conformation, in which Lys120 no
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longer makes sequence-specific contacts, but rather interacts with the phosphate
backbone. The structure resolves the controversies of whether p53 and its target DNA
change conformation upon binding, the unusual feature of p53 that it uses both a loop and
a helix to contact the major groove of DNA, and why loop L1 is not targeted by cancerassociated mutations.

Introduction
The first determined three-dimensional structure of a core p53 DNA binding
domain in complex with DNA elegantly showed that most of the mutations in cancer
target residues that contact DNA (2). However, this structure also left some unanswered
questions. First, even though p53 physiologically binds DNA as a homotetramer, a model
of four p53 DNA binding domains in complex with B-form DNA leads to steric clashes
between the p53 subunits (3). Second, the structure showed that p53 uses an α-helix (H2)
and a loop (L1) to make sequence-specific contacts with the major groove of the DNA.
However, some experimental evidence argues against loop L1 making sequence-specific
contacts: amino acid substitutions targeting loop L1 generally do not compromise DNA
binding (4) and the structure of the DNA binding domain of C. elegans p53, which has
been determined only in the absence of DNA, shows loop L1 in a conformation
compatible only with non-specific contacts (5).

Since p53 functions as a homotetramer, the questions raised above could perhaps
be addressed by determining the structures of p53 oligomers in complex with DNA.
Towards this goal two groups have determined structures of 2 or 4 core p53 DNA
binding domains bound to DNA. The tetramer structure reported by the first group shows
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2 DNA binding domains bound to a 12-mer DNA site; there are 2 such complexes in the
asymmetric unit, creating a larger complex of 4 core domains bound to 2 semi-continuous
DNA molecules (6). In this structure, loop L1 binds DNA as reported in the original p53
monomer-DNA structure (2). The structures reported by the other group relied on a
sulfur-bearing three-carbon linker to attach 2 or 4 core p53 DNA binding domains to 16mer or 23-mer oligonucleotides, respectively. In the dimer structure, loop L1 is
disordered, while in the tetramer structure, loop L1 s displaced from the DNA, probably
by the chemical crosslinker (7, 8). Thus, none of the p53 oligomer structures determined
so far have demonstrated how four p53 DNA binding domains with well-defined DNA
binding elements - including loop L1 - contact physiological DNA sites.

Experimental procedures
To determine the three-dimensional structure of a p53 oligomer bound to DNA,
we expressed a p53 polypeptide that included not only the core DNA binding domain, but
also the oligomerization domain. This required the introduction of stabilizing amino acid
substitutions in the DNA binding domain, which otherwise has a very low melting
temperature (9). The designed substitutions targeted non-conserved residues far away
from the DNA binding surface and sampled residues from the repertoire of amino acids
present at that position in p53 proteins from other species with the goal of maximizing
the hydrophobic effect. A similar strategy has been employed by others (10, 11) and we
incorporated some of the substitutions identified by them in our designed p53 proteins.
After several rounds of mutagenesis and functional testing we obtained a human p53
protein (stabilized 6, ST6) with 12 amino acid substitutions, of which 4 were previously
identified by others (10, 11). p53-ST6, whose melting temperature was about 15o C
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higher than the melting temperature of native p53, had wild-type DNA binding and tumor
suppressor activities and could be expressed as a soluble protein in E. coli, but aggregated
when mixed with p53 target DNA and did not prove useful for obtaining crystals of p53DNA complexes (Figs. 2.1a & c, and 2.2).

Computational protein design: R209P substitution
We reasoned that the p53-DNA aggregation was due to non-specific DNA
binding mediated by basic residues of the p53 core domain located far away from the
sequence-specific DNA binding surface and used an algorithm to identify energetically
favorable amino acid substitutions that replaced such basic residues with non-charged
residues (12). Substitution of Arg209 with Pro fit these criteria and was introduced in the
stabilized p53-ST6 protein (Fig. 2.1b) to generate p53-ST7 (Fig. 2.2), a protein whose
melting temperature exceeded 70o C and which did not aggregate when mixed with DNA
(Fig. 2.1c). p53-ST7, hereafter referred to as p53-ST, had DNA binding and tumor
suppressor activities that were indistinguishable from those of wild-type p53 (Figs. 2.3 &
2.5b).

Multi-domain p53 variants
We generated a multitude of p53-ST proteins for crystallization screens. All
spanned residues 94-358 of human p53, but had deletions of different length between the
DNA binding and oligomerization domains. In addition, they either contained a wild-type
tetramerization domain or a mutant p53 oligomerization domain that can assemble as a
dimer, but not as a dimer of dimers (13). All p53-ST proteins were incubated with DNA,
22-28 nucleotides long, containing a high affinity p53 DNA binding site consisting of
four contiguous pentamer repeats (Fig. 2.5a) or without DNA. The only two proteins that
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yielded crystals are referred to as p53CR1 and p53CR2. p53CR1 crystallized only in the
absence of DNA, whereas p53CR2 crystallized only in the presence of a 26 nucleotidelong DNA (Fig. 2.5a). Both p53CR1 and p53CR2 have the mutant p53 oligomerization
domain (13), but differ in the length of the deletion between the DNA binding and
oligomerization domains; this deletion spans residues 292-321 and 292-320 of full-length
human p53 in p53CR1 and p53CR2, respectively (Fig. 2.4).

Results
p53 Dimer
The three-dimensional structure of p53CR1 in the absence of DNA was
determined at a resolution of 2.0 Angstroms [Å] (Table 2.1). As predicted, the protein
crystallized as a dimer (Fig. 2.5c). The ST DNA binding domains adopted the same
conformation as the wild-type DNA binding domain (2). The dimerization domain also
adopted the same conformation as the half wild-type tetramerization domain (13, 14).
The two DNA binding domains of the dimer did not interact with one another. Instead,
their orientation relative to one another was dictated by crystal packing interactions.
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Figure 2.1
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Figure 2.2
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p53 tetramer bound to DNA
The three-dimensional structure of two p53CR2 dimers bound to DNA was
determined at a resolution of 2.3 Å (Table 2.1). We labeled the DNA pentamer repeats a,
b, c and d, reflecting their 5-prime to 3-prime order in the DNA sequence (Fig. 2.5a).
Repeats b and c are at the center of the p53 DNA binding site and will also be referred to
as the "inner" repeats, whereas repeats a and d will be referred to as the "outer" repeats.
The p53 protein subunits are labeled A, B, C and D, matching the label of the pentamer
repeat, whose major groove they contact (Fig. 2.5d). According to this terminology, one
p53 dimer is formed by subunits AC, while the other by subunits BD. With some
exceptions listed below, the p53 subunits adopt very similar three-dimensional structures
to those observed in the absence of DNA. However, while in p53CR1 there were no
contacts between the DNA binding domains, in the structure of p53CR2 bound to DNA,
there were extensive contacts between the 4 DNA binding domains (Fig. 2.5d & e). In
what follows, we first describe how the DNA bound by p53 deviates from B-form
conformation and then the p53-DNA contacts and p53-p53 intersubunit contacts that are
responsible for this deviation.

DNA is shifted upon p53 binding
To visualize changes in the conformation of DNA upon p53 binding, we plotted
in the three-dimensional space for each base pair its C1'-C1' vector and its helical axis
(Fig. 2.6). The same was done for B-form DNA. As indicated by the orientation of the
C1'-C1' vectors, there is no significant bending of the DNA, except at the edges of the
p53 binding site (base pairs a4, a5, d4 and d5). Instead, there is significant shifting of the
helical axes, especially between base pairs b5 and c5 at the center of the p53 binding site
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(Fig. 2.6a, compare to B-form DNA), but also between base pairs b1-b4 and c1-c4 and to
a lesser extent between base pairs a1-a4 and d1-d4 (Fig. 2.6b, related by a 90o rotation to
the view shown in Fig. 2.6a). (Note that we do not distinguish between shifting and
sliding of the DNA helical axis (15) and, for simplicity, we refer to both as shifting). As a
result, the helical axis of the DNA shifts from repeat a to repeat d by about 4.8 Å (Fig.
2.6c), of which 3.0 Å are due to the shift at the center of the p53-binding site (Fig. 2.6d).
Interestingly, the shift in the DNA axis is not associated with significant deviations in the
values of base pair twist angles from those present in B-form DNA (Fig. 2.6e).

Figure 2.3
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Figure 2.4
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Figure 2.5
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DNA binding detail
Inspection of the p53-DNA contacts provides a first level of understanding of how
the four p53 DNA binding domains induce the 4.8 Angstrom shift in the DNA helical
axis. The sequence-specific contacts involve predominantly base pairs 2 and 3 of each
pentamer repeat and are similar for all p53 subunits. Using p53 subunit B as an example,
one observes the previously-described hydrogen bonds between the NH1 and NH2 atoms
of Arg280 and the O6 and N7 atoms, respectively, of the guanine base at position 2 of
repeat b (Fig. 2.7a; refs. 2, 6-8). In addition, we observe sequence-specific hydrogen
bonds involving atoms N2 and N3 of the same guanine base and the NH1 atom of
Arg248 from p53 subunit A. One network of these minor groove hydrogen bonds is
mediated by a water molecule and is observed in all four p53 subunits. In addition, a
novel direct hydrogen bond between the N3 atom of the guanine base and Arg248 is
observed between p53 subunits A and D and the inner pentamer repeats, for which the
distance between the interacting atoms is 3.7 Å; for subunits B and C and the guanine
bases at position 2 of the outer repeats, the corresponding distance is 4.2 Å. In the
previously-determined p53-DNA structures, Arg248, the most frequently mutated residue
in human cancer (16), was shown to contact oxygen atoms in the sugar-phosphate DNA
backbone (2, 6-8). The multitude of sequence-specific interactions involving the guanine
base at position 2 of the pentamer repeat, explains why this nucleotide is invariant and the
most critical determinant of p53 binding specificity (Fig. 2.5b). Base pair 3 of each
pentamer repeat also makes sequence-specific contacts with p53 (2, 6-8). Again using
p53 subunit B as an example, the SG atom of Cys277 makes a hydrogen bond with the
N4 atom of the cytosine base at position 3 of repeat b (Fig. 2.7b). In repeats a and c the
- 59 -

corresponding base is a thymine, in which case the SG atom of Cys277 contacts the
corresponding thymine O4 atom. In addition, in repeats a and c, the C5A atom of the
thymine base is equidistant (about 3.7 Å) to the SG atom of Cys277, the CB atom of
Ala276 and the CZ atom of Arg280 (Fig. 2.7b). Thus, the sequence-specific interactions
of p53 with base pairs 2 and 3 dictate the relative position of these base pairs to each
other. If one superimposes a B-form DNA to the p53-bound DNA using base pairs a2, a1,
b1 and b2 for the superimposition (Fig. 2.5a), then one observes that base pair b3 is
already shifted by 1.7 Å in the p53-bound DNA relative to B-form DNA (Fig. 2.7b).

Differences between binding inner and outer DNA repeats
Unlike the contacts of p53 with base pairs 2 and 3, which are essentially similar in
all four p53 subunits, the interactions with base pairs 4 and 5 vary depending on whether
the p53 subunit contacts an inner (repeats b and c) or an outer (repeats a and d) repeat.
Using p53 subunit B as an example of the contacts of subunits B and C to the inner
repeats b and c, respectively, the NZ atom of Lys120 makes hydrogen bonds with atoms
O6 and N7 of the guanine base at position 4' of repeat b (Fig. 2.7c). However, it is not
clear how much these hydrogen bonds contribute to DNA binding specificity, because the
side chain atoms of Lys120 had high B factor values. In contrast, the main chain of
Lys120 and the remaining loop L1 residues had low B factors. The main chain N atom of
Lys120 of p53 subunit B makes a hydrogen bond with the O2P atom of the phosphate
backbone at position 5' of repeat b, whereas the main chain O atom of the same lysine
and the OG atom of Ser121 make hydrogen bonds with oxygen atoms of the sugarphosphate backbone at position 5 of repeat c (Fig. 2.7c). All these interactions are
possible thanks - and probably contribute - to the shift in the DNA helical axis.
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Table 2.1
Data collection and refinement statistics for the hp53 dimer and hp53 tetramer /
DNA complex datasets*.

Data Collection
X-ray Wavelength
Space Group
Cell Dimensions (Å)
Resolution (Å)
Observations
Unique reflections
Data coverage (%)
<I/σ(Ι)>
Rsym (%)
Refinement statistics
Resolution range (Å)
Reflections used (>0 sigF)
Protein atoms
DNA atoms
Water molecules
R factor (%)
Rfree (%)
R.m.s. deviations
Bonds (Å)
Angles (o)
Ramachandran plot
Most favored (%)
Allowed (%)
Generously Allowed (%)
Disallowed (%)

hp53 Dimer

hp53 Tetramer / DNA

0.87260 Å
P212121
a=69.68, b=73.82, c=106.69
60.86-2.00 (2.11-2.00)
290,077 (41,979)
38,096 (5,459)
100.0 (100.0)
11.7 (5.1)
16.3 (36.0)

0.87260 Å
P21212
a=163.30, b=169.76, c=55.66
58.62-2.30 (2.42-2.30)
301,262 (40,665)
67,333 (9,800)
97.9 (98.6)
9.4 (1.7)
12.2 (61.7)

20-2.0
37,833
3,704
0
135
24.7
26.9

30-2.3
67,333
7,452
1,060
351
23.3
27.0

0.005
1.26

0.006
1.18

92.5
7.5
0.0
0.0

85.6
13.0
1.2
0.1

.

.

Values in parentheses refer to the highest resolution shell.
Rsym = ΣhΣi|Ih,i - Ih| / ΣhΣiIh,i for the intensity (I) of i observations of reflection h.
R factor = Σ|Fobs - Fcalc| / Σ|Fobs|, where Fobs and Fcalc are the observed and calculated structure factors,
respectively.
Rfree = R factor calculated using 5% of the reflection data chosen randomly and omitted from the start of
refinement.
R.m.s. deviations for bonds and angles are the respective root-mean-square deviations from ideal values.

*

Software used for analyzing the X-ray diffraction data sets and for refinement of the
structure described in references 29, 30 & 31
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Figure 2.6
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Figure 2.7
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As mentioned above, the DNA helical axis shifts by 3 Å between base pair 5 of
repeat b and base pair 5 of repeat c (Fig. 2.6a & d). In addition, in the axis perpendicular
to the one shown in Fig. 2.6a, the helical axis of base pairs b5 and c5 can be seen to have
moved away from the p53 DNA binding domains by 3 Å relative to the helical axis of
base pairs b2 and c2 (Fig. 2.6b). Without these shifts, residues 119-121 of loop L1 would
sterically overlap with the DNA backbone (Fig. 2.7d). In the previously determined p53
monomer-DNA structure (2), loop L1 adopts a conformation that allows it to barely
squeeze past the B-form DNA, Ser121 does not contact DNA and its CA atom has moved
4.2 Å away compared to its position in subunit B of the structure reported here (Fig.
2.7d).

Differences in loop L1 position per DNA repeat
The shift in the DNA helical axis is much smaller within the outer repeats than
within and especially between the 2 inner repeats. Accordingly, in subunits A and D loop
L1 cannot adopt the same conformation as in subunits B and C. In fact, the conformation
of loop L1 and its contacts with DNA differed in subunits A and D. In subunit A, loop L1
adopted a recessed conformation relative to the one observed in the absence of DNA or in
subunits B and C of the DNA-bound structure (Fig. 2.7e). The side chain of Ser121 faced
away from and did not contact DNA; the side chain of Lys120 did not make any
sequence-specific contacts, but rather interacted with the phosphate backbone of the
guanine located one position 5 prime of repeat a; while the main chain O atom of the
same residue interacted with the phosphate backbone of the thymine located two
positions 5 prime of repeat a (Fig. 2.7e). The CA atoms of Lys120 and Ser121 have
moved 3.9 and 5.5 Å away, respectively, compared to their position in subunit B (Fig.
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2.7f). The recessed conformation of loop L1 is reminiscent, although different, from the
recessed conformation of loop L1 in C. elegans p53 (5) and allows subunit A to contact
DNA that adopts regular B-form conformation (Fig. 2.7f). In subunit D, loop L1 adopted
a conformation similar to that observed in the monomer p53-DNA structure (2); the side
chain of Lys120 made a sequence-specific contact with the N7 atom of the guanine base
at position 5 of repeat d; and the phosphate-sugar backbone of the DNA corresponding to
repeat d had a conformation in between the conformations of repeat a and repeats b and c
(Fig. 2.8).

Protein-protein interfaces within the p53 tetramer
The four p53 DNA binding domains contact each other in the DNA-bound
structure (Fig. 2.5d). Two different p53-p53 interfaces are evident: an anti-parallel
interface between subunits A and B and between subunits C and D and a parallel
interface between subunits A and C and between subunits B and D, reflecting the
orientation of the interacting DNA binding domains to one another. The anti-parallel
interface buries 310 Å2 per two interacting subunits and is essentially as described in the
previously determined structures of p53 oligomer core domains bound to DNA with only
minor differences in the conformations of a few amino acid side chains (6-8). In contrast,
the parallel interface is completely different from any of the previously observed such
interfaces. Compared to the parallel interface observed in the structure of the four core
DNA binding domains crosslinked to DNA (8), to which it is more similar, the p53
subunits have shifted at the interface by between 3-7 Å; the buried surface area is almost
twice as large, at 552 Å2 per two interacting subunits; and the interaction is mediated by
evolutionarily conserved residues. Two main areas of interaction are evident at the
- 65 -

parallel interface. One area is dominated by hydrogen bonds involving the side chains of
Thr123, Thr140 and Glu198 and the main chain O atom of Thr140 from one subunit and
the side chains of Ser166, Gln167 and Thr170 from the other subunit (Fig. 2.9a). The
second area shows hydrophobic interactions between Val225 from one subunit and
Tyr103 and Leu264 from the other subunit, as well as electrostatic interactions and
hydrogen bonds between Glu224, Ser227 and Asp228 from one subunit and Ser99,
Lys101 and Arg267 from the other subunit (Fig. 2.9b). Residues Ser166, Gln167 and
Arg267 are targeted by mutations in human cancer with the same frequency as residues
Pro177, His178 and Arg181, which form the anti-parallel interface (16). In terms on their
effect on DNA binding, the anti-parallel interface helps determine the position of Arg248
from one subunit relative to Arg280 from the other subunit and, thus, facilitates the
recognition of the guanine base at position 2 of the pentamer repeat (Fig. 2.7a). On the
other hand, the parallel interface helps determine the relative position of subunits AB to
CD to stabilize the 4.8 Angstrom shift in the DNA helical axis observed between repeats
a and d (Figs. 2.5d & 2.6c).

Discussion
Cooperativity in p53 DNA binding
The vast majority of the known p53 binding sites in the human genome, about
90%, consist of four contiguous pentamer repeats with no gaps in between them, similar
to the DNA site present in the p53CR2-DNA structure reported here, while the remaining
10% of the sites have only a spacer of one nucleotide between repeats b and c (17). The
presence of four contiguous pentamer repeats allows the establishment of moderatelysized interfaces between the DNA binding subunits. The buried surface areas of these
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interfaces are not sufficiently large, on their own, to mediate oligomerization of the DNA
binding domains in the absence of DNA, but help explain the observed cooperativity in
p53 DNA binding (18). As expected, this cooperativity is greater for p53 binding sites
that contain four contiguous pentamer repeats; when a spacer of even one nucleotide is
introduced between the inner pentamer repeats, then DNA binding cooperativity is
significantly reduced (19), as would be expected, since then the interactions observed
here at the parallel interface would not be maintained.

Shifted DNA accommodates p53 tetramer
The structure reported here also resolves the question of steric clashes when four
p53 DNA binding domains bind DNA (3). Instead of p53 tetramers bending DNA, as
previously contemplated (3, 20), the helical axis of DNA is shifted by 4.8 Å (Appendix II,
Table a2.2). This allows the p53 subunits that bind to the inner pentamer repeats to
recognize the major groove of DNA using both an α-helix and a loop, which is highly
unusual among DNA binding proteins (2, 21). Without the shift in DNA helical axis, only
the α-helix would be able to fit in the major groove of DNA, as is, indeed, observed for
subunit A. The high B factors of the side chain atoms of Lys120 further suggest that the
main role of loop L1 may not be to contribute to DNA binding specificity, but rather to
facilitate the shift in the DNA helical axis. Substitution of Lys120 with Ala has little
effect on the DNA binding and tumor suppressor properties of wild-type p53 (4), whereas
substitution of Thr123 with Ala, which may stabilize the conformation of loop L1
observed in subunits B and C, enhances both DNA binding and apoptotic activities (4,
22).
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The most unusual feature of the multidomain p53 oligomer structure bound to
DNA is the shift in DNA helical axis. The biological significance of this shift remains
unclear. However, one hypothesis is that the shift is necessary for p53 to activate
transcription. Indeed, some transcription factors simply bind B-form DNA and then
recruit enzymes that modify histones post-translationally (23). But other transcription
factors, notably, TATA-binding protein [TBP], induce large architectural changes in the
DNA that result in histone eviction (24). While p53 induces a much more modest change,
binding of p53 to DNA may also lead to eviction or displacement of histones.

The structure reported here suggests that the sequence-specific recognition of the
base pairs at positions 2 and 3 of the pentamer repeats facilitates the shift in DNA helical
axis. Interestingly, p53 can both activate and repress transcription, depending on the
specific site in the genome to which it binds (25). The target sites that mediate activation
of transcription match well the p53 consensus sequence at positions 2 and 3; whereas the
target sites that mediate repression of transcription do not match the p53 consensus
sequence at position 3 (26), raising the possibility that binding of p53 tetramers to
repressor DNA sites does not induce a major shift in the DNA helical axis.
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Figure 2.8

Figure 2.9
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Methods
Protein sample preparation and crystallization.
p53 polypeptides were expressed in E. coli. The cells were lysed in buffer
consisting of 25 mM bis-tris propane (BTP) [pH 6.8], 250 mM NaCl, 5 mM DTT and
protease inhibitors, and the polypeptides were purified by cation exchange (Sepharose SP
column; Pharmacia Biotech, Uppsala, Sweden) and gel filtration (Superdex 200 column;
Pharmacia Biotech). After purification the p53 protein was concentrated to 8 mg/ml in 25
mM bis-tris propane [pH 6.8], 150 mM NaCl, 5 mM DTT buffer and was crystallized
under standard hanging drop vapor diffusion conditions in 48-well plates (Hampton
Research, Aliso Viejo, CA, USA) or in a novel microfluidics system (27) at 4o C in the
absence of DNA or in the presence of DNA at a 1:1.1 protein:DNA molar ratio. The
precipitant solutions used for crystallization were 0.2 M ammonium acetate, 0.1 M
HEPES [pH 7.5], 45% v/v 2-Methyl-2,4-pentanediol for p53CR1 in the absence of DNA
and 0.15 M DL-Malic Acid [pH 7.0], 20% Polyethylene Glycol 3350 for the p53CR2DNA complex (Appendix II, Fig. a2.5).

Data collection and structure refinement.
All X-ray diffraction data sets were collected at the ID23-2 microfocus beam line
of the European Synchrotron Radiation Facility (Grenoble, France). Reflection data were
indexed, integrated and scaled using the CCP4 software package. Initial solutions were
determined by molecular replacement and refined using non-crystallographic symmetry
restraints using the programs CNS and O. Base pair origins and origin vectors were
determined using the program 3DNA (28).
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Electrophoretic mobility gel shift assay.
[35S]-methionine-labeled full-length human wild-type p53 and the equivalent p53
protein containing the stabilizing amino acid substitutions (ST7, Fig. 2.2) were expressed
by in vitro translation in rabbit reticulocyte lysate (Promega Corporation, Madison, WI,
USA). The radiolabeled proteins were then incubated at ambient temperature with
oligonucleotides containing consensus or variant p53 DNA binding site and analyzed for
DNA binding by electrophoresis on non-denaturing tris-glycine gels as previously
described (5).
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CHAPTER 3
Discussion: p53 DNA-binding
Key questions concerning how p53 binds DNA as a tetramer were answered by
the results presented here;
Do p53 and its target DNA change conformation upon binding?
How does p53 use loop L1 and helix H2 to contact the major groove of DNA?
Why is loop L1 not targeted by cancer-associated mutations?
As previously discussed, the current p53-DNA structures leave ambiguities in describing
how p53 binds DNA, arising mainly from the strategies employed in order to crystallize
p53 with DNA. The initial structure reported in 1994, while defining the architecture of
the DBD (Fig. 1.5) and providing valuable insight into how cancer mutations affect DNA
binding, consisted of three DBDs bound to DNA, with only one of the DBDs making
base-specific contacts. A decade later three more p53-DNA structures were released that
described DBD multimers bound to DNA, yet the DBDs were either crosslinked to the
DNA or incubated with RE half-sites, failing to provide a structure of the p53 tetramer
bound to a full-length response element. The structures reported here describe stable p53
variants that contain both DBD and oligomerization domains, dimerize in the absence of
DNA, tetramerize in the presence of DNA, and form substantial protein-protein interfaces
by inducing a shift in the DNA response element upon binding. Furthermore, these stable
variants retain wild-type DNA binding specificity in vitro and reflect wild-type
transactivation functions in vivo.
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Structure: multidomain p53 tetramer bound to a full-length RE
Oligomerization domain
The p53 protein functions most efficiently as a tetramer, reflected by the high
affinity for binding DNA REs in a tetrameric state (Kern et al. 1991; Tokino et al. 1994,
Weinberg et al. 2005). Tetramerization of p53 monomers occurs through interactions
within the oligomerization domain formed by residues 325-356 (Jeffrey et al. 1995).
Each oligomerization domain consists of a short β-strand and α-helix connected by a
sharp hairpin. Four monomeric oligomerization domains can self-assemble via helix
packing and intermolecular β-sheet formation. Yet although all four monomer domains
interact within the tetramer, the A-B (and C-D) interface is more extensive than those of
A-C or A-D, implying that the tetramer can be regarded as a dimer formed through
association of AB and CD dimers (Jeffrey et al. 1995). Indeed, dimeric forms of p53
exhibit comparable DNA-binding and transactivation functions in vivo (Pietenpol et al.
1994)
Therefore in order to reduce the complexity of the p53-DNA system and to
increase chances of obtaining p53-DNA crystals, the oligomerization domain was altered
so that dimers, but not dimers of dimers, can form (Davison et al. 2001). The two residue
substitutions introduced, M340Q and L344R, affected neither the structure of the
oligomerization domain (Fig. 3.1), nor the DNA binding capabilities of p53 both in vitro
(Fig. 2.5b) and in vivo (Fig. 2.3). The oligomerization domains of the stable p53 variant
structures reported here, both in the DNA-free dimer and DNA bound tetramer, are
structurally similar to previously reported structures of this domain (backbone atom root
mean square deviation [RMSD] of 0.35 Å to structure PDB code: 1C26) (Fig. 3.2).
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Figure 3.1
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Figure 3.2
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DNA-binding domain
The DNA-binding domains of the stable p53 variant structures presented here
exhibit the same compact domain architecture as other p53 DBD structures. Overall, the
DBDs of both the DNA-bound tetramer and DNA-free dimers align to the DBD of Cho et
al. with a 0.5 Å RMSD between backbone atoms (Fig. 3.3). Alignment to human DBDs
from other structures generate similar results with RMSD values of 0.416 Å and 0.334 Å
for a DBD dimer bound to DNA (Kitayner et al. 2006; PDB code: 2ACO) or a stable
DBD monomer (Joerger et al. 2005; PDB code: 2BIM), respectively. The similarity
among the various DBD structures reflects the high level of conservation found among
species (Appendix II, Fig, a2.4) and highlights the importance of the three-dimensional
domain architecture required to form protein-protein and protein-DNA contacts critical
for p53 DNA-binding and subsequent transactivation functions.

Domain rearrangement upon DNA binding
As described in chapter two, the structures of the stable multi-domain p53 both
unbound and bound to DNA reveal conformational changes among domains, reinforcing
the idea of cooperativity upon DNA binding. The binding event causes the DBDs of each
monomer to rotate relative to the oligomerization domains to form a robust anti-parallel
interface involving conserved residues (Fig. 3.4). Furthermore, both parallel and antiparallel interfaces within the tetramer situate the DNA-binding residues in coordinated
positions to make backbone and base-specific contacts inducing a shift among bases
within the 26-bp p53 response element (Fig. 2.6). Compared to other p53-DNA structures
(Fig. 1.4), the shift increases binding by maximizing both backbone and base specific
contacts, with the invariable guanines at position 7 and 17 within the RE helping to
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anchor the p53 tetramer (Fig. 3.9d), which in turn aligns the four p53 monomers,
increasing the protein-protein interfaces and stabilizing the complex.

Figure 3.3
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Figure 3.4
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Cooperative interactions upon DNA binding
Anti-parallel interface
Our tetrameric structure, compared to the human DBD dimer of dimers (Kitayner
et al. 2006), and the mouse DBD crosslinked to DNA (Ho et al. 2006; Malecka et al.
2009), has similar residues implicated in the anti-parallel interface (Fig. 3.5). This is in
agreement with in vivo data demonstrating p53 first dimerizes and then binds REs as a
dimer of dimers (McLure KG & Lee PW 1998).

DNA binding involves four p53 monomers forming a tetramer on DNA whose
sequence contains four repeats, with each repeat interacting with each monomer. As the
p53 subunits come together, a total of four protein-protein interfaces are formed. Two
anti-parallel interfaces form between chains AB and CD crossing the DNA axis. The antiparallel interfaces from the tetrameric structure reporter here are similar to the antiparallel interfaces of previously determined p53-DNA structures (Fig. 3.5). The antiparallel interface involves the zinc-coordinating loop L2, helix H1 and loop L3 (Fig. 1.5).
The regions involved in coordination of the zinc atom are highly conserved, and these
same areas have a high frequency of cancer-related mutations (Fig. 1.2).
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Figure 3.5
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Parallel interface
Our tetrameric structure, compared to the human DBD dimer of dimers (Kitayner
et al. 2006), and the mouse DBD crosslinked to DNA (Ho et al. 2006; Malecka et al.
2009), has a more robust and consistent parallel interface (Fig. 3.6). The parallel
interfaces are created on each side of the DNA, between chains AC and BD. Our p53
tetramer structure demonstrates that the same interface residues are used in parallel
interfaces I and II. Furthermore, our structure has 16 residues at the parallel interface that
are the same within each dimer, whereas the structure from Malecka et al. has 10 residues
in common, and the structure of Kitayner et al. has 4 residues in common (Fig. 3.6). The
significance of these novel parallel interactions is reinforced by the observation that there
are twice as many residues involved at the parallel interface, the same residues are used
by both dimers on each side of the DNA, that the majority of residues are conserved (Fig.
3.7), and that the buried surface area per two interacting subunits is almost twice as large
as other tetramer structures (Fig. 3.8).
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Figure 3.6
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Figure 3.7
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Figure 3.8

- 87 -

Characterization: DNA binding properties
DNA-binding gel shift assays with 15 different p53 RE variations (Fig, 2.5b)
reveal that the ST p53 variants used for crystallography retain the same binding
properties as wild-type p53 in vitro. DNA binding studies were carried out as described
in the methods section. For creating p53-DNA complexes used in crystallographic
experiments, ST p53 was also assayed for binding to oligonucleotides of length 21 to 27bp using size exclusion chromatography (Methods: Table m.1, Figs. m.3 & m.4).

The results show that ST p53 binds to dsDNA oligonucleotides of length 24-bp
and greater. No stable complexes were observed for dsDNA of length 23-bp or shorter.
However, other groups have crystallized human or mouse p53 DBDs with DNA as short
as 12-bp. This seemingly contradictory observation can be explained by the fact that the
p53 variants used in this study have a shortened linker, which positions the
oligomerization domain much closer to the DBD compared to wild-type p53. Although
these p53 variants retain wild-type DNA-binding and functionality in vitro and in vivo,
the p53 dimer does not straddle the DNA (via the anti-parallel interface) as shown in
other structures. Rather, the ST p53 dimer binds to DNA in a parallel manner along the
DNA axis, contrary to the other structures in which p53 dimers bind across the DNA in
an anti-parallel orientation. Regardless of binding orientation, similar DBD anti-parallel
interfaces are created in the tetrameric complex (Fig. 3.5). A double-stranded DNA
oligonucleotide of 24 base-pairs accommodates the two DBDs of each dimer binding to
each long edge of the DNA. DNA that is 23-base pairs or shorter is not long enough to
accommodate two complete DBDs of each dimer in a parallel interface in our system,
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and thus could destabilize the complex by removing protein-DNA interfaces that in turn
can reduce protein-protein contacts.
Cooperativity in DNA-binding is demonstrated by the structures reported here in
conjunction with the results obtained from size exclusion chromatography. As described,
the ST p53 dimer does not stably bind to dsDNA shorter than 24-bp, and the DBDs do
not associate with each other in the absence of DNA. The DNA-bound structure reveals
that the dimer forms on each side of the DNA and makes robust parallel interfaces (Figs.
3.6 & 3.8). However if the parallel interface between p53 DBDs forms a stable proteinprotein interaction, then it could be expected that the tetramer would form on shorter
dsDNA containing only one half-site. These observations therefore provide more
evidence that the response element acts as a template, helping to orient the p53 DBDs
relative to each other in order to form both the anti-parallel and parallel interfaces.

The vast majority (99%) of known p53 response elements have no spacer
nucleotide between half-sites (such as the RE in our structure), and the majority of the
remaining 1% have only one nucleotide spacer (Wang et al. 2009). Response element
half-sites separated by 2 or more nucleotides would reduce or abolish the anti-parallel
interface by separating the p53 dimers. While it is easy to see how a large spacer can
prevent the parallel DBD interface by separating each p53 dimer, it is not as evident why
a single or double nucleotide spacer could affect binding. However, at about 10.5 basepairs per complete 360° helical turn of B-form DNA, each nucleotide contributes
approximately 34° of rotation about the central DNA axis. Therefore with even a two- 89 -

nucleotide spacer between response element half sites, one DNA-bound p53 dimer could
be rotated 68° in relation to the other. Even if the distance between p53 dimers on the
DNA is close enough to accommodate parallel protein-protein interactions, the rotation
would most likely prevent alignment of the surfaces used in the parallel interface.

New DNA contacts
In addition to previously described p53-DNA contacts, we observe novel contacts,
some of which are different from subunit to subunit. The structure reported here shows a
sequence-specific contact made by Arg248 to the invariable guanine base of the response
element through the minor groove. We also observe that helix H1, which contacts DNA,
can move like a piston by 0.9 Å from subunit to subunit; and that this movement allows
the helix to adapt to the induced DNA distortions.

Interaction of tetramer with DNA: K248 & K280
In the p53-DNA structure reported here, we observe a new sequence-specific
contact made by Arg248, the most frequently mutated residue of p53 in cancer (Fig. 1.2).
In previously reported p53-DNA structures, this residue makes occasional non-specific
contacts with the DNA backbone (Cho et al. 1994; Kitayner et al. 2006; Malecka et al.
2009). However, the extensive protein-protein interactions at both the parallel and antiparallel interface in the tetramer reported here serve to position residues Arg248 and
Arg280 of each monomer to interact with the conserved guanine nucleotide in the
consensus p53 RE. Furthermore, the C4 and G7 within the consensus p53 response
element half site are invariable (Fig. 3.9d; Wang et al. 2009). Our p53 tetrameric
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structure demonstrates a striking link between residues Arg248 and Arg280 and the
conserved C4 and G7 of the p53 RE.

We observe not only the previously reported nucleotide-specific contacts of
Arg280, but also Arg248, to each invariant guanine base within the p53 RE. Upon
binding DNA, opposing p53 DBDs make nucleotide specific contacts to the same
guanine using these two arginines across the anti-parallel interface (Fig. 5.9a, b & c). For
example, Arg280 of monomer A and Arg248 of monomer B both contact the same
guanine at position 7 in the RE. Arg248 binds G7 through the minor groove while
Arg280 binds through the major groove. This pattern is repeated 4 times within the
tetrameric complex, each time involving the invariable guanines at positions 7 and 17 of
the RE sense-strand, with a similar pattern on the anti-sense strand (Fig. 5.9d).
The significance of this interaction is two-fold. First, as demonstrated by the
sequence composition of the p53 RE, the guanines at these four positions within the fulllength RE could act as anchor points used for guiding p53 DBDs to the RE. Once p53
recognizes and binds the response element, each monomer is aligned relative to the next
by interacting with two guanines. In other words, each guanine interacts with two DBDs,
and each DBD interacts with two different guanines. Second, the reciprocality created
through the coordination of a “shared” DNA base can in turn help align each DBD
relative to the next, in order to guide formation of the anti-parallel and parallel interfaces
observed in the tetramer complex.
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Evidence supporting the significance of the Arg248-[G]-Arg280 interaction
comes from the fact that repressor REs, response elements that lead to down-regulation of
associated genes upon p53 DNA binding, have a slightly different composition than
activating REs. The repressor response elements contain guanines at neighboring
positions relative to the invariable guanine. One model suggests that these neighboring
guanines might compete with invariable guanines for Arg248 and Arg280 interactions.
This can be likened to noise in a signal, with the ‘signal’ representing the activating RE
invariable guanines, and the ‘noise’ representing the neighboring guanines. If either
Arg248 or Arg280 were to interact with different guanines within the RE, then the
relative positions of each DBD on the surface of the DNA could be altered, in turn
potentially weakening the anti-parallel or parallel interfaces, leading to either different
conformations or lowered binding affinities that could affect downstream transactivation
functions.

DNA conformational changes upon p53 binding
The 26-nucleotide long dsDNA containing the complete p53 consensus response
element sequence, when bound by a p53 tetramer, is different than a structure of B-form
DNA with the same sequence. As described in this chapter (and previously in chapter 2),
although there is no significant bending of the DNA, p53 binding induces a shift among
the base pairs in the response element that accommodates extensive protein-protein
interfaces among the four p53 monomers. The details of these shifting (and sliding)
effects are presented in appendix II (Figs. a2.7 & a2.8). The largest effect occurs at the
junction between the two p53 RE half sites with a slide of approximately 3 Å and is
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situated at the parallel p53 protein interface (Fig. 3.8 & Table a2.2). Furthermore, a shift
of approximately 1 Å is observed between each of the symmetric response element
quarter-sites, located at the anti-parallel interfaces. This shifting and sliding of the DNA
base pairs within the RE helps to establish protein-DNA contacts as well as facilitate
protein-protein interactions (presented in chapters 2 and 3).

Model of full-length p53 bound to DNA
Our structure is in agreement with the size and shape of electron density of fulllength p53 bound to DNA. Recent SAXS and NMR experiments have revealed the threedimensional shape of full-length p53 bound to a p53 RE (Tidow et al. 2007). Although
the 25-30 Å resolution is not detailed enough to outline individual domains, the overall
shape of the electron density fits well with our crystallographic p53 tetramer-DNA
structure.

By overlaying the tetrameric structure onto the cryo-EM density, the DNA and
the DBDs of the tetramer fit well into the lower portion (Fig. 3.10). The DBDs do not fill
the density completely; however the ~100 N-terminal residues making up the
transactivation domain and the proline-rich region in full-length p53 could fit into the
lower void of the density not occupied by the DBDs. The oligomerization domains
protrude from the cryo-EM density (Fig. 3.10d, e & f), which can be explained by the
shortened linker used in the ST p53 variants. In the context of a ~30 residue full length
linker (Fig. 3.10g, h & i), the oligomerization domain would fit into the EM density
located 40 Å from the DBDs (a 30-amino acid peptide could span 100 Å if fully
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extended). In sum, our tetrameric p53-DNA structure agrees with the full-length p53DNA complex.

Outlook
Energetics of p53 binding
Nucleotide variations are common in the p53 response elements located within
the promoters of a diverse array of genes under the control of p53 (Wang et al. 2009).
These sequence variations may be an important determinant of the p53 response element
DNA plasticity. This variation in conformational flexibility could, in turn, dictate the
affinity of p53-DNA interactions central to gene transcription and regulation.

In future studies, the p53-DNA interactions could be further characterized at
higher resolution using isothermal titration calorimetry (ITC). This technique makes use
of a syringe containing a particular ligand that is titrated into a chamber containing a
protein solution. As the two elements interact, heat is released or absorbed in direct
proportion to the amount of binding. Measurement of this heat allows for accurate
determination of binding constants (Kb), reaction stoichiometry (n), as well as
thermodynamic properties such as observed molar calorimetric enthalpy (∆Hobs), entropy
(∆Sobs), heat capacity of binding (∆Cp,obs) and change in free energy (∆G) (Liang 2008;
Seldeen et al. 2009).

For example, ITC was recently used to investigate the effect of single nucleotide
variants of the Jun-Fos transcription factor response element. This study showed how
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small sequence variations in the response element dictate the energetics of Jun-Fos
heterodimer binding. In addition to the wealth of protein-DNA binding information that
was obtained, thermodynamic dependencies on the position of nucleotide substitution
within the response element could also be calculated (Seldeen et al. 2009). The ITC
analysis thus provides a novel approach to dissecting interacting forces that may
determine the overall binding affinity of protein-DNA interactions.

One important observation was that conformational plasticity, such as the ability
of the Jun-Fos response element to bend and wrap around Jun and Fos to attain a close
molecular fit, is critical for high-affinity binding. Even though DNA bending is not
observed in the crystal structure of the Jun-Fos heterodimer bound to the response
element (Glover & Harrison 1995), several solution studies support the intrinsic
flexibility of DNA as being a key factor in its ability to bind to Jun-Fos heterodimer with
high affinity (Kerppola & Curran 1993; Leonard et al. 1997). Potentially, the subtle
effects of response element nucleotide variation on p53-DNA binding may not appear in
crystal structures, and would be better characterized with ITC analysis of p53 and p53
response element variants.

Structural characterization of p53 response elements
High-affinity binding of p53 to the p53 response element requires the conserved
C[A/T][A/T]G motif in each RE half site, however nucleotide polymorphisms at other
locations within the 20 base pair motif can affect the transcriptional behavior of p53 (Inga
et al. 2002; Osada et al. 2005; Jordan et al. 2008; Wang et al. 2009). In this study we
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show that the response element, composed of the consensus sequence, shifts base pairs to
accommodate novel protein-DNA contacts. Although we compare the shifted RE to the
same sequence modeled as B-form DNA (Table a2.2), it is possible the consensus
sequence does not have such an ideal B-form conformation in vivo in an unbound state.

The wide variety of nucleotide substitutions found within confirmed p53 response
elements in humans suggests DNA conformation plays a role in p53 recognition and
binding (Wang et al. 2009). Therefore, the generation of additional high-resolution
structures of both p53-bound and p53-free response element variants could provide more
insight into p53 response element recognition, and what influence the DNA sequence and
structures have on p53 binding. With the enhanced thermostability of the multi-domain
p53 variant presented in chapter 2, and given that the binding and crystallization
protocols have already been established, obtaining novel multi-domain p53-DNA
structures should be relatively straightforward.
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Figure 3.9
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Functional consequences of p53-RE binding
The selective mutagenesis and probabilistic protein design strategies that are
described in chapter 5 and applied to human p53 have made it possible to substantially
increase p53 stability without compromising response element recognition and binding,
generating the means to determine the first multi-domain structure of p53 bound to a fulllength response element. While the structures presented in chapter 2 provide greater
detail of the p53-DNA binding mechanisms, other p53-DNA structures could
substantially contribute to the understanding of p53 function.

While the research presented here focuses on p53 binding to a consensus response
element, recent evidence points to the existence of RE sequences that lead to p53mediated down regulation of genes as well (Wang et al. 2009). These repressor REs
differ in sequence to the canonical RE which might, in turn, propagate conformational
differences in p53 upon binding. As described in the previous section, continued
crystallographic studies probing p53 bound to a variety of response elements, including
those with suppressor sequences, could provide more insight into the mechanisms of RE
recognition, binding and transactivation.

There is, however, evidence that mutant p53 can bind a variety of other DNA
structures such as those formed by matrix attachment regions and Holliday junctions.
Likewise, the observed gain of function activity for certain p53 mutants might be a result
of binding to DNA secondary structures of non-canonical effector genes (Fig. a2.6; Will
et al. 1998; Göhler et al. 2002 & 2005). New, computationally re-designed stable p53
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variants containing these mutations could provide the means to determine high-resolution
structures of p53 bound to different conformations of DNA, thus providing more insight
into the diverse modes of p53 binding, and possibly explaining why and how certain p53
mutations result in oncogenic function.

Atomic detail of full-length p53 complexes
The newly acquired DNA-binding functions of p53 reported in various
investigations could involve different binding orientations of the DBDs relative to the
DNA that simply have yet to be characterized. A full-length linker connecting the DNAbinding and oligomerization domains of p53 could thus serve to probe these potential
complex structure variants. Computational probabilistic protein design strategies have
already been used to solubilize trans-membrane proteins and re-engineer enzyme
substrate specificity (see chapter 5). Therefore protein re-design strategies have
demonstrated the potential to stabilize the linkers, in turn facilitating crystallographic
study. Through linker residue sequence analysis, ensembles of mutations could be
sampled, potentially highlighting substitutions that would increase linker stability and
facilitate experimental investigation of p53 variants containing full-length linkers. The
ability to study p53 dimers or tetramers with more relative freedom of movement among
DNA binding domains could provide insight as to how the DNA-binding domains adopt
various conformations on different DNA structures. In addition to focusing on p53-DNA
complexes, stabilized multi-domain p53 variants could be complexed with regulatory
factors such as Mdm2 and MdmX, or with other interacting proteins involved in DNA
metabolism and cell cycle control, in order to uncover more structural detail of the p53
complexes leading to activation or suppression of target genes.
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Figure 3.10
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Structures of p53, p53 isoforms, p63, and/or p73 complexes
More multi-component structural studies on p53 and its various isoforms, or
homologs p63 and p73, could provide information on how specific functions are
enhanced through different, if any, domain arrangements. This might explain how
different modes of oligomerization occur among the various p53 isoforms and family
members. Additionally, solving structures of the p53 ancestral proteins p63 and p73 will
help to further define their architectures and to analyze the evolutionary changes that
have shaped such a universal effector molecule as p53. While p63 and 73 structural data
is currently unavailable, comparative modeling using p53 as a guide structure, coupled
with various protein design strategies, could aid in stabilizing these proteins for
crystallographic analysis.

Benefits to computational research
A growing number of computational studies probing the p53 regulatory network
(and other biochemical and cell-related pathways) contribute to the understanding of how
p53 functions in a wide range of cellular processes (Lev Bar-Or et al. 2000; Ma et al.
2005; Yip et al. 2006). Many of these computational approaches use structural
information as a basis for defining various parameters used in the calculations. Highresolution X-ray crystal structures of proteins, and protein complexes, can therefore serve
to further increase the accuracy and predictive powers of the computational models
created to help decipher complex biological networks and processes.
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Background
In this chapter we present a novel microfluidics platform that we have adapted for
protein crystallization, in a format that is automated and has high throughput capacity.
The unique combinatorial fluid multiplexing capabilities of the SpinX lab makes it well
suited to serve as a high-throughput screening platform for protein crystallography. The
microfluidic gCards each contain over 500 reaction chambers, all within a space smaller
than a compact disc, that are connected together during each experiment at precise
locations and times to dilute, mix and incubate assay components. Each chamber holds
200 nanoliters of liquid and contains enough space to grow crystals to sizes beyond 300
micrometers in size (Fig. 4.1). Furthermore, diffraction patterns can be obtained from the
crystals without removing them from the screening card, thus drastically reducing hit-tolead optimization time (Fig. 4.2). Additionally, the programmability and precision of the
fluid mixing in the cards offers a high-level of customization that can be applied to many
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protocols such as optimization of conditions with additives, crystal cryo-preservation and
even ligand or small molecule mixing for co-crystal experiments.

Figure 4.1
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Figure 4.2

Abstract
Microfluidics is a promising technology for the rapid identification of protein
crystallization conditions. However, most of the existing systems utilize silicone
elastomers as the chip material which, despite its many benefits, is highly permeable to
water vapor. This limits the time available for protein crystallization to less than a week.
Here, the use of a cyclic olefin homopolymer-based microfluidics system for protein
crystallization and in situ X-ray diffraction is described. Liquid handling in this system is
performed in 2 mm thin transparent cards that contain 500 chambers, each with a volume
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of 320 nl. Microbatch, vapor-diffusion and free-interface diffusion protocols for protein
crystallization were implemented and crystals were obtained of a number of proteins,
including chicken lysozyme, bovine trypsin, a human p53 protein containing both the
DNA-binding and oligomerization domains bound to DNA, and a functionally important
domain of Arabidopsis Morpheus’ molecule 1 [MOM1]. The latter two polypeptides have
not been crystallized previously. For X-ray diffraction analysis, either the cards were
opened to allow mounting of the crystals on loops or the crystals were exposed to X-rays
in situ. For lysozyme, an entire X-ray diffraction data set at 1.5 Å resolution was
collected without removing the crystal from the card. Thus, cyclic olefin homopolymerbased microfluidics systems have the potential to further automate protein crystallization
and structural genomics efforts.

Introduction
Crystallization of proteins and determination of their three-dimensional structure
provides biological information that is often critical to understanding their function.
Indeed, it has been proposed that the three-dimensional structures of all proteins should
be solved and the term ‘structural genomics’ has been used for these efforts. So far, these
efforts have met with mixed success (Service 2002; Chandonia & Brenner 2006), in part
because protein crystallization is a tedious and time-consuming process that is not easily
amenable to automation. Nevertheless, progress towards automation has been made and
currently many crystallographers rely on some level of automation for their daily
experiments.
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Perhaps the most widely used systems for automating protein crystallization are
pipetting/robotic systems that simply recapitulate the steps performed by humans (Hui &
Edwards 2003). One set of pipetting systems prepares crystallization reactions by mixing
a precipitant solution with the protein to be crystallized in very small drops (about 200 nl
in volume). These drops are placed in chambers containing a much larger volume of
precipitant solution. Through vapor diffusion, the volume of the protein drop slowly
decreases, leading to protein crystallization. This type of pipetting system has gained
acceptance because vapor diffusion is a well established method of protein crystallization
(Hui & Edwards 2003; Chayen & Saridakis 2008) and because it utilizes about ten times
less protein than would be required if the same reactions were set up manually. However,
a disadvantage of pipetting systems is that the small volume of the protein-precipitant
drops leads to significant water evaporation before the chambers are sealed. The degree
of evaporation can vary from drop to drop, creating heterogeneity in the experiment, and
even occurs when the reactions are prepared in a humidified environment. Robotic
systems have also been developed to identify crystals in protein-precipitant drops; these
systems consist of a cabinet, in which crystallization plates are stored, a robotic arm and a
microscope (Hui & Edwards 2003). Several images are acquired from each drop (at
various focal planes, since the drops are not flat) and these images are then processed by
software that attempts to identify protein crystals, which is a difficult task because the
drop geometry leads to poor images. Finally, a robotic system has also been developed to
position crystallization trays in the path of a synchrotron X-ray beam (Jacquamet et al.
2004). This system can screen crystals for their ability to diffract X-rays and allows some
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crystal parameters, such as space group and unit-cell size, to be determined without
manual handling of the crystals.

As an alternative to the systems described above, efforts have been made to use
microfluidics for protein crystallization. Several such systems have been developed, most
of them employing chips made of elastic silicone (Hansen & Quake 2003). In one system,
the chips contain wells that are connected by a channel; the elastomeric nature of the
chips permits the channel to be sealed by applying mechanical pressure to the chip
(Hansen et al. 2002, 2004 & 2006). In its most simple form, two wells are filled with
protein and precipitant solution, respectively; the pressure on the channel connecting
these two wells is then released, allowing the contents of the wells to mix by a process
called free-interface diffusion. Depending on the viscosity of the liquids, equilibration of
the contents of the two connected chambers is achieved in as little as 1 hour. Crystal
growth is followed over a period of a few days, but generally for less than a week. The
observation time is limited by evaporation of water through the silicone, which is
intrinsic to the nature of these microfluidic chips because the silicone elastomer is
permeable to water vapor. On the other hand, water evaporation also offers the advantage
that it results in higher protein-precipitant concentrations, which may favor
crystallization.

Another microfluidics system mixes protein and precipitant in nanoliter-volume
droplets that are formed within water-immiscible fluids flowing inside capillary channels
(Zheng et al. 2003, 2004; Li et al. 2006). The droplets initially form in silicone elastomer
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channels, but are eventually guided into glass or Teflon capillary tubes, which are then
sealed to prevent evaporation. Depending on the nature of the fluid separating the
droplets, this system crystallizes proteins by microbatch or vapor-diffusion methods.
When the oil separating the droplets is impermeable to water, the proteins crystallize by
the microbatch method. For vapor diffusion, protein-precipitant droplets alternate with
droplets containing high concentrations of salt and are separated by a water-permeable
oil; this allows the slow transfer of water from the protein-precipitant droplets to the
high-salt droplets, resulting in a vapor-diffusion effect.

The use of silicone elastomer is prevalent in microfluidics systems and offers
certain advantages, as described above. However, the water-vapor permeability of
silicone limits its use in cases where protein crystallization requires incubation with
precipitant for more than a few days. Thus, microfluidics systems that utilize vaporimpermeable chips could provide an alternative to silicone elastomer-based systems.
Here, we describe our experience with a microfluidics system that uses cyclic olefin
homopolymer (COP) as the chip material. We demonstrate the crystallization of several
proteins at 277 K and at room temperature using microbatch, vapor-diffusion and freeinterface diffusion protocols.

Experimental procedures
Protein-sample preparation
Chicken egg-white lysozyme (gene accession code NM_205281) and bovine
pancreatic trypsin (gene accession code NM_001113727) were purchased as lyophilized
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powders from Sigma-Aldrich (St Louis, Missouri, USA) and AppliChem (Darmstadt,
Germany), respectively. Lysozyme (140 mg/ml) was resuspended in 50 mM sodium
acetate pH 4.5, whereas trypsin (80 mg/ml) was resuspended in 25 mM HEPES pH 7.0,
10 mM calcium chloride, 10 mg/ml benzamidine hydrochloride. A polypeptide consisting
of residues 94-291 of human p53 (gene accession code NM_000546) fused to residues
322-356 was expressed in Escherichia coli. The cells were lysed in a buffer consisting of
25 mM bis-tris propane (BTP) pH 6.8, 250 mM NaCl, 5 mM DTT and protease inhibitors
and the polypeptide was purified by cation exchange (Sepharose SP column; Pharmacia
Biotech, Uppsala, Sweden) and gel filtration (Superdex 200 column; Pharmacia Biotech).
After purification, the p53 protein was concentrated to 8 mg/ml in 25 mM bis-tris
propane pH 6.8, 50 mM NaCl, 5 mM DTT buffer. A polypeptide corresponding to amino
acids 1699-1814 of Arabidopsis thaliana Morpheus’ molecule 1 (MOM1; gene accession
code NM_179277) was also expressed in E. coli. The cells were lysed in buffer
consisting of 25 mM MES pH 6.0, 200 mM NaCl, 5 mM DTT and protease inhibitors; the
polypeptide was then purified by cation exchange (Sepharose SP column; Pharmacia
Biotech) and gel filtration (Superdex 200 column; Pharmacia Biotech) and concentrated
to 6 mg/ml in 25 mM MES pH 6.0, 150 mM NaCl, 5 mM DTT .

Protein crystallization
Proteins were crystallized either under standard hanging-drop vapor-diffusion
conditions in 48-well plates (Hampton Research, Aliso Viejo, California, USA) or in
COP cards using a dedicated microfluidics instrument (SpinX Technologies, Meyrin,
Switzerland). Lysozyme and trypsin were crystallized at room temperature and the
- 109 -

MOM1 fragment was crystallized at 277 K; human p53 was crystallized in the presence
of double-stranded DNA containing a high-affinity p53 DNA-binding site at 277 K at a
1:1.1 protein:DNA molar ratio. The double-stranded DNA was prepared by annealing the
following two oligonucleotides: 5’-AGAC GGG CATG TCT GGG CATG TCT CA-3’
and 5’-CTTG AGA CATG CCC AGA CATG CCC GT-3’. The precipitant solutions
used for crystallization were as follows: 4-30%(w/v) PME 5000, 1 M sodium chloride, 50
mM sodium acetate pH 4.5 for lysozyme; 30%(w/v) PEG 8000, 0.2 M ammonium
sulfate, 0.1 M sodium cacodylate pH 6.5 for trypsin; Index Screen No. 87 [20%(w/v)
PEG 3350, 0.2 M sodium malonate pH 7.0], Index Screen No. 89 [15%(w/v) PEG 3350,
0.1 M succinic acid pH 7.0] and Index Screen No. 90 [20%(w/v) PEG 3350, 0.2 M
sodium formate pH 7.0] (Hampton Research, CA, USA) for p53-DNA complexes and
0.2-0.4 M magnesium formate, 0.1 M Tris pH 8.5 for MOM1.

Data collection and processing
All data sets were collected on the FIP-BM30A beam line of the ESRF (Grenoble,
France; Roth et al. 2002). For in situ data collection, COP cards containing lysozyme
crystals were positioned in the path of the X-ray beam using a robotic arm, as described
previously (Jacquamet et al. 2004). Reflection data were indexed, integrated and scaled
using the program XDS (Kabsch 1993). The crystals formed in space group P43212, with
unit-cell parameters a = 77.1, b = 77.1, c = 37.2 Å, and contained one molecule in the
asymmetric unit. The coordinates of lysozyme (PDB code: 1iee) were used as input for
refinement, which was performed with the program CNS (Brünger et al. 1998). The
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electron-density maps and the protein atoms were visualized using the program O (Jones
et al. 1991).

Figure 4.3

Establishment of protein crystallization protocols in COP microfluidics cards. (a) Image of a
microfluidics card. Samples are loaded at the top and then move through the card by centrifugal force. (b)
Diagram of a cross section of a COP card illustrating how defined volumes of liquid are ‘pipetted’. Liquid
is contained within a chamber by the thin membrane separating the chambers from the vertical channels
(1), holes are opened in the thin membrane by a laser (yellow arrowheads; 2) and the liquid above the hole
moves through the vertical channel to a chamber ‘below’ (3). The volume transferred is determined by the
vertical position of the hole in the thin membrane. (c) Vapor-diffusion protocol. Equal volumes of protein
and precipitant were dispensed into one chamber and precipitant only was dispensed into an adjacent
chamber. Holes were then opened in the thin membrane above the liquid level to establish connections
between the chambers, according to the paths shown by the red lines. (d) Changes in liquid volume
consistent with vapor diffusion after 6 days of incubation of the COP card at room temperature. The level
of liquid at day 0 is indicated by the red lines. The level of liquid in the ‘precipitant’ chamber increases,
while the level of liquid in the ‘protein-precipitant’ chamber decreases. In this example, the protein was
lysozyme and the black arrow indicates a crystal that formed within 6 days. (e) Free-interface diffusion
protocol. Protein and precipitant were dispensed into two adjacent chambers. Holes were then opened in the
thin membrane below the liquid level to establish connections between the chambers, according to the
paths shown by the red lines. All images of individual chambers were acquired using the camera built into
the microfluidics instrument. Images showing multiple chambers were assembled from images acquired
using an inverted microscope and a low-magnification lens (Zeiss, Gottingen, Germany).
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Results
Principle of operation of a cyclic olefin homopolymer-based microfluidics device
Most microfluidics devices use either silicone elastomers or rigid COPs as the
chip material. The vapor-permeability of COPs is several orders of magnitude lower than
that of silicone (Mair et al. 2006), which in theory should make COPs better suited for
traditional methods of protein crystallization, where no vapor exchange of the
crystallization chamber with the outside environment is desirable (Chayen & Saridakis
2008). To explore the potential of COPs in protein crystallization, we used a
microfluidics instrument in which the movement and mixing of liquids in COP chips is
controlled by centrifugal forces (SpinX Technologies, Meyrin, Switzerland). In this
particular system, the microfluidics chip takes the form of a card made of two COP
pieces bonded together via a thin COP membrane (Figs. 4.3a & 4.3b). One side of the
COP card has chambers arranged in rows and horizontal channels. The chambers have
dimensions of 2 x 0.7 x 0.25 mm, corresponding to a volume of about 320 nl. The other
side of the COP card contains vertical channels. Connections between chambers and
vertical channels, and between vertical and horizontal channels are made by a laser that
opens holes in the thin membrane that separates the two sides of the card. Depending on
where the openings are made, specified volumes of liquid can be directed from a chamber
in one row to a chamber in the row ‘below’ (Fig. 4.3b). The movement of the liquids is
driven by the centrifugal force generated as the cards are spinning in the instrument.
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Establishment of microbatch, vapor-diffusion and free-interface diffusion
crystallization protocols.
The COP cards used in this study permit the establishment of several protocols for
protein crystallization. In the traditional microbatch protocol, protein and precipitant
solutions are mixed and the resulting aqueous solution is overlaid with low-density
paraffin oil, which is impermeable to water vapor (Chayen & Saridakis 2008). This
protocol can easily be established in the COP cards simply by directing appropriate
volumes of protein and precipitant solutions to the same chamber. Even though the holes
that are opened to direct the liquids in the chambers are never sealed, the very small
cross-sectional area of the channels results in very small evaporation rates; even after
several months the volume of liquid in the chambers does not change appreciably (data
not shown).

The second protocol that we established in the COP cards was vapor diffusion
(Chayen & Saridakis 2008). Protein and precipitant solutions were mixed in one
chamber, while an adjacent chamber was filled with precipitant solution only.
Connections were then established between these two chambers by opening holes above
the liquid level (Fig. 4.3c). When the COP cards were incubated at room temperature,
changes in the volumes of the liquids in the two chambers consistent with vapor diffusion
were observed within 6 days (Fig. 4.3d). However, at 277 K vapor diffusion proceeded
more slowly, as would be expected.
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The third protocol established in the COP cards was free-interface diffusion
(Chayen & Saridakis 2008). One chamber was filled with protein solution, while an
adjacent chamber was filled with precipitant solution. Connections between these two
chambers were again established, but in this case by opening holes below the liquid level
(Fig. 4.3e). For both the vapor-diffusion and free-interface diffusion protocols, the rate of
diffusion can be controlled by opening a larger or smaller number of connections
between the chambers (between one and five for vapor diffusion and between one and
three for free-interface diffusion).

Protein crystallization in COP cards
The suitability of new protein crystallization platforms is usually documented in
the literature using proteins that crystallize readily. Following this tradition, we used the
microbatch method to monitor the crystallization of chicken egg-white lysozyme and
bovine pancreatic trypsin in the COP cards. For both proteins crystallization was
performed in final volumes of 200 nl at room temperature. For lysozyme we implemented
a grid of final protein concentrations ranging from 20 to 60 mg/ml and PME 5,000
concentrations ranging from 4 to 30%. Crystals formed at protein concentrations of
between 22 and 30 mg/ml and at PME concentrations of between 18 and 30% (Fig. 4.4a).
For trypsin, the final protein concentrations ranged from 15 to 40 mg/ml and PEG 8,000
was used at a concentration of 30%. Crystals formed at protein concentrations of between
25 and 30 mg/ml (Fig. 4.4a). Lysozyme and trypsin also crystallized in the COP cards
using the vapor-diffusion and free-interface diffusion protocols (Fig. 4.3d and data not
shown).
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Figure 4.4

Protein crystallization in COP cards. (a) Lysozyme and trypsin crystals formed in COP cards using the
microbatch protocol. (b) Crystallization of human p53-DNA complexes in COP cards using the microbatch
and vapor-diffusion protocols and three precipitant solutions (Index Screen Nos. 87, 89 and 90). Each
condition was performed in triplicate or quadriplicate (numbered 1-3 and 1-4, respectively) and the results
are color-coded as follows: protein precipitate, grey; protein crystals, purple; clear solution, white.
Examples of the crystals that were formed using each protocol are shown. (c) Crystallization of A. thaliana
MOM1 in COP cards using the microbatch, vapor-diffusion and free-interface diffusion protocols. Each
condition was performed in quadriplicate (numbered 1-4) using magnesium formate as the precipitant at the
indicated concentrations. The results are color-coded as described for the p53-DNA complexes in (b). For
the free-interface diffusion protocol, both the protein (left half) and the precipitant (right half) chambers
were scored, since over time both chambers will contain both protein and precipitant. Examples of the
crystals formed using each protocol are shown. All images were acquired using the camera built into the
microfluidics instrument. The width of the chambers is 750 µm. The detailed compositions of the
precipitant solutions are described in the experimental procedures section.
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Because lysozyme and trypsin crystallize readily, we then studied other proteins
that might be more difficult to crystallize. We first focused on the human p53 tumorsuppressor protein. The gene encoding p53 is the most frequently mutated gene in human
cancer (Hollstein et al. 1991). The p53 protein contains a transactivation domain, a
sequence-specific DNA-binding domain (residues 94-289) and a homotetramerization
domain (residues 325-356). The latter two domains are independently folding domains
and their three-dimensional structures have been determined (Cho et al. 1994; Jeffrey et
al. 1995); however, no structure is available of a p53 polypeptide containing both of these
domains. Polypeptides containing more than one independently folding domain are
generally not easy to crystallize, as the linker between the domains imparts
conformational flexibility, which inhibits crystallization. We engineered a p53
polypeptide containing residues 94-291 of human p53 fused to residues 322-356. Based
on the boundaries of the crystallized DNA-binding and tetramerization domains, this
polypeptide has a flexible interdomain linker that is five amino acids long. Two aminoacid substitutions were introduced in the tetramerization domain of this polypeptide to
convert it into a dimerization domain (Davison et al. 2001). In addition, 13 amino-acid
substitutions were introduced in the DNA-binding domain in order to increase its melting
temperature and solubility (TJP and TDH, chapters 1-3). The resulting polypeptide
retained its sequence-specific DNA-binding activity. We therefore examined its ability to
crystallize in complex with an oligonucleotide containing a p53 DNA-binding site using
the microbatch and vapor-diffusion protocols and three different crystallization buffers.
Crystals formed with both protocols after 6 days of incubation at 277 K in the COP cards.
Tabulating the results shows that vapor diffusion yielded p53-DNA crystals with all three
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crystallization buffers, whereas with the microbatch method p53-DNA crystals were only
obtained with two of the three crystallization buffers (Fig. 4.4b). The p53 polypeptideDNA complex also crystallized using the hanging-drop vapor-diffusion method in 48well plates under the same crystallization conditions (TJP and TDH, chapters 1-3).

As a second protein that had not been previously crystallized, we focused on A.
thaliana Morpheus’ molecule 1 (MOM1), a protein that regulates chromatin structure and
gene expression without affecting DNA and histone methylation (Amedeo et al. 2000;
Habu et al. 2006). An evolutionarily and functionally conserved domain of MOM1 maps
to a region approximately between amino acids 1734 and 1815 (Caikovski et al. 2008).
We expressed various MOM1 fragments in E. coli and found by systematic deletion
analysis that a MOM1 polypeptide corresponding to residues 1699-1814 of the fulllength protein is soluble. This polypeptide was purified to homogeneity and examined for
crystallization at 277 K by the microbatch, vapor-diffusion and free-interface diffusion
methods in COP cards, varying the concentration of the precipitant from 0.2 to 0.4 M.
The best results were achieved using the vapor-diffusion protocol (Fig. 4.4c). This
fragment of MOM1 also crystallized using the hanging-drop vapor-diffusion method in
48-well plates under the same crystallization conditions (data not shown).

Collection of X-ray diffraction data from crystals in COP cards
The crystals that formed in the COP cards could easily be harvested after opening
the cards; these crystals could then be cryopreserved, mounted on cryoloops and frozen,
thus allowing complete X-ray diffraction data sets to be collected. When there is a need
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to examine many crystals, the ability to collect X-ray diffraction data while the crystals
are still in the COP card could allow significant savings in time and effort. A robotic arm
that is able to position crystallization multi-well plates in front of an X-ray beam has
already been described (Jacquamet et al. 2004). By comparison to multi-well plates, the
geometry of the COP cards used in this study appears to be well suited for in situ X-ray
diffraction analysis.

To examine whether we could actually collect X-ray diffraction data, COP cards
containing p53-DNA, MOM1 and lysozyme crystals were positioned by the robotic arm
in the path of the X-ray beam. The robotic arm was programmed to rotate the card during
data collection, allowing oscillation of the crystal over a 1° range. For all crystals, we
could observe diffraction patterns that were of sufficient quality to allow indexing (Figs.
3a and 3b and data not shown). The p53-DNA and MOM1 crystals exposed to X-rays in
situ diffracted to a somewhat lower resolution level than crystals that had been harvested
from the cards, cryopreserved, mounted on loops and frozen. For example, cryopreserved
p53-DNA crystals diffracted to 3 Å resolution, whereas the same crystals in COP cards
diffracted to about 4.5 Å. We attribute this difference to the temperature shift that
occurred during data collection, since the p53-DNA and MOM1 crystals formed at 277
K, whereas the in situ data collection was performed at room temperature. In contrast, the
lysozyme crystals, which were formed at room temperature, diffracted to a resolution of
1.5 Å when exposed to X-rays through the COP cards (Fig. 4.5b).
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Figure 4.5

Collection of X-ray diffraction data sets from crystals in COP cards. (a) X-ray diffraction
pattern of a p53-DNA crystal exposed to the X-ray beam while still in the COP card. The
oscillation range was 1°. (b) X-ray diffraction patterns of a lysozyme crystal exposed to the X-ray
beam while still in the COP card. Two regions of the diffraction image are shown, one
encompassing a resolution range lower then 3.5 Å (left) and the other a region from 1.9 to 1.6 Å
resolution (right). The oscillation range was 1°. Note that COP absorbs X-rays in the resolution
range between 5.4 and 5.1 Å. (c) Part of the lysozyme electron-density map contoured at 1.9σ for
the 2Fo-Fc map (olive green) and at 3σ for the Fo-Fc map (dark blue, positive values; orange,
negative value). The map shows residues Trp46, Val47 and Ile116 and part of the side chain of
Trp126.
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To evaluate the quality of the data collected from crystals in COP cards, we
obtained 45 consecutive X-ray diffraction images, each over an oscillation range of 1°,
from a lysozyme crystal. The COP absorbed X-rays, but only over a narrow resolution
range from 5.4 to 5.1 Å (Fig. 4.5b). In lower and higher resolution ranges the COP did
not compromise data collection, as evidenced both by observing the X-ray diffraction
images (Fig. 4.5b) and also from the statistics describing the integration of the X-ray
reflection intensities over the 45 frames of collected data (Table 4.1). Data in the
resolution range 40-1.5 Å were used for refinement using a previously determined
lysozyme structure as input (Sauter et al. 2001). The refined structure had excellent
statistics (Table 4.1) and well resolved electron-density maps (Fig. 4.5c), especially
considering that data from only 45 frames were used for refinement.

Discussion
The need to optimize the efficiency with which X-ray diffraction-quality protein
crystals are produced has led to the development of methods for automating the setup of
protein crystallization reactions and for reducing the amount of protein required (Chayen
& Saridakis 2008). Most microfluidics systems utilize silicone elastomers as the chip
material and have achieved exceptional economies in the amount of protein consumed: in
one system, 10 nl protein solution is required per crystallization condition. However,
silicone elastomers are also highly permeable to water vapor and this limits their utility to
proteins that crystallize within a few days (Hansen & Quake 2003). Materials that are
impermeable to water vapor have also been explored in protein crystallography at a
miniaturized scale, but in general these systems require significant human intervention or
are compatible with only one method of protein crystallization, usually free-interface
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diffusion (Ng et al. 2003 & 2008). This is because materials that are impermeable to
water vapor, such as COPs, are rigid. Unlike chips made of silicone elastomers, in which
liquids can be moved by deforming the chip itself, the movement of nanoliter volumes of
liquid in rigid chips is not a trivial task. The system we used here solves the ‘pipetting’
problem by opening holes at defined positions to control the volume of liquid to be
dispensed and by spinning the cards to move the liquids by centrifugal force. Once the
problem of pipetting had been addressed, COP-based microfluidic chips could easily be
adapted for protein crystallization using several well established protocols, as
demonstrated here.

COP cards may overcome some of the limitations inherent in microfluidics chips
made of silicon elastomers. The first is the issue of water-vapor permeability. In COP
cards there is very little water evaporation even after months of incubation at room
temperature. A second limitation of silicone elastomer chips is that crystals cannot
readily be isolated for X-ray diffraction analysis. This means that new protein crystals
have to be obtained using traditional protein crystallization methods. In some cases, it is
not straightforward to translate the conditions under which proteins crystallize by freeinterface diffusion in the microfluidics chip to conditions under which they will
crystallize by the traditional hanging-drop vapor-diffusion method in multi-well plates.
COP cards overcome this limitation, because the volume of the chambers (320 nl) allows
even relatively large protein crystals to form; these crystals can then be easily harvested
from the COP cards for the collection of X-ray diffraction data sets. Alternatively, limited
diffraction data can also be collected from the crystals in situ, because COPs absorb X- 121 -

rays only within a defined resolution range of about 5.4-5.1 Å (Fig. 4.5a; Ng et al. 2008).
In exceptional cases, as illustrated here with the example of lysozyme, entire X-ray
diffraction data sets can be collected. However, this was possible with lysozyme because
sufficient data could be collected from just 45 images and because the lysozyme crystals
did not suffer extensive radiation damage, even though the COP card was at room
temperature during data collection. In the case of the MOM1 and p53-DNA crystals only
about ten images could be collected per crystal.

COP-based microfluidics systems compare favorably with automated pipetting
systems that set up crystallization reactions in multi-well plates (Chayen & Saridakis
2008). In the latter systems all pipetting steps are performed in an open environment,
which allows water to evaporate while the drops are being set up, especially when the
volume of these drops is in the nanoliter range. In contrast, in microfluidics systems all
pipetting steps are performed in a closed environment, thus eliminating the problem of
water evaporation during setup. Further, the COP cards described here can be stacked in
holders, so that their inlets adopt the same geometry as the wells of 384-well plates. Thus,
the initial loading of protein samples and precipitant solutions in the COP cards can be
performed with standard pipetting robots. A final advantage of the COP cards is the
geometry of their chambers, which allows easy visualization of their contents. Thus,
protein crystals can be easily identified, a task that is much harder to accomplish with
crystals formed in round hanging or sitting drops. Based on our experience, we anticipate
that COP-based microfluidics will play an important role in protein crystallization efforts
in the near future.
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Table 4.1
Data collection and refinement statistics for a lysozyme data set, comprised of 45
consecutive frames, each having an oscillation range of 1º. Values in parenthesis are for
the highest resolution shell.
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Introduction
Protein design algorithms identify protein sequences consistent with a particular
fold, and often simultaneously quantify the many subtle, non-covalent interactions that
govern protein folding, stability and function. Efforts in protein design stand to advance
our knowledge of protein folding and function and also can identify new proteins with
applications to biotechnology, catalysis, and materials research. Here, recent
developments in protein design are discussed with a focus on features common to many
of the computational design methods. A sampling of studies is presented in which
computationally designed proteins have been experimentally realized; exemplifying what
may be learned and accomplished with protein design.

Advances in protein design inform our understanding of the molecular basis of
life processes and provide tools for new applications in biotechnology. Proteins are
molecular workhorses, and they play central roles in cellular functions such as
cytoskeleton assembly, transport, signaling, bioenergetics, metabolism and gene
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regulation. Structural proteins (e.g. actin, microtubules, collagen) are vital for
maintaining the morphological properties of organelles, cells, and tissues. Enzymes
catalyze reactions selectively and efficiently, and protein-based hormones and receptors
are critical for inter- and intracellular communication. Thus proteins exhibit a multitude
of functions, and this versatility can potentially be leveraged. Polypeptide synthesis and
protein overexpression are often straightforward, facilitating the realization of natural and
non-natural sequences. Designed proteins obtained using such methods provide systems
for critically testing our present understanding of the molecular features most relevant to
protein folding, stability, and function. In addition, novel proteins can provide new
biotechnological applications, such as selective catalysts and sensors.

Protein folding enables function to be encoded in sequence. Most polymers can
take on a large number of conformations in dilute solution. Folding, however, implies
that a protein has a well-defined three-dimensional structure under physiological
conditions, a structure that is usually requisite for the protein’s function. Anfinsen (1)
showed that ribonuclease could be denatured and refolded without loss of enzymatic
activity. This led to the general acceptance of the ‘‘thermodynamic hypothesis,’’ which
states that ‘‘the three-dimensional structure of a native protein in its normal physiological
milieu . . . is the one in which the Gibbs free energy of the whole system is lowest; that is,
that the native conformation is determined by the totality of inter-atomic interactions and
hence by the amino acid sequence, in a given environment.’’ (1) While there are certainly
exceptions to this rule, the three-dimensional structures of most proteins are encoded in
their amino acid sequences. Due to the complexity of proteins and the many possible
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compact structures to which they can fold, protein structure prediction from amino acid
sequence remains one of the fundamental open problems of molecular science, but much
progress has been made in recent years (2). In addition, protein folding dynamics remains
an active area of research. Such studies are motivated in part by Levinthal’s paradox (3):
how is it that proteins having exponentially large numbers of conformations are able to
fold on timescales of minutes or less? There has been much recent development of
mechanisms and models that quantitatively describe folding kinetics (4–9), including the
energy landscape theory of protein folding (10–20).

Proteins are involved in an increasing number of industrial applications such as
chemical production, pharmaceuticals and fine chemicals, pulp and paper, food, textiles,
and energy (21–23). Exploiting the structural and functional features of proteins stands
also to give rise to new biomaterials. Peptides may respond structurally and functionally
to environmental changes in pH, temperature, pressure, salt concentration, UV or visible
light exposure. Such ‘‘smart-material’’ peptides may be used as building blocks for
filaments and fibrils, scaffolds, hydrogels, and surfactants (24). These protein and
peptide-based systems have applications in tissue and surface engineering, as drug or cell
carriers, for patterning of targeted cell growth, as miniaturized solar cells or in optical and
electronic devices (25–31). Commercial biocatalysts have been obtained from natural
enzymes or via the directed mutagenesis of such enzymes (22). Advances in genomics,
directed evolution, and bioinformatics (21) have led to the development of recombinant
enzymes and biomolecular pathways (32–36). For example, a recently developed
industrial process uses a re-engineered and extended E. coli pathway to convert D- 128 -

glucose into the polymer precursor 1,3-propanediol within a single organism (36); such
efforts illustrate the ‘‘green chemistry’’ (37) possible with biomolecular systems. Protein
design efforts have also led to the discovery of new sensors and enzymes (38–42).
Therapeutic proteins may affect intercellular communication and the physiology of the
human immune system, and there remains enormous potential for the development of
therapeutic agents for autoimmune diseases, cancer, infections, and inflammatory
diseases (43–45). Thus, the ability to reliably design structure and function into proteins
stands to inform our basic understanding of biomolecular function and can lead to a wide
variety of biotechnological and biomedical applications.

Although realizing a particular protein sequence may be straightforward
(problems with protein synthesis or expression notwithstanding), protein design is nontrivial. Proteins are large macromolecules that range in length from tens to tens of
thousands of amino acid residues. The number of possible sequences is exponentially
large. For a protein with 100 variable residues, there are 20100 possible sequences. In
addition, many amino acids have multiple possible side-chain conformations, further
increasing the complexity of the search for sequences consistent with a desired structure.
Non-covalent interactions such as van der Waals forces, hydrogen bonding, salt bridges,
and solvation effects stabilize the protein structure. Many of these interactions are
coupled and interdependent in protein structures, and their parameterization in the form
of a molecular energy function is necessarily approximate. As a result, accurate
determination of the stabilities of proteins using molecular simulations is often
impractical and remains computationally intensive (46, 47). The difficulties of protein
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structure prediction suggest that the mapping from sequence to structure is subtle (2, 48).
Ultimately, the best assessment of the quality of a particular protein design effort is to
create and study the resulting sequences. This validation of design is typically more
experimentally intensive than structure prediction, where thousands of structures already
in the protein structural database may serve as test cases.

Empirical approaches to protein design
Hierarchical protein design
Early work in protein design, also referred to as the inverse folding problem (49),
applied knowledge gleaned from biochemical experiments and structural databases to the
construction of small proteins. Often a hierarchical approach was used, where sequences
likely to form particular substructures or secondary structures were assembled with a
particular tertiary structure in mind (50, 51). Principles guiding the design process
included the trend to have largely hydrophobic amino acids within the interior of the
folded protein (52, 53), and the propensities of individual amino acids to appear in
particular secondary structures such as α-helices or β-sheets (54–56). Early design efforts
often focused on α-helical proteins and did not necessarily use all 20 amino acids (57–
61). Electrostatic interactions were found to play a smaller role in determining topology
than the relative positioning of interior hydrophobic residues (62). Via such qualitative
protein design, it was found that two proteins having 50% or greater sequence identity
could have different folds (63, 64).

Helical proteins have been targets of many design efforts. Designed, α-helical
peptides have been constructed to solubilize membrane proteins (65) and to retard the
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HIV-1 infection of human T cells (66). Rational, structure-informed de novo design based
on α-helical bundles has been used to design proteins that bind metal ions such as zinc
(67–70), iron (71,72), copper (73), cadmium (74), mercury (75), and calcium (68), as well
as proteins that bind metal-containing cofactors such as heme (76–78). The B1 domain of
Streptococcal IgG-binding protein G was also used as a template for designing a zinc
binding protein (79). A four-helix peptide (maquette) was shown to efficiently
incorporate an iron-sulfur cluster as a tetramer and exhibit properties typical of natural
ferredoxins (80). While successfully realizing some of the targeted functionality and
structure, often these designed proteins did not have well-defined tertiary structures.
These proteins exhibited more mobility in the interior than native proteins, and in many
cases had the features of a molten-globule-like state (50,51,81). The approaches used
often consider the secondary structure propensities of the amino acids and the appropriate
patterning of hydrophobic residues for a particular tertiary structure. These methods do
not typically consider, however, the complementarities of steric and other inter-atomic
interactions (e.g. hydrogen bonding) observed in the structures of natural proteins. As a
result, such designed proteins may be compact and have a large degree of the appropriate
secondary structure but may not form well-defined tertiary structures.

Combinatorial methods
Generating and screening combinatorial protein libraries for variants with new or
improved function or stability has become an established method for protein engineering
(82). Diverse, partially random libraries are experimentally obtained by using degenerate
oligonucleotides during gene assembly (83), by performing the polymerase chain reaction
under mutagenic conditions (84), or by using DNA shuffling (85,86). In directed
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evolution protocols, these methods are used as part of an iterative mutation-selectionenrichment cycle. The use of such protocols has been spurred by the development of
high-throughput assays and the availability of various library platforms for expressing
and displaying proteins. Phage display libraries are popular tools in directed evolution
(87), but bacterial (88), yeast (89), and ribosomal (90) display systems are also widely
used.

Combinatorial libraries have been used to examine protein folding and stability
(91–94). Proper patterning of hydrophobicity was found to be a key determinant of
whether variants of λ repressor are compatible with the wild-type fold (91), and multiple
substitutions in the helix-turn-helix region of λ repressor are largely additive with regard
to their impact on folded state stability of the protein (92). Combinatorial libraries have
been constructed to investigate the utility of binary patterning of hydrophobic and
hydrophilic amino acids in a manner consistent with predetermined secondary and
tertiary structures. Such efforts have identified native-like protein structures that fold into
well-ordered four-helix bundles and beta proteins (95–102).

Directed evolution
Directed evolution and related methods have identified proteins with a variety of
functionally important properties. Partial randomization of sequence followed by
selection is a powerful, evolutionarily inspired, tool for introducing new function into
proteins. Through directed evolution, protein function can be engineered if a suitable
selection assay is available. Applications include the ability to maintain binding affinity
when removing segments non-essential for a protein (103), improve binding affinity
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(104), evolve RNA polymerase from DNA polymerase (105), endow an antibody with
catalytic activity (106–109), and accelerate the maturation of a red fluorescent protein
(110). Retroviruses have been reengineered to greatly enhance their spreading efficiency
through human fibrosarcoma cells for possible use in gene therapy (111). New
biosynthetic pathways have been engineered in E. coli for the production of non-native
carotenoids (33), and a new genetic circuit has been evolved (112). These studies show
that directed evolution methods have a broad reach into exploring and tailoring the
functions of proteins. Complex functional properties may be engineered without
requiring a detailed molecular understanding as to how these are achieved. The
development of a selection method yielding proteins with the desired properties is one of
the key features of such methods. The particular selection strategy usually is dependent
on the desired function. Affinity columns with immobilized ligands are useful for
selecting tight binding proteins. For more subtle and complex functions, such as catalysis,
more sophisticated selections must be used and often are tied to cell (or phage) viability.
In addition, the targeted functions must be accessible via evolution methods where
usually only a few mutations are accumulated per generation.

Intrinsic limitations
Despite some of the striking successes of hierarchical protein design,
combinatorial, and directed evolution methods, these techniques are not without
shortcomings. Optimizing the many interactions within a particular folded state structure
can be difficult by inspection alone and, as mentioned, many designed proteins do not
have well-defined tertiary or oligomeric structures (50). While combinatorial methods
can address large numbers of sequences, 103 to 106 for high-throughput screening and
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1012 for display methods, these numbers are far smaller than the number of possible
sequences. Thus, such approaches may miss proteins with the desired properties and
structures. Directed evolution methods often require a well-folded protein as a starting
point for evolving new structures and functions (82,113), and as a result these methods
are usually limited to the redesign of natural proteins. DNA shuffling protocols often
require high degrees of sequence homology (60%) for appreciable rates of recombination
(114). Several approaches have been developed to overcome this limitation (115,116),
but functional hybrids often become more sparse.

It is of interest to explore sequence and structure more extensively and to arrive at
proteins having novel structures that differ from natural proteins. The development of
methods that allow simultaneous consideration of the myriad of interactions and levels of
structure present in proteins quantitatively permit detailed predictions about structure,
stability, and sequence variability that may be rigorously tested. Such studies can further
our physical chemical understanding of the stability, folding, functions, and dynamics of
proteins.

Computational approaches to structured-based design
Computational protein design involves the search for sequences compatible with a
given fold with the aid of computer modeling methods to address and quantify protein
structure and amino acid variability. The template fold is often represented in atomistic
detail and, as opposed to more qualitative design methods, inter-atomic interactions
involving variable residues are explicitly quantified and evaluated. Computational design
involves simultaneous consideration of multiple interacting residues. A complete
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enumeration of all possible sequences, however, is only possible when only a few
residues are varied. As a result, powerful methods for sampling or characterizing
sequences consistent with a particular fold must be employed when large numbers of
residues are varied. Such methods may be used to design particular sequences or to guide
the construction of combinatorial libraries and directed evolution experiments.

Although there are different approaches to computational protein design, most
make use of similar methods for specifying the properties of the target protein and for
quantifying the physical and chemical interactions that stabilize structure and confer
functionality. A target polypeptide backbone structure serves as a template to guide the
selection of sequences. At each variable position, residue degrees of freedom include the
allowed amino acids and their side-chain conformations, which are usually treated as a
discrete set of rotamer states. The interactions between all residues are quantified through
energy or scoring functions, which often contain terms representing such effects as
hydrogen bonding, van der Waals interactions, electrostatic interactions, and solvation.
Energy functions are often used to arrive at foldability criteria, which take unfolded states
into account and quantify the degree to which a particular sequence is likely to fold into
the target structure. There have been several studies that examine protein design and
variability through the use of sequence alignment methods (117,118), but herein we focus
on the design of structure and sequence based upon the physico-chemical properties of
the amino acids.
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Backbone structure and sequence constraints
A backbone structure specifies the coordinates of the main chain atoms, the
bonded series of carbon, nitrogen, and oxygen atoms associated with each amino acid
residue in a protein. This structure serves as the target for computational protein design.
The backbone coordinates may be obtained from a known structure (119) or from
modeling novel structures (120–123). Naturally occurring protein structures are often
used, as many such structures support a wide variety of biological functions, e.g. the TIM
barrel superfamily (124). This specification of the template structure partially defines the
design problem, reduces the number of degrees of freedom, and avoids some of the
difficulties of structure prediction. The fixed-backbone approximation has been
successfully used in computational protein design, but flexibility of the main chain may
be included to accommodate backbone readjustments that result from changes in
sequence (125,126). While flexible-backbone protein design is more computationally
intensive than fixed-backbone design, recent studies have shown that such methods can
yield well-structured proteins (121,127).

Residue degrees of freedom
Since the backbone structure is largely predetermined, the degrees of freedom in
protein design mainly involve the distinguishable states of the amino acid residues. These
residue degrees of freedom include both the allowed amino acids at each variable
position as well as the side-chain conformations of these amino acids. The naturally
occurring 20 amino acids are most often used, but this number may be reduced, as in the
patterning of residue properties (95,128), or expanded with the inclusion of non-natural
amino acids. Most amino acids may assume multiple, distinguishable side-chain
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conformations (rotamers) (129–131). Libraries of allowed rotamer states reduce the
complexity of the side-chain states to a discrete set of side-chain conformations. Such
rotamer states have been statistically deduced from protein structure databases, and
usually are consistent with bond and torsion angles corresponding to local energy minima
(131). Depending on the size and topology of an amino acid, the number of possible
rotamers can range from one (glycine and alanine) to as many as 80–100 (or more) for
larger side chains. Rotamer libraries have been developed that are backbone-independent
or are sensitive to the local backbone and secondary structure (129,132–143). Atomistic
representations of side chains and their conformations enable the design of well-packed
protein interiors. Rotamer libraries may also be developed for non-biological amino acids
by identifying local torsional minima using a molecular mechanics force field (144,145).

In order to make the design of larger proteins more tractable, approaches have
been introduced that reduce the residue degrees of freedom. Such methods include
reducing the number of allowed amino acids, often in a patterned or site specific manner
(95,128), or simplifying the representation of the amino acid side chains. Studies with
limited numbers of amino acids can suggest the minimal set of amino acids necessary for
certain structures. For example, a 108-residue, four-helix bundle structure has been
constructed using only 7 of the 20 possible amino acids (146). Similarly, only five amino
acids have been used to reconstruct large portions of an SH3 domain structure (147).
Simplified models of side chains have been successfully used in the design of proteins,
using an energy landscape approach (148).
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Energy function
Quantification of intra- and intermolecular interactions is critical to computational
protein design. The energy functions used in protein design are often similar to those
used in molecular modeling and simulation (149), such as the atom-based molecular
mechanics force fields Amber (150), CHARMm (151), and Gromos (152). Energy
functions like these may comprise contributions arising from deformation of bond
lengths, bond angles, and dihedral angles, as well as non-bonding interactions arising
from van der Waals, electrostatic, and hydrogen bonding interactions. In protein design,
the non-bonding interaction terms often dominate, since the approximation of discrete
rotamer states and the rigid backbone largely fixes bond lengths and bond angles. So as
not to overestimate the repulsive energies of van der Waals interactions, which may often
be readily alleviated by slight backbone adjustments, the van der Waals radii are often
uniformly diminished using ad hoc scaling factors (153,154).

In addition to atom-based physico-chemical energy functions, effective energies
quantifying the structural propensities of the amino acids can be included using scoring
functions. Statistical analysis of protein structure databases reveals that the relative
frequencies of amino acids may depend on the local structural environment, and
experimental studies have quantified the degree to which different amino acids
destabilize secondary structures (55,56,149,155–157). Such experimental or database
studies can yield effective scoring functions. The individual terms in the energy function
may be weighted in order to combine molecular mechanics potentials and empirical
scoring functions. This weighting may be subtle, and is often accomplished by
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comparison with known sequences and structures (158), or with training sets of
randomized sequences (159).

Solvation
Solvation and hydrophobic effects play critical roles in protein folding (160).
Hydrophobic residues tend to be sequestered in the interior of the protein, while
hydrophilic residues are found more frequently on the exterior. In protein design,
evaluating free energies of solvation through explicit modeling of solvent is
computationally prohibitive. Solvation effects, and indirectly the hydrophobic effect, are
often approximated using energies expressed in terms of the solvent accessible area of
each atom. The corresponding free energy cost per unit area exposed is often
parameterized using a structural protein database, or known free energies of transfer
between water and either a vacuum or organic phase (161–164). Although much simpler
than the explicit modeling of solvent, calculating such surface areas may still be
computationally expensive (165), particularly since these areas are sequence dependent.
As an alternative method, a statistical potential may be introduced that quantifies the
propensities of the amino acids to reside in buried and exposed local environments (166).

Foldability criteria and negative design
A designed protein should fold into a unique three-dimensional structure defined
as the ‘‘native’’ state. Non-target conformations of the protein should not be appreciably
populated. In order to achieve this, the conformational energy landscape should have
‘‘funnel’’ shape, with the folded state at the free-energy minimum (11–13,167). Including
information about stabilization with respect to misfolded structures is often referred to as
‘‘negative design’’ (60). In order to achieve structural specificity, the target structure
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should correspond to an energetic ground state that has an energy gap separating the
target from other competing structures (13,168,169).

Many approaches to computational protein design focus on energy minimization
(through variation of sequence) as the foldability criterion. However, the notion that
decreasing energy is correlated with improved foldability can be problematic, particularly
for models involving reduced representations of the amino acids (170). The absence of
explicit negative design may result in proteins that populate multiple topologies (171).
For simple models of proteins, other foldability criteria that more accurately approximate
the free energy of folding and/or address unfolded structures explicitly may be used. Such
criteria can act as objective functions in sequence design (169,172–174). Such quantities
include Δ/Γ, where Δ is the energy gap between the target structure and the average
energy of other competing, unfolded structures and Γ2 is the variance of the energy
averaged over this same ensemble of unfolded structures (169,172–175).

For atomistic representations of proteins, however, energy minimization appears
to be a viable strategy. This is not unreasonable, given that most design algorithms yield
structures that are sterically and energetically self-consistent, in keeping with what is
observed in natural structures. For proteins comprising a single chain, such tightly packed
sequences are specific to the target backbone structure, and it is unlikely that the same
interior packing could be observed in alternative backbone conformations. Viewed in
another way, the use of explicit side-chain conformations in protein design increases the
effective number of monomer types by associating a set of rotamers with each amino
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acid, and tailoring a sequence for a particular tertiary structure becomes more
straightforward with the expanded monomer set (13,176,177). Elements of negative
design may also already be involved in the design process in an indirect manner, via the
use of effective energies of the residues in unfolded structures (i.e. reference energies)
(120,178), by imposition of composition constraints on the numbers of each amino acid
(179,180), or by application of hydrophobic and hydrophilic patterning (128). Explicit
negative design can become crucial in cases where degenerate or low-energy competing
structures are likely to compete with the target structure, such as may be the case in lowresolution protein models (coarse-grained or simplified representations of amino acids)
(148) or in cases involving protein–protein interfaces, which may have smooth energy
landscapes supporting multiple possible orientations of the associating proteins (181).

Implementations of negative design have yielded well-folded proteins. Qualitative
use of negative design based on the patterning of hydrophobic and hydrophilic amino
acids enabled the conversion of a designed amyloid-forming protein into a monomeric βsheet protein (102). In the redesign of a three-helix bundle topology, an ensemble of
denatured structures from folding simulations was used as a set of competing unfolded
structures (148). Optimal sequences were selected using a modified Δ/Γ score, and one
such sequence appeared native-like upon experimental characterization. Explicit negative
design has also been implemented in an algorithm for designing coiled-coil interfaces
(181), where sequence specificity was selected by comparing energies of the target
structure with non-target, misfolded, homodimeric and heterodimeric states.
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Search and characterization of sequence ensembles
Protein design involves identifying viable sequences subject to imposed
constraints on structure, sequence, and function. Various algorithms can be utilized for
the identification of sequences consistent with the target structure and target protein
properties. These approaches may be grouped into two categories: directed or searchbased methods that seek to identify sequences optimizing a particular scoring or energy
function; and probabilistic approaches that seek to characterize the properties of the
ensemble sequences likely to fold to the desired structure.

In an optimization approach, the goal is identification of a high-scoring (lowenergy) sequence for the target using energy or other scoring functions. Since exhaustive
enumeration of sequences and rotamer positioning are only tractable for cases involving
just a few variable residues, approaches such as genetic algorithms (125), simulated
annealing (158,182), and Monte Carlo methods (183) are used. Alternatively, elimination
and pruning methods identify global optima by successively removing residue states that
cannot be a part of the optimal solution (153,184–186).

A statistical approach estimates the site-specific probabilities of the amino acids
among sequences consistent with the targeted structure and other desired properties
(166,174). Such a probabilistic approach is motivated by several considerations. Nature
often provides multiple sequences that fold to the same structure, so there are usually
multiple possible solutions in protein design. Probabilistic information regarding the
likelihoods of the amino acids is a natural input into combinatorial studies of proteins.
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Many aspects involved in design, such as parameterized energy functions, discrete sidechain conformations, fixing backbone atoms, and effective solvation energies, involve
approximations. The sequences identified by optimization-based approaches are likely to
be sensitive to the details of the energy function used and to the nature of these
approximations, whereas statistical features may be more robust. Site-specific amino acid
probabilities can highlight the allowed mutations at each location, and provide a broad
characterization of the ensemble of sequences. Such methods are implemented in two
complementary approaches: maximization of an effective entropy to determine the most
likely set of site-specific amino acid probabilities (120,166), and sampling of sequences
using Monte Carlo methods (183,187). These probabilities may then be used to determine
specific protein sequences or to specify the composition in a combinatorial library. This
approach has been termed a statistical, computationally assisted design strategy (SCADS)
(120,188).

Recent successes in protein design
De novo designed proteins have appeared within recent years that make use of
advances in computational design methods. We discuss only a few here, but other
noteworthy design achievements include biocatalysts (42,189,190), sensors (191), and
protein–protein interactions (192). Several recent reviews have also appeared that detail
further exploration of this field (126,127,169,176,177,193–195).

Verification of a designed protein sequence is best accomplished by experimental
realization and characterization. Empirical structure determination efforts, via X-ray
crystallography or NMR structure determination, provide demanding but time-intensive
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assessments of design. Often stringent biophysical and functional assays are used. The
examples discussed here involve the computational design of proteins that have been
characterized experimentally, affirming the theoretical methodology employed.

Designing structure and sequence
Protein design can suggest not only variants of naturally occurring proteins but
also lead to de novo designed proteins as well, where structure, sequence, and even
function are elements of the design process. A small protein based on a zinc finger
topology has been successfully computationally designed (153). Novel sequences that
fold into desired target structures have been identified by cycling between sequence
design and backbone optimization (158,179,209–211). A computationally designed 97residue α/β protein, Top7, based upon a topology not found in isolation, has recently been
realized (121,212). This design was achieved using backbone templates assembled from
structural fragments with subsequent design of sequence (158). These findings suggest
that additional protein folds not yet found in nature may be physically possible (Fig. 5.1).

Probabilistic methods have also been successful in large-scale protein design.
SCADS has been applied to the de novo design of DFsc, a 114-residue four-helix bundle
containing a di-iron center (120). The backbone template was based on the crystal
structure of a previously designed dimeric helix protein DF1 (213). The topology of DF1
was re-engineered by altering the interhelical turns in an effort to arrive at a stable and
monomeric (single-chain) protein. Residue identities and conformations were fixed at 26
positions to confer metal binding, provide access to the active site, and initiate helix
formation. SCADS was used to identify the remaining 88 residues. The structure of the
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final sequence has been characterized using CD and NMR spectroscopy. DFsc is well
structured and may be catalytically active (120).

Computational methods have also been extended to the design of β-sheet
metalloproteins (123). The rubredoxin protein family consists of simple iron sulfur beta
proteins having a redox active Fe(II)/Fe(III) ion in an tetra-cysteine binding site (213). A
novel backbone was obtained by simplifying the metal binding site of rubredoxin to a
pair of pseudo-equivalent β-hairpins. The two-stranded sheet was extended into a threestranded structure, resulting in a dimer that was connected with a tryptophan zipper
hairpin (214). The resulting structure contained only 40 residues, compared to the 54 in
rubredoxin, and consisted of an entirely different overall topology. Some residues were
fixed prior to computational design including the Trpzip linker, the four metal binding
cysteines, two glycine residues that adopt an αL conformation, and an isoleucine to shield
the active site from solvent. The remaining residues were chosen based on the highest
probabilities from SCADS calculations, resulting in the protein RM1. Experimental
studies confirmed that the metal ions bound in the proper geometry with the expected
stoichiometry, and that RM1 is monomeric and properly folded with the expected β-sheet
structure, both with and without metal ions. RM1 could be reversibly reduced and
oxidized over 16 cycles under aerobic conditions, suggesting a protein that is
significantly

more

robust

electrochemically

metalloproteins.(71,215).
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than

previously

designed

Outlook
The design of a novel protein may appear to be a daunting process, given the
many degrees of freedom and myriads of subtle interactions that guide folding.
Computational methods have been successful, however, in overcoming these hurdles by
leveraging some of the fundamental rules governing protein folding and by addressing
many coupled degrees of (sequence) freedom simultaneously. Through the use of
computational design methods it is now feasible to sample, search, and characterize
sequences for a variety of target proteins. Several challenges still remain. It will be of
interest to quantify sought-after properties in a manner consistent with protein design
algorithms. Such properties include solubility, cellular toxicity, or lack thereof, highaffinity ligand binding, selective protein–protein association, and specificity in enzyme
catalysis. With continued efforts in protein design, a greater understanding of these
properties will become available as well as an improved understanding of protein folding
and assembly.

Although the field of computational design is still under development, it has
already proven successful in generating new proteins with a diverse range of structures
and functions. Computational design methods may also be extended to proteins
containing unnatural amino acids and non-biological folding systems or ‘‘foldamers’’
(231,232). Aided by computational methods, novel molecular ‘‘machinery’’ comprising
proteins (or other polymers) may potentially be designed that can carry out desired
functions with the same specificity and selectivity of natural proteins.

- 146 -

Figure 5.1
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Abstract
Endothelial lipase [EL] is a member of a subfamily of lipases that act on
triglycerides and phospholipids in plasma lipoproteins, which also includes lipoprotein
lipase and hepatic lipase. EL has a tropism for high density lipoprotein, and its level of
phospholipase activity is similar to its level of triglyceride lipase activity. Inhibition or
loss-of-function of EL in mice results in an increase in high density lipoprotein
cholesterol, making it a potential therapeutic target. Although hepatic lipase and
lipoprotein lipase have been shown to function as homodimers, the active form of EL is
not known. In these studies, the size and conformation of the active form of EL were
determined. Immunoprecipitation experiments suggest oligomerization, and ultracentrifugation experiments show that the active form of EL has a molecular weight
higher than the molecular weight of a simple monomer, but less than a dimer. A construct
encoding a covalent head-to-tail homodimer of EL [EL-EL] was expressed and had
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similar lipolytic activity to EL. The functional molecular weights determined by radiation
inactivation were similar for EL and the covalent homodimer EL-EL. We previously
showed that EL could be cleaved by proprotein convertases, such as PC5, resulting in
loss of activity. In cells overexpressing PC5, the covalent homodimeric EL-EL appeared
to be more stable, with reduced cleavage and conserved lipolytic activity. A comparative
model obtained using other lipase structures suggests a structure for the head-to-tail EL
homodimer that is consistent with the experimental findings. These data confirm the
hypothesis that EL is active as a homodimer in head-to-tail conformation.

Three members of the triglyceride lipase family, lipoprotein lipase [LPL], hepatic
lipase [HL], and endothelial lipase [EL], contribute to lipoprotein catabolism in the
plasma compartment. They are all secreted proteins that bind to heparin sulfate
proteoglycans on the luminal side of endothelial cells where they interact with their
lipoprotein substrates. They have different specificities for lipoproteins, and all hydrolyze
triglycerides and phosphatidylcholine at the sn-1 position, albeit with widely differing
efficiencies (1). The preferred lipoprotein substrates for LPL are the triglyceride-rich
lipoproteins, chylomicrons, and very low density lipoproteins; the triglyceride lipase
activity of LPL is more than 100-fold greater than its phospholipase activity. The primary
lipoprotein substrates for HL are chylomicron remnants, intermediate density
lipoproteins, and large triglyceridase-enriched HDL; its triglyceride lipase activity is
about 20-fold higher than its phospholipase activity. EL is much more active on HDL,
and its phospholipase activity is quite similar to its triglyceride lipase activity.
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These three lipolytic enzymes share a number of structural features. By analogy to
the crystal structure of pancreatic lipase (2), another member of the triglyceride lipase
family, each has a clearly defined N- and C-terminal structural domain, joined by a hinge
region. They are all serine esterases with a catalytic triad of serine, aspartic acid, and
histidine located in the N-terminal domain. The catalytic triad is covered by a lid domain
that contributes to the preference for either triglyceride or phospholipid substrates (3-6).
The C-terminal domain contributes to lipid binding and determines the preferences for
binding to lipoproteins (7-12). The N-terminal portion of the EL molecule contains the
active site of the enzyme. However, when this portion of the molecule is expressed
without the C-terminal domain, it lacks enzymatic activity against phospholipid (13),
triglyceride, and the more soluble micellar substrate tributyrin. Thus, the presence of the
C-terminal domain is necessary for activity. All three enzymes are glycosylated to
varying degrees, and two of the glycosylation sites (one each in the N- and C-terminal
domains) are common to all three enzymes (14, 15). All three enzymes are also heparinbinding proteins, and regions that contribute to heparin binding are found in both the Nand C-terminal domains (16-18).

EL and, to a lesser extent, LPL are subject to proteolytic cleavage by proprotein
convertases at a prototypical RXKR site in the hinge region, but HL lacks the site and is
not cleaved (19, 20). The catalytically active forms of both LPL and HL have been shown
to be homodimers (18, 21-27), and in the case of LPL, the orientation of the subunits of
the dimer has been shown to be head-to-tail (28-30). The present study tested the
hypothesis that EL also functions as a head-to-tail dimer.
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Experimental Procedures
Construction of a head-to-tail dimer of EL (EL-EL)
We used PCR to engineer a head-to-tail dimer of two monomeric subunits of EL [EL-EL]
in an approach similar to that of Wong et al. (28) for LPL using the same short hinge of 8
amino acids (GSIEGRLE) to create the head-to-tail dimer of EL (Fig. 6.1).

Figure 6.1

Schematic diagram of EL-EL construct. Shown is a schematic diagram representing EL-EL,
the homodimer of EL in a head-to-tail conformation. A short hinge (linker) of 8 amino acid
residues (GSIEGRLE) joined the two monomeric subunits of EL using overlap extension PCR.
EL-EL contained sequences coding for the signal peptide (SP) of EL, the mature EL protein, the 8
amino acid-peptide linker containing a factor Xa site, and another mature EL protein. Each
monomeric subunit of mature EL protein has an N-terminal domain (N) and a C-terminal domain
(C). To allow comparison of the levels of expression of the dimeric construct (EL-EL) and wildtype EL, we constructed C-terminal myc-His-tagged proteins.
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Two cDNAs of human EL were amplified separately by PCR. Each cDNA
contained engineered restriction sites to facilitate assembly and subcloning into the
expression plasmid pcDNA3.1/myc-His(-)A (Invitrogen). The sense primer of the first
cDNA of EL (5’-ACGTTCTAGAGGCAGGATGAGCAACTCCG-3’) contained an XbaI
restriction site and the first 13 coding nucleotides of the EL cDNA.

The

antisense

primer

of

the

first

cDNA

of

EL

(5’-

CGCTCTCGAGACGACCTTCGATGGATCCGGGAAGCTCCACAGTGGGAC-3’) contained

the last 20 coding nucleotides of the EL cDNA, a factor Xa site (coding for 8 amino
acids, GSIEGRLE), and an XhoI restriction site. The sense primer of the second cDNA
of EL (5’-GCGTCTCGAGAGCCCCGTACCTTTTGGTC-3’) contained an XhoI restriction
site and the first 19 coding nucleotides of the mature EL protein. The antisense primer of
the second cDNA of EL (5’-TGACAAGCTTTCAGGGAAGCTCCACAGTGGGAC-3’)
contained the last 23 coding nucleotides of the EL cDNA and a HindIII restriction site.
These two PCR products were purified, digested using XbaI, XhoI, and HindIII
restriction enzymes, and then ligated using T4 ligase from a rapid ligation kit (Roche
Applied Science). The final product contained sequences coding for the signal peptide of
EL, the mature EL protein, an 8-amino acid-peptide linker containing a factor Xa site,
and another mature EL protein (Fig. 6.1). To allow comparison of the levels of
expression of the EL-EL dimeric construct and wild-type EL, we constructed C-terminal
myc-His-tagged proteins by inserting the full-length cDNA into pcDNA3.1/myc-His(-)A
plasmid expression vector (Invitrogen). The construct was sequenced to confirm
accuracy.
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Cell culture and transfections
HEK293 cells and sub-lines stably expressing profurin or PC5a were maintained
in Dulbecco's modified Eagle's medium, 10% fetal bovine serum, and 1X—
antibiotic/antimycotic supplement (Invitrogen). The cells were transfected with EL
constructs using LipofectamineTM reagent (Invitrogen). Twenty-four hours after
transfection, the medium was replaced with Dulbecco's modified Eagle's medium
containing 10 units/ml heparin (Sigma) and incubated for another 24 h. Thirty min prior
to harvesting this conditioned medium, more heparin was added to the medium, bringing
the final concentration of heparin to 20 units/ml. Conditioned media were collected,
subjected to low speed centrifugation, and frozen in aliquots at -80°C. For some
experiments where high enzyme activity was required (sucrose gradients and radiation
inactivation), the conditioned medium was concentrated 5-fold using an Amicon
ultracentrifugal filtration device (30,000 Mr cutoff; Millipore).

Western blotting
The levels of protein expression of wild-type EL and EL-EL were estimated by
Western blot. For each experiment, we used conditioned medium from cells transfected
to express green fluorescent protein (GFP) as a negative control. Ten µl of conditioned
media were resolved on 10% BisTris or 7% Tris acetate SDS-PAGE (Invitrogen) and
transferred to Hybond ECL nitrocellulose membrane (Amersham Biosciences). Proteins
were detected using either a polyclonal rabbit anti-human EL primary antibody specific
for a peptide in the N-terminal region or a monoclonal mouse anti-Myc primary antibody
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(clone 9E10) and a horseradish peroxidase-conjugated secondary antibody (Jackson
ImmunoResearch).

Co-immunoprecipitation
Conditioned media from HEK293 cells transfected with GFP and co-transfected
with EL-myc-His and EL-FLAG or a 1:1 mixture of media from HEK293 cells, which
had been transfected with EL-myc-His or EL-FLAG, were incubated with mouse (or
rabbit) anti-Myc (Abcam) or mouse anti-FLAG IgG (Sigma) at 4°C in the presence of
0.1% Triton X-100 (Fisher) for 2 h. Protein G magnetic beads (New England Biolabs)
were added to each sample, and samples were incubated overnight at 4°C. Supernatant
and pellet were separated after centrifuging for 10 min at 10,000 X g, 4°C. Pellets were
washed three times with phosphate-buffered saline and eluted from the beads with 4X
loading buffer and 10X— dithiothreitol (Invitrogen). Western blot analysis of samples
was performed using a rabbit anti-EL antibody or a rabbit anti-Myc (Biovision) or a
mouse anti-FLAG antibody (HRP conjugate, Sigma).

Sucrose gradient ultracentrifugation
Sucrose gradients were prepared as described (27). Briefly, 5-20% sucrose
gradients containing 50 mM ammonium hydroxide, pH 8.1, were prepared. Glucose-6phosphate dehydrogenase (G6PDH) (110 kDa) was added to each sample to serve as an
internal standard. Cytochrome c (12.5 kDa), ovalbumin (45 kDa), malate dehydrogenase
(74 kDa), and catalase (240 kDa) were centrifuged in two separate tubes and served as
external standards. After centrifugation (22 h at 200,000 X g at 4°C), 600-µl fractions
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were collected and assayed for enzyme activity and protein concentration. The protein
concentration was determined in each fraction of external standards using a commercially
available kit (BCA protein assay kit, Pierce).

Radiation inactivation
Conditioned medium containing partially cleaved myc-His-tagged EL was
prepared by transfection in HEK293 cells as described above. Media containing either
uncleaved myc-His-tagged wild-type EL or uncleaved myc-His-tagged EL-EL dimer
were prepared in a similar manner by transfection in HEK293 cells that stably express
profurin. Apotransferrin (2 mg/ml, Sigma) and G6PDH (4 units/ml, Sigma) were added
to the media. Samples of these media (0.55 ml) were placed in glass vials, quick frozen,
sealed, and stored at -80°C. Vials were shipped and returned on dry ice. Irradiations were
performed with a linear electron accelerator at the Armed Forces Radiobiology Research
Institute, Bethesda, or at the National Institute of Standards and Technology,
Gaithersburg, MD. Frozen samples were irradiated at -135°C with a beam of 13-MeV
electrons as described (31). Two aliquots not irradiated served as the zero dose controls.
Radiation dose was determined with thermoluminescent or alanine dosimeters. Irradiated
frozen samples were stored at -80°C until assayed for triglyceride lipase activity. The
activity (A) at each dose was divided by the activity at zero dose (A0) to determine the
fractional residual activity at each dose. For each enzyme preparation, the natural
logarithm of the fraction remaining was plotted as a function of radiation dose. The
slopes of these lines were determined by linear regression (GraphPad Prizm) and were
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used to calculate molecular mass as described previously (31). The slopes for the
inactivation of G6PDH were identical in all sample sets.

Triglyceride lipase and phospholipase assays
Emulsions of triolein or dipalmitoylphosphatidylcholine were used to measure
triglyceride lipase or phospholipase activity, respectively (1, 32, 33). For the triglyceride
lipase assay, the emulsion contained triolein and egg phosphatidylcholine containing
glycerol tri[9,10-3H]oleate stabilized with glycerol. For the phospholipase assay, a
similar glycerol-stabilized emulsion was used that contained radiolabeled phospholipids
([14C]dipalmitoylphosphatidylcholine) and cholesteryl oleate as the neutral lipid core.
Samples were incubated for 15 min at 37°C. All enzyme activities are reported as
nanomoles of free fatty acid liberated/h-ml conditioned medium as source of enzyme. All
assays were done in triplicate.

Other enzyme assays
Malate dehydrogenase activity was measured by incubating 2 µl of sample with
294 µl of substrate made of 367.4 µM oxaloacetate and 204 µM NADH in 40 mM TrisH2SO4, pH 7.4, at 25°C. The decrease in absorbance was monitored at 340 nm. G6PDH
activity was measured by incubating 5 µl of sample in a final volume of 200 µl
containing 50 mM Tris-HCl, pH 7.8, 3 mM MgCl2, 0.2 mM NADP, and 3.3 mM glucose
6-phosphate for 15 min at 25°C and monitoring the increase in absorbance at 340 nm.
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Comparative protein structure modeling methods
The human EL models were generated using the molecular modeling suite
MODELLER version 8v1 (Accelrys Discovery Studio, San Diego) and evaluated with
MODELLER versions 8v1 and 9v1 (34-37). As input for the modeling algorithm, the
human EL protein sequence, NCBI protein data base accession code NP_006024.1, was
aligned to the following lipase structures obtained from the Protein Data Bank: Homo
sapiens pancreatic lipase and Sus scrofa co-lipase complex (PDB accession code 1N8S),
H. sapiens pancreatic lipase and S. scrofa co-lipase complex inhibited by undecane
phosphonate methyl ester (PDB accession code 1LPB), and Equus caballus pancreatic
lipase (PDB accession code 1HPL). Multiple sequence alignments with the human EL
protein sequence and those of the aforementioned three protein structures were generated
by ClustalW (EMBL-EBI) using default parameter settings (38). The human EL sequence
has 27% identity to human pancreatic lipase and 25% identity to horse pancreatic lipase.
These identical residues located throughout the crystal structures of the pancreatic lipases
served as anchors to guide the modeling of human endothelial lipase. The EL sequence
contains 37 residues at the C-terminus that were not used in the modeling process
because there is no significant sequence homology to the other template lipase structures
in this region. The human EL models were evaluated using the discrete optimized protein
energy algorithms of MODELLER version 9v1 (39). To investigate the model structure
in the context of a homodimer, the best scoring human endothelial lipase monomer
models were structurally aligned to each monomer of the horse pancreatic lipase
homodimer using MacPyMOL version 0.96.
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Results
EL is a dimer that forms intracellularly
To understand the intermolecular interaction of EL, we used two EL constructs,
one encoding a FLAG tag and the other a myc-His tag at the C-terminus. Neither tag had
any effect on EL lipolytic activity (data not shown). Constructs encoding EL-myc-His
and EL-FLAG were co-transfected in HEK293 cells. Conditioned medium was harvested
and subjected to immunoprecipitation using an anti-Myc antibody to precipitate any
Myc-containing proteins. The precipitated proteins were examined by Western blotting
using an anti-FLAG antibody as well as an anti-EL antibody specific for a peptide in the
N-terminal domain. No immunoreactive bands were detected in conditioned medium
from cells transfected with a construct encoding GFP. As shown in Fig. 6.2, when
constructs encoding EL-myc-His and EL-FLAG were co-transfected in HEK293 cells,
the anti-FLAG antibody detected FLAG-tagged EL in the material that had been
immunoprecipitated with anti-Myc antibody, indicating that there was interaction
between EL-FLAG and EL-myc-His proteins, consistent with dimer formation. When
conditioned medium containing EL-FLAG was mixed with conditioned medium
containing EL-myc-His and subsequently immunoprecipitated, no interaction was
detected, suggesting that the association between monomeric units occurs intracellularly
and that the association between subunits is very strong.
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Figure 6.2

EL protein forms immunoprecipitable complex during secretion but not after secretion.
HEK293 conditioned media were prepared as follows. Lanes 1 and 4 are from cells expressing
GFP; lanes 2 and 5 are mixtures of media from cells separately transfected with either EL-mycHis or EL-FLAG; lanes 3, 6, and 7 are media from cells co-transfected with EL-myc-His and ELFLAG. Western blots (WB) show supernatants (lanes 1-3) and pellets (lanes 4-6) after
immunoprecipitation (IP) with mouse anti-Myc from samples as indicated. Lane 7 shows the
pellet after immunoprecipitation with mouse anti-FLAG from conditioned media from HEK293
cells co-transfected with EL-myc-His and EL-FLAG. These Western blots used either an
antibody against an EL peptide, FLAG tag, or Myc tag for detection. F indicates the full-length
monomer size of EL; N indicates the N-terminal domain of EL, and C indicates the C-terminal
domain of EL.
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Active EL is larger than a monomer and consistent with partially cleaved dimer
Sucrose gradient centrifugation of conditioned medium from cells expressing
wild-type EL was used to determine the size of the functional unit of EL. The major peak
of the triglyceride lipase activity of EL appeared as a distinct species somewhat smaller
than G6PDH (which has a molecular weight of 110,000) as shown in Fig. 6.3A. A linear
relationship was observed when the molecular weights of standard proteins versus
sucrose concentrations were plotted (Fig. 6.3B). The relative molecular weight of the EL
functional unit was 94,500, considerably smaller than a dimer of full-length monomers
(136 kDa) and larger than a monomer (68 kDa). This functional size is most consistent
with partially cleaved forms where part of the cleaved monomer remains associated with
an uncleaved monomer (Fig. 6.4A).

A covalent head-to-tail EL dimer is highly active
We engineered a construct encoding a covalent head-to-tail dimer of two
monomeric subunits of EL [EL-EL] joined by a short hinge of eight amino acid residues
(GSIEGRLE) using an approach similar to that of Wong et al. (28) for LPL. The final
cDNA product contained sequences coding for the signal peptide of EL, the mature EL
protein, the 8-amino acid peptide linker followed by another mature EL protein, and a Cterminal myc-His tag (Fig. 6.1). The expression of the dimeric EL-EL construct was
compared with wild-type EL, which was also myc-His-tagged. Western blots of
conditioned media of transiently transfected HEK293 cells using an antibody against the
myc tag as primary antibody (Fig. 6.4B) showed a band corresponding to a full-length
monomer (68 kDa) in the case of wild-type EL and a dimer (136 kDa) in the case of EL- 177 -

EL, as well as the cleavage products that are myc-His-tagged. Although dimeric forms
are not always present in Western blots for wild-type EL, a dimeric form and partially
cleaved dimer are also visible in the wild-type EL lane. In the Western blot of the same
media using an antibody against EL as primary antibody (Fig. 6.4C), we observed the
full-length monomer of wild-type EL (68 kDa) and the full-length dimer of EL-EL (136
kDa), and as expected some cleavage products (20). Interestingly, in the case of EL-EL
we detected cleavage products of intermediate size between a monomer and a dimer
corresponding to a monomer plus the N-terminal domain (108 kDa) and a monomer plus
the C-terminal domain (96 kDa).

We compared the enzymatic activity of wild-type EL and EL-EL using lipid
emulsions of triglyceride and phospholipid to measure triglyceride lipase and
phospholipase activity, respectively. The EL-EL dimer showed both triglyceride lipase
and phospholipase activities. For each transfection, we consistently measured more lipase
activity (both triglyceride lipase and phospholipase) in EL-EL despite the protein band in
the respective Western blot often appearing of similar or lesser intensity than the band of
the full-length wild-type EL (Fig. 6.4B). The ratio of the triglyceride lipase activity to
phospholipase activity (triglyceridase/phospholipase ratio) reflects the substrate
specificity of the enzyme and was not significantly different for EL-EL (1.46 ± 0.57) than
for EL (1.56 ± 0.24). Thus the EL protein in a dimeric head-to-tail conformation (EL-EL)
was active both as a triglyceride lipase and phospholipase. These data are consistent with
a model that EL is active as dimer in a head-to-tail conformation.
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Figure 6.3

A) Sucrose gradient centrifugation of wild-type EL. After 5-20% sucrose gradient
ultracentrifugation, samples were collected. Each fraction was tested for TG lipase activity (♦)
and G6PDH activity (■). The percentage of sucrose was also measured in each fraction collected.
B) Molecular weight of wild-type EL determined by ultracentrifugation. The molecular
standards used in this experiment were cytochrome c (12.5 kDa), ovalbumin (45 kDa), malate
dehydrogenase (74 kDa), G6PDH (114 kDa), and catalase (240 kDa). After centrifugation (22 h
at 200,000 x g at 4°C), fractions were collected and assayed for enzyme activity and protein
concentration. There is a linear relationship between the molecular weights of standard proteins
and the sucrose percentage.
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Figure 6.4

A) Cleavage products of EL monomer and EL dimer. A schematic diagram is shown of all the
potential intermediate forms of EL monomer and EL dimer induced by the proteolytic cleavage of
EL by proprotein convertases. All the possible forms varying from uncleaved to partially cleaved
and fully cleaved in the case of EL monomer and EL dimer are represented. The relative
molecular mass of each of these forms in kDa is shown.
B) Western blot of EL and EL-EL detected by an antibody against Myc tag. Expression in
HEK293 conditioned media of Myc-tagged EL and EL-EL was detected by Western blot using a
mouse anti-Myc monoclonal antibody and HRP-conjugated secondary antibody. Schematic
diagrams of the different forms of EL detected by the anti-Myc antibody are shown.
C) Western blot of EL and EL-EL detected by an antibody against EL. Expression in
HEK293 conditioned media of Myc-tagged EL and EL-EL was detected by Western blot using a
rabbit anti-human EL polyclonal antibody and HRP-conjugated secondary antibody. Schematic
diagrams of the different forms of EL as detected by the anti-EL antibody are shown.
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Intermediate oligomeric forms of EL are enzymatically active
EL is active as a dimer in a head-to-tail conformation, but other intermediate
forms could potentially also be active provided that an intact active site is present and
preserved. To test that hypothesis, we expressed wild-type EL and EL-EL in HEK293
cells under conditions promoting different levels of cleavage. We used HEK293 cells
stably expressing profurin, which has been reported to prevent EL cleavage, or
expressing PC5a, which has been reported to fully cleave EL (20). Figure 6.5 shows that
indeed more full-length EL and EL-EL dimer were present in the media of cells
expressing profurin, whereas wild-type EL and EL-EL dimer were more heavily cleaved
in the presence of PC5a expression. Interestingly, EL-EL appeared more resistant to
cleavage in HEK293 cells and in the absence or presence of PC5a in comparison with
wild-type EL. These data support the concept that the oligomeric state of EL is dimeric
and that the linker hinge in the EL-EL protein stabilizes the enzyme, making it less prone
to inactivating enzymatic cleavage by enzymes of the proprotein convertase family such
as PC5a. The linker hinge also ensures that the N-terminal and C-terminal domains
remain attached and presumably preserve an active site.

We measured the triglyceride lipase and phospholipase activity of wild-type EL
and EL-EL in these three experimental conditions (Table 6.1). In the case of EL, both the
triglyceride lipase and phospholipase activity of wild-type EL decreased as the amount of
cleavage increased (Fig. 6.5 & Table 6.1). Similar results were observed in the case of
EL-EL, where both the triglyceride lipase and phospholipase activity of EL-EL decreased
as the amount of cleavage increased (Fig. 6.5 & Table 6.1). EL-EL differed from wild- 181 -

type EL only in the extent of the effect. Indeed, EL-EL only partially lost activity in the
presence of PC5a, whereas wild-type EL was more drastically affected. Our activity data
(triglyceride lipase and phospholipase) associated with the mass indicated that as less
protein was cleaved in the case of EL-EL compared with wild-type EL, more lipolytic
enzymatic activity remained (Fig. 6.5 & Table 6.1). These data indicated that not only is
EL active as a homodimer but that the cleavage of EL results in a loss of activity and the
partially or wholly cleaved forms of EL are less active or inactive.

Comparison of the molecular mass of uncleaved wild-type EL and uncleaved
dimeric EL
The functional size of EL was examined using radiation inactivation. Conditioned
medium was prepared from cells expressing myc-His-tagged wild-type EL that was
partially cleaved. The same construct was transfected in cells expressing profurin to
produce EL that was uncleaved, as was the myc-His-tagged head-to-tail construct EL-EL,
to produce the covalently linked dimer, also uncleaved. As shown in Fig. 6.6, all three
preparations gave single exponential decays as a function of radiation dose. Unlike the
sucrose density analysis, radiation inactivation is not influenced by glycosylation. The
inactivation is a function only of the protein component of the enzyme. The predicted
protein mass of a dimer of wild-type EL is 109,201 Da and of the dimer with the covalent
linker is 110,061 Da. Both of the uncleaved preparations gave highly similar decay
functions, which indicated a functional molecular mass of protein of 103.3 kDa for the
uncleaved wild-type EL and 108.5 kDa for the uncleaved dimer that contains the
additional 8-amino acid linker. Thus we can conclude that EL functions as a head-to-tail
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homodimer. The wild-type EL that had undergone cleavage also gave a single
exponential decay as a function of radiation dose that was clearly different from the other
two. The functional molecular mass of protein calculated for that preparation was 79
kDa. The predicted molecular masses of the protein components of partially cleaved
forms are 90,629 and 82,629 Da, respectively (these are the 108- and 96-kDa forms in
Fig. 6.4A with carbohydrate). These data indicate that, after cleavage, one of the domains
can dissociate from the intact monomer, whereas the other remains with the monomer
and the molecule remains active.

Structural modeling of EL
Comparative models of EL were created computationally to assess the feasibility
of head-to-tail homodimer formation with EL and the possible impact of such a
configuration on activity. Presently, no high-resolution structures of EL have been
determined, in part due to the marginal stability of the EL protein under laboratory
conditions. Therefore, comparative modeling was employed to infer likely structures of
the protein. Previously published structures of pancreatic lipases from human and horse
were used as structural templates in conjunction with multiple sequence alignments of
lipase sequences from several different species to generate three-dimensional models of
human EL monomers. After model refinements using the MODELLER suite, the best
scoring EL monomer models were aligned to the structure of the horse pancreatic lipase,
which crystallized as a head-to-tail dimer (40). The EL dimer model (Fig. 6.7) aligns well
to each monomer within the horse pancreatic lipase dimer, and the overall positions of
the N-terminus, activation lid, hinge, and C-terminal domains are similar to those of
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horse pancreatic lipase. The EL dimer model contains no steric clashes between
monomers at the dimer interface. Within the EL dimer model, the N-terminal catalytic
triad is in proximity (within 30 Å) to the C-terminal domain of the other monomer.

Figure 6.5

Western blot of EL and EL-EL under conditions promoting different levels of cleavage. The
level of protein expression in HEK293 conditioned media was detected by Western blot using a
mouse anti-Myc monoclonal antibody (Ab) and HRP-conjugated secondary antibody. GFP (as
negative control), EL, and EL-EL were expressed in HEK293 cells under conditions promoting
different levels of cleavage. HEK293 cells stably expressing profurin prevented EL cleavage, and
HEK293 cells stably expressing PC5a promote the cleavage of EL.
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Discussion
LPL, HL, and EL are members of the triglyceride lipase gene subfamily involved
in plasma lipoprotein metabolism. EL has a particular tropism for HDL and modulates
HDL metabolism in mice and in humans (41,42). To date, only the three-dimensional
structure pancreatic lipase has been resolved by X-ray crystallography (2). Based on the
high amino acid homology and the conservation of the catalytic triad, LPL, HL, and EL
are assumed to present three-dimensional structures similar to pancreatic lipase. Both HL
and LPL have been shown to be active in a homodimeric form, using methods varying
from ultracentrifugation, gel filtration, antibody inhibition, to radiation inactivation (18,
21, 23, 24, 26-28, 43). Mutants of LPL engineered by molecular biology have shown that
LPL is active as a homodimer in a head-to-tail conformation (28-30).

The purpose of this work was to determine the active form of EL. Initial
experiments of immunoprecipitation of media from co-transfection of constructs
encoding EL-myc and EL-FLAG showed that proteins immunoprecipitated with antiMyc antibody contained both Myc-tagged EL and FLAG-tagged EL. Thus, there was an
interaction between EL-FLAG and EL-myc proteins, consistent with an oligomerization
of EL. However, when conditioned media from cells expressing either EL-myc or ELFLAG were incubated together prior to immunoprecipitation, no evidence of interaction
was observed. This suggests that dimerization occurs intracellularly, before secretion, and
that there is a high affinity, stable interaction between subunits.
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Ultracentrifugation studies of other triglyceride lipase family members suggested
that the plasma compartment lipases are dimers. Human HL was shown to have a
molecular mass of 121 kDa (43), and similar studies of rat HL showed 113 kDa (26).
Together, these data suggested that HL exists as a dimer. Analysis of the sedimentation
coefficient of bovine LPL yielded a molecular weight of 96,900, whereas the molecular
weight of the monomer was 48,300 (21). Thus the native LPL enzyme appears to be a
dimer of presumably identical subunits. Similarly, the bovine LPL activity profiles from
sedimentation equilibrium as well as from gel filtration indicated that activity was
associated almost exclusively with the dimer fraction (24). Sucrose density gradient
centrifugation was also used to determine that monomeric LPL refolded in the presence
of calcium becomes dimeric (44).

A complicating issue in determining the functional size of catalytically active EL
relates to its susceptibility to proteolytic cleavage by proprotein convertases (19, 20). One
can predict that, upon cleavage of a dimeric uncleaved EL, a number of possible forms
might be obtained (Fig. 6.4A) and that some of these partially cleaved forms could
potentially retain catalytic activity. The lack of enzymatic activity of the N-terminal
portion of EL (14) indicates that an interaction with the C-terminal domain is essential to
activity. Even if EL is active as a dimer in a head-to-tail conformation, other intermediate
forms could potentially also be active as long as an intact active site is present and the
contribution of the C-terminal domain is preserved. Using classic sucrose density
ultracentrifugation methods, we compared the mobility of wild-type EL to that of several
proteins of known molecular masses and calculated that the molecular mass of wild-type
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EL was 94.5 kDa. As this preparation of EL was made in HEK293 cells, which also
secrete proprotein convertases, EL in the preparation was at least partially cleaved. The
estimated molecular mass is consistent with either of the partially cleaved forms (Fig.
6.4A) where an intact N- or C-terminal domain remains associated with an intact
monomer. These data suggest that one or both of these partially cleaved forms is active.

We then prepared EL in a head-to-tail homodimer using methods similar to those
used by Wong et al. (28), wherein we made a construct encoding such a dimer covalently
linked by an 8-amino acid hinge region (Fig. 6.1). The construct also contained a mycHis tag to allow estimation of expression. The dimer construct expressed nearly as well
as the wild-type. However, the triglyceride and phospholipase activities of the dimer
preparations were consistently higher that those of the wild-type. The ratios of
triglyceride to phospholipase activities were essentially unchanged, indicating that the
covalent linkage of the dimer had no effect on substrate specificity. To determine the
effect of cleavage on activity, we compared activity from wild-type to that of the dimer in
conditions of normal, high, or low activity of proprotein convertases. As shown in Table
6.1, activity was highest in the absence of cleavage for both wild-type and dimeric EL
and lowest for both in the presence of the highest degree of cleavage. Interestingly, the
dimeric form appeared to be more resistant to loss of activity than the wild-type. This
may be due to a resistance to cleavage by proprotein convertases or to the fact that the
covalent hinge between the C-terminus of the original first EL monomer keeps the Nterminus of the second EL monomer attached so that an active molecule is retained. Even
with a high degree of cleavage (Fig. 6.5) of EL prepared in cells expressing PC5, robustly
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detectable activity remains (Table 6.1), suggesting that fully cleaved N- and C-terminal
fragments can remain together and maintain an active site.

Table 6.1
293 cells

Lipases

PC5a

EL
EL-EL
EL
EL-EL
EL
EL-EL

Profurin

TG activity
nmol P/h/ml
172.5 ± 8.4
425.5 ± 8.6
265.9 ± 3.8
484.9 ± 20.2
445.2 ± 10.5
673.5 ± 22.1

PL activity
nmol P/h/ml
92.7 ± 7.4
173.1 ± 10.6
172.4 ± 1.1
226.0 ± 11.3
306.5 ± 79.1
313.1 ± 4.5

TG/PL ratio
(mean ± S.D.)
1.92 ± 0.12
1.56 ± 0.62
1.56 ± 0.24
1.46 ± 0.57
1.72 ± 0.24
1.79 ± 0.58

Triglyceride lipase and phospholipase activities of EL and EL-EL under conditions
promoting different levels of cleavage
Wild-type EL and EL-EL were expressed in HEK293 cells under control conditions and under
conditions promoting different levels of cleavage. HEK293 cells stably expressing profurin
prevent EL cleavage, and HEK293 cells stably expressing PC5a promote the cleavage of EL. The
triglyceride lipase activity (TG activity) and phospholipase activity (PL activity) of each
conditioned medium were expressed in nanomoles of free fatty acid product (P) formed/h-ml of
conditioned media as source of lipase. The activity values reported in this table are the mean
values and the standard deviations (mean ± S.D., n = 3). The ratio of the triglyceride lipase to
phospholipase activity (TG/PL ratio) represent the substrate specificity of the enzyme. The last
column represents the mean values and the mean ± S.D. of the triglyceride/phospholipase ratios
across independent experiments (n = 5 for HEK 293 cell media and n = 4 each for cell media
from HEK293 cells expressing profurin or PC5a). Statistical analysis was run using an unpaired t
test to determine whether the mean of the triglyceride/phospholipase ratios were significantly
different (p < 0.05). The triglyceride/phospholipase ratios of EL-EL and wild-type EL were not
statistically different experimentally whatever the cell types used for the transfection.

- 188 -

The functional size of EL was also examined using radiation inactivation to
determine the size of the active unit. The radiation inactivation method was developed to
determine the size of enzymes (45) and has been previously used to determine the
functional molecular mass of both LPL (23, 46) and HL (25, 44). For bovine milk LPL,
the combined data of radiation inactivation under a number of different conditions
yielded a functional size of 72 kDa for the unglycosylated protein, which is close to that
expected for a dimer, 77 kDa (23). For rat LPL the functional molecular mass was
calculated to be 127 kDa, again the unglycosylated size (46), consistent with a dimer.
Thus the smallest unit required for enzyme function constitutes a dimer in the case of
LPL. There is some discrepancy in the literature with regard to the functional unit of HL.
When recombinant human HL was subjected to radiation inactivation, the size of
functional HL was calculated to be 109 kDa (unglycosylated), the size of a homodimer
(43). An examination of rat HL from liver, adrenal gland, and ovaries showed that the
liver enzyme had a functional molecular mass of 63 kDa (monomeric), but the enzymes
from the adrenals and ovaries both showed functional molecular masses of 117 kDa
(dimeric) (26). Unlike the sucrose density analysis, radiation inactivation is not
influenced by glycosylation and might therefore be a more accurate method in the case of
glycosylated protein such as EL. Another advantage to the radiation inactivation is that it
is a method for determining the functional size of a protein without the need of prior
purification. Uncleaved preparations of wild-type EL and EL-EL gave similar functional
molecular mass estimates, consistent with the concept that EL is active as a homodimer
and are in agreement with the data previously generated for LPL (23, 46) and HL (25,
43). Interestingly, cleavage of only one “side” of the homodimer results in an
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intermediate size form (Fig. 6.4A) that is still active, although less so than the full
homodimer.

In an elegant model of LPL (47), a head-to-tail conformation was proposed where
the monomers associate side-by-side. This conformation has enough space for the lid to
move freely to enable a conformational change upon substrate binding (47). Based on
this, we developed a similar model for EL (Fig. 6.7). Our EL dimer model contains no
steric clashes between monomers at the dimer interface. Within this model, the Nterminal catalytic triad of one-half of the dimer is in close proximity to the C-terminal
domain of the other half. This model suggests how the C-terminal domain could affect
substrate specificity by playing a role in positioning the substrate in proximity to the
catalytic triad of the other half of the dimer across the dimer interface. In contrast, in a
monomer model, the C-terminal domain is almost twice as far from the catalytic triad
(~60 Å). Indeed in the EL dimer model, a hydrophobic collection of amino acids
(Met351, Leu382, Pro383, Ile386, Val387, Phe398, Leu399, Val400, Pro437, Pro440,
and Gly441) in the C-terminal domain is in proximity to the catalytic triad (under the
activation lid) of the N-terminal domain of the other monomer (Fig. 6.7). Furthermore,
there is ample volume for the activation lids of each monomer to open into the middle
part of the dimer interface, and therefore head-to-tail packing could help stabilize the
opening of the lid through ionic or hydrophobic interactions on the surface of the
opposing monomer, similar to the observations of Kobayashi et al. (29) with their
computational model of LPL. These observations, in conjunction with the biochemical
activity data, suggest that head-to-tail dimerization of EL may help position the C- 190 -

terminal domain, important for substrate specificity, in close proximity to the catalytic
region of the enzyme while in turn stabilizing the movement of the activation lid.

In conclusion, HL and LPL have been shown using a variety of methods to be
active in a homodimeric form and, at least for LPL, in a head-to-tail conformation. We
comprehensively studied EL functional size using a variety of similar methods, including
ultracentrifugation, radiation inactivation, covalent EL homodimer, immunoprecipitation,
and molecular modeling. Our data are wholly consistent with a model in which EL
oligomerizes into a homodimer that is active in a head-to-tail conformation. Only the full
length EL is present on the cell surface (data not shown), and it is conceivable that
dimerization of EL confers optimal activity against and interaction with its substrates,
HDL, on the endothelial surface. Furthermore, EL is proteolytically cleaved in the hinge
region by proprotein convertases, resulting in partially cleaved dimeric forms of EL that
retain some activity and could have particular physiologic roles. Because EL is a
pharmacologic target for inhibition as a strategy to raise HDL cholesterol levels, detailed
structural information regarding the active forms of EL could be important to the optimal
design of EL inhibitors.
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Figure 6.6

Radiation inactivation of EL and EL-EL. The loss of triglyceride lipase activity of EL as a
function of radiation dose (megarads) is shown. Three sources of EL were studied as follows:
conditioned medium from cells expressing myc-His-tagged wild-type EL that was partially
cleaved (◊, wt(cleaved)), conditioned medium from cells expressing profurin to produce EL that
was uncleaved (∆, wt(uncleaved)), and conditioned medium from cells expressing profurin to
produce EL-EL that was uncleaved (+, dimer(uncleaved)).
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Figure 6.7

Molecular model of the EL dimer. Top view of the human endothelial lipase dimer model is
shown. The N-terminal “head” domains are shaded in blue; the C-terminal “tail” domains are
colored red and the activation lid is shaded green. The three catalytic residues, Ser169, Asp193,
and His274 are rendered in a space-filling format and located under the activation lid. A
collection of exposed hydrophobic residues, Met351, Leu382, Pro383, Ile386, Val387, Phe398,
Leu-399, Val400, Pro437, Pro440, and Gly441, is highlighted in pink on monomer 1. Monomer 2
is rendered so as to reveal the N- and C-terminal domains, hinge, and secondary structure.

- 193 -

The abbreviations used in chapter 6 are:
BisTris

2-[bis(2-hydroxyethyl)amino]-2-(hydroxymethyl)propane-1,3-diol

Da

Dalton

EL

endothelial lipase

G6PDH

glucose-6-phosphate dehydrogenase

GFP

green fluorescent protein

HDL

high density lipoprotein

HL

hepatic lipase

HRP

horseradish peroxidase

LPL

lipoprotein lipase

PDB

Protein Data Bank.
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Abstract
Endothelial lipase [EL] is a plasma enzyme that previous reports have shown to
be important in high-density lipoprotein [HDL] metabolism. A collection of EL
comparative models was developed based on the crystal structure of pancreatic lipase.
Based on this suite of models, four surface regions of basic charge were identified,
14

KLHKPK19,

292

RKNR295,

304

KKMRNKRNSK313 and

427

RRIRVK432. Alanine scanning

mutants were generated and studied for heparin-binding capacity and enzymatic activity
using both radiolabeled emulsion substrates and isolated human HDL2 and VLDL. The
mutant

14

ALAAPA19 bound to heparin with a KD_apparent of 35.6 + 4.5 nM, compared to

wild-type EL with a KD_apparent of 19.8 + 2 nM, but had only 50% activity toward isolated
human HDL, suggesting that
292

AANA295 and

304

14

ALAAPA19 is important to HDL binding. The mutants

KKMRNAANSK313 had heparin-binding affinities of 3.2 + 0.6 nM

and 5.0 + 0.8 nM, respectively, with less than 50% of the binding capacity and loss of
>90% of their enzymatic activity, suggesting that these segments are important for both
structure and heparin-binding. The mutant

427

AAIAVA432 had normal heparin-binding

but had nearly complete loss of enzymatic activity. Based on the molecular models, the
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carboxyterminal region,

427

RRIRVK432, is a potential site of substrate coordination and

could also be implicated in dimer interaction. This interaction may be essential for EL
enzymatic activity (discussed in chapter 6).

Introduction
Endothelial lipase [EL] is a member of the triglyceride lipase family that is unique
in its synthesis by endothelial cells. EL has significant sequence homology and
remarkably similar domain structure to lipoprotein lipase and hepatic lipase (1). While
the two latter enzymes have well-characterized substrate preferences for triglyceride
emulsions and triglyceride-rich lipoproteins (2-4), EL has greater activity toward
phospholipids and high density lipoprotein [HDL] particles (5).

EL is active within the plasma compartment and has been shown to be released by
heparin sulfate (6). The nature of the interaction between EL and proteoglycans [PGs] is
likely to be electrostatic, involving surface-exposed, basic amino acids (Fig. 7.1). EL
contains several regions of basic amino acids that are positively charged at physiologic
pH, a number of which are located in the carboxyterminus. We have previously reported
that the carboxyterminal domain of EL is essential to its hydrolysis of HDL (7). The
interaction(s) between EL and HDL may be electrostatic as well as hydrophobic, between
the negatively charged HDL particle and positively charge regions of EL (8). The amino
acids involved in these interactions have not been identified.

- 199 -

We developed molecular models of EL, based on the crystal structures of
pancreatic lipases from human and horse. These models were used to generate
hypotheses about the regions of EL that might be involved in binding to PGs and to HDL
as a substrate. In this report, we describe the details of these EL models and the results of
studies showing that certain positively-charged regions of EL are important for heparinbinding and activity while others are necessary for the enzymatic activity of EL.

Figure 7.1
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Results
Molecular models of EL
The Discrete Optimized Protein Energy (DOPE) profiles and scores for all models,
in addition to the template structures, were calculated using MODELLER version 9v1 with
a smoothing window of 15 residues. A single pancreatic lipase chain in each crystal
structure was used in the calculations, disregarding co-lipases and in the case of the
1HPL dimer structure, disregarding one of the monomers. The overall DOPE score of the
endothelial lipase models is 87% of the score for 1HPL crystal structure, 88% that for
1N8S, and 88% that for 1LPB. Thus the models adopt structures with scores comparable
to those obtained for related structures that have been determined experimentally (See
Appendix I for more detail).

The human EL amino acid sequence shares many similarities to other lipase
family members, including those of the pancreatic lipases used as guide structures in the
modeling process. The aminoterminal domain, defined here as the first 320 residues of
endothelial lipase, has 49% sequence similarity to lipoprotein lipase, 42% similarity to
hepatic lipase, and 29% similarity to human and 28% similarity to horse pancreatic
lipase. The C-terminal domain, defined by the remaining 123 residues, has 32%
similarity to lipoprotein lipase, 31% similarity to hepatic lipase, 13% similarity to the
human pancreatic lipase, and 14% similarity to horse pancreatic lipase (Fig. 7.2).
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Figure 7.2
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The models provide viable representations of the EL structure. Although four
surface exposed regions in the model (4-51, 268-315, 339-347, 427-440) exhibit slightly
higher DOPE scores than those of the templates, the remaining regions of the models,
especially those regions surrounding the conserved catalytic triad (S149, D173, H254)
exhibit DOPE scores similar to those of the template structures. After structurally
aligning the α-carbon backbones of the human EL models to the templates, the three
catalytic residues were analyzed for variability among the models. Each of the three
catalytic residues had residue RMSD values of less than 0.6 Å when comparing pairs of
models considered in this study (Appendix I). This small positional variability of these
functionally significant residues from model to model further supports the viability of
these comparative models.

We then examined regions of the EL models that are enriched in basic residues:
Four regions,

14

KLHKPK19,

292

RKNR295,

304

KKMRNKRNSK313,

427

RRIRVK432, are

located on the surface of the models. From a structural standpoint, three of these regions
(292-285, 304-313, 427-432) appear to be exposed across the same surface of the protein
(Fig 7.3) opposite the lid. When the 427-432 region is examined in the context of a model
dimer (Fig 7.4), it is involved in part of a hydrophobic surface 403WYNLW407 positioned
within 4 angstroms of the dimer interface and approximately 25-30 angstroms from the
lid of the opposite monomer. The 14KLHKPK19 region is positively charged and may be
involved in binding to PGs on the endothelial surface. In lipoprotein lipase, a heparin
binding region is located in the hinge region between the two domains, and this region is
similar to

292

RKNR295 and

304

KKMRNKRNSK313 in EL, which are also located at the
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hinge. The proximity of the
403

427

RRIRVK432 region to the highly hydrophobic sequence

WYNLW407 suggests that it may be involved in lipid binding. The models, therefore,

suggest the following hypotheses:
•

The 14KLHKPK19 aminoterminal region binds to PGs on the endothelial surface.

•

The

292

RKNR295 and

304

KKMRNKRNSK313 regions bind to PGs on the

endothelial surface.
•

The 427RRIRVK432 region is part of a lipid substrate binding region.

Recombinant expression of EL and EL mutants
The concentrations of wild-type and mutant EL were determined by ELISA. The
average concentrations of wild-type and mutant EL in medium from 2 transfections are
shown in Table 7.2. The concentrations were very similar between the two transfections.
With the exception of the 292-295 and 304-313 mutants, protein expression levels were
equal to or greater than wild-type. The low expression of the
304

292

RKNR295 and

KKMRNKRNSK313 mutants suggests that mutation in these areas results in misfolded

protein that is not secreted. This region, which forms a hinge between the aminoterminal
and carboxyterminal domains, may be important in the formation of the proper
conformation of the protein. An examination of the intracellular content of these mutants
was not conducted, however.
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Figure 7.3
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Figure 7.4
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Binding of EL and EL mutants to heparin
Previous studies of HL and LPL binding to heparin have used NaCl elution
profiles from heparin sepharose columns to distinguish between the two proteins (23, 29).
To determine differences in binding affinities between wild-type EL and protein with
mutations in potential heparin binding sites, we employed equilibrium binding studies to
estimate apparent KD values. EL binds to heparin with an affinity of 19.8 + 2 nM. (Fig.
7.5). The mutant,

427

AAIAVA432, was equal to wild-type in its affinity to heparin, 19.1+

2.3 nM but had a slight decrease in binding capacity, Bmax = 2.5 absorbance units. The EL
mutant

14

ALAAPA19 had an approximately 2-fold lower affinity, 35.6+ 4.5 nM, with a

lower Bmax of 2.1 absorbance units, suggesting that it contains a high affinity, low
capacity heparin-binding site. In contrast, the EL mutants,
304

292

AANA295 and

KKMRNAANSK313, had heparin-binding affinities of 3.2+ 0.6 nM and 5.0 + 0.8 nM,

respectively, and Bmax of 0.5 and 1.0 absorbance units, respectively, suggesting that they
represent a high capacity heparin-binding site.
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Figure 7.5

Lipase activity using emulsion substrates
The triglyceridase and phospholipase activity of wild-type EL and each mutant
are summarized in Figure 4.6a and b, respectively. Wild-type EL hydrolyzed the
triglyceride substrate, generating 6.17 + 2.3 nmol FFA/hr/µg protein. There was an
approximate 50% loss of activity in the 14ALAAPA19 mutant, 3.2 + 0.23 nmol FFA/hr/µg
protein, and even greater loss of activity in the other mutants:
304

KKMRNAANSK313, 1.5 + 0.28 and

427

292

AANA295, 2.5 + 0.19,

AAIAVA432 , 0.66 + 0.39 nmol FFA/hr/µg

protein, p<0.001 for all in comparison to wild-type EL.
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The results from the phospholipid substrate assay demonstrated some differences
in the relative importance of these charged areas (Fig. 7.6b). Wild-type EL hydrolyzed
the phospholipid substrate, generating 5.88 + 1.23 nmol FFA/hr/µg protein. The
14

ALAAPA19 mutant retained 85% of the activity of wild-type EL, 4.98 + 0.53 nmol

FFA/hr/µg protein, while the

292

AANA295 mutation lost 88% of its activity, 0.70 +0.33,

the 304KKMRNAANSK313 lost 98% of its activity, 0.135 + 0.06 nmol FFA/hr/µg protein,
and the 427AAIAVA432 mutant lost all activity.

Figure 7.6

Tributyrin assay
The loss of positive charge associated with alanine-scanning mutagenesis can
result in marked changes in protein structure that could alter the function of the active
site. To examine this possibility, we assessed the integrity of the active site conformation
using tributyrin, a triglyceride with three 4-carbon fatty acids used as an active sitespecific substrate. The results of these assays are summarized in Table 7.3. With the
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exception of the

427

AAIAVA432 mutant, the specific activity of wild-type and the EL

mutant constructs was nearly identical. This suggests that the

427

AAIAVA432 mutant is

essential for active conformation of the protein. In contrast, the other mutants appear to
be important for substrate and surface-binding.

Lipase activity using native lipoproteins
Although the use of emulsion substrates provides insight into the relative
triglyceride versus phospholipid preference of EL and the influence of different regions
of the protein in facilitating the activity of the enzyme, in vitro assays using native
lipoproteins may be more useful in determining the effect of these regions on EL activity
in vivo. We therefore examined the activity of EL and mutated EL constructs on the
hydrolysis of the larger VLDL and smaller HDL lipoprotein particle. The results are
summarized in Table 7.3.

Similar to the results of the emulsion substrate assays, the

14

ALAAPA19 mutant

lost ~50% of its ability to hydrolyze HDL2 particles and 86% of its activity toward
VLDL. The 292AANA295 and 304KKMRNAANSK313 mutants lost ~95% of their ability to
hydrolyze HDL2 and had no ability to hydrolyze VLDL. The 427AAIAVA432 mutant again
lost all activity. Given that the specific activity of native EL in hydrolyzing VLDL was
~50% of that of HDL2, the complete loss of VLDL hydrolysis by the mutated EL proteins
may be due to activity that is below the detection level of the assay.
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Discussion
In this study, we combine computational and experimental approaches to
investigate the functional and substrate-specific aspects of EL, the most recently
identified member of the plasma lipases. Although other members, such as pancreatic and
LPL are well characterized, the lack of a crystal structure complicates efforts to explore
the particular functional aspects of EL. To this end, we developed a suite of molecular
models of human EL to gain further insight into various functional subtleties.

In an attempt to better understand the differentiating features of each lipase family
member in the absence of crystal structures, modeling approaches have already been used
to investigate human LPL (23) and HL (24). Here we have developed molecular models
of human EL that provide an appropriate context to develop hypotheses concerning
heparin binding, substrate-specificity, and lipase functionality.

Endothelial lipase topology
Human EL shares significant amino acid sequence homology to other family
members such as lipoprotein and hepatic lipases, yet this enzyme has a uniquely high
affinity for phospholipids within HDL particles. From amino acid sequence alignments
alone, the conservation of the residues surrounding and including the catalytic triad
suggests the presence of an α/β hydrolase fold characteristic of the esterase, lipase and
thioesterase superfamily. Furthermore, conservation of cysteine pairs throughout the
primary sequence is consistent with a two-domain structure of the enzyme stabilized by
disulfide bridges. Indeed, the EL models are consistent with the crystallized structures of
pancreatic lipase in that the catalytic triad is structurally similar, cysteines are positioned
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to form disulfide bridges as occurs at similar locations of other lipases, and the overall
topology comprises two domains separated by a hinge region (Fig. 7.1).

The human endothelial lipase models have noticeably large differences in surface
residue composition in the four basic regions analyzed in this study when compared to
the crystal structures of the pancreatic lipases. Four out of six, approximately 67%, of the
surface exposed residues in region 14-19 of endothelial lipase contain basic residues,
whereas only 1 in 6 residues are charged in the corresponding regions of the horse and
human pancreatic lipases, leading to a near 4-fold increase in basic residues in this same
region. This increase in basic residue density is also evident elsewhere in the surface of
EL, with the 292-296 region having a 3-fold increase and the 304-313 region having an
approximately 2-fold increase in basic residues over the pancreatic lipases. The most
extreme differences are found in the

427

RRIRVK432 positively charged surface region of

human endothelial lipase. In contrast to EL, the same surface regions in the pancreatic
lipases are void of basic residues, and have only one or two acidic residues that would
confer a negative charge at physiological pH. This dramatic difference in local charge
between lipase types, in conjunction with the loss of enzymatic activity observed from in
vitro experiments, further supports the idea that region 427-432 could be implicated in
substrate coordination as well as dimer stabilization particular to endothelial lipase.

These region-specific surface residue composition comparisons between the EL
models and PL structures are dependant upon the sequence alignments. However, often
there is not one ‘best’ multiple sequence alignment. Although the conserved residues
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positioned throughout the EL sequence served as useful anchors to guide the construction
of the models, the first N-terminal 30 residues were subject to slight variations in
alignments since this region has only 15% sequence similarity and multiple insertions.
This small variation in alignment position could alter the spatial positions of 14-19 in the
generated models of EL.

In addition to the differences found in the four basic regions of human EL and the
horse and human pancreatic lipases, the activation lid of EL is also different in both
residue composition and structure. Amino acid variation between the lid residues of the
various lipases has been implicated as a reason for their substrate specificity. Indeed, the
residues Gly233, Tyr243, Val250 and Lys251 located in the lid region are conserved in
the endothelial lipases from species to species (Appendix I), yet differ within the lipase
family. From a structural standpoint, the pancreatic lipases have larger lids that contain a
small alpha-helical turn in the middle of the lid.

Substrate recognition and specificity
Of particular interest in this study are four basic regions implicated in heparin
binding and/or substrate recognition and specificity. Region 14KLHKPK19 exhibits a twofold lower affinity for heparin and a decrease in binding capacity when these lysines are
mutated to alanines. This distal aminoterminal region shows little sequence similarity to
the other lipase family members, and it seems that EL alone possesses a lysine-rich
cluster at this location. LPL and HL have two tandem arginines in this area but lack
additional basic residues. Region

14

KLHKPK19 also has ~ 50% loss of activity toward
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triglyceride substrate and HDL with an 86% loss of ability to hydrolyze VLDL. This
finding suggests that this region contributes to substrate binding.

Mutation
304

of

basic

amino

acids

in

the

regions

292

RKNR295

and

KKMRNKRNSK313 yielded a significant decrease in heparin-binding affinity and

capacity as well as on enzymatic activity. The solvent-exposed

292

RKNR295 cluster,

located opposite the catalytic center, is directly flanked by two conserved cysteines
capable of forming a disulfide bridge in the models (Figs. 7.1 & 7.2); a similar bridge is
also present in the crystal structures of pancreatic lipase (11). These four residues are
conserved in LPL, and mutational studies with LPL demonstrated that these basic
residues constitute a high-affinity, heparin binding site (25). This sequence has also been
shown to be a proprotein convertase cleavage site (26, 27). HL has a similar sequence in
that region, KKGR, but it has not been shown to be involved in heparin-binding.

In the models, adjacent to the four residues, 292RKNR295, lies another basic cluster
304

KKMRNKRNSK313. Together, the 292-295 and 304-313 clusters may form a

positively charged surface at physiological pH opposite the catalytic core of the enzyme.
Similar to the residues located in the 292-295 cluster, many of the basic residues from
304-313 are conserved in LPL and HL. In HL, this region was shown to be a heparinbinding site (28). Similarly, in the comparative models of EL, this likely heparin binding
site is positioned on the opposite face from the catalytic triad.
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The decrease in secretion of protein with loss of positive charge in these areas, as
well as the decrease in heparin-binding capacity and loss of enzymatic activity suggest
that this region of EL is essential for proper folding. These findings also suggest that
binding to a negatively charged surface is important for enzymatic activity, in particular
phospholipase activity.

Active form of endothelial lipase
We previously reported that the carboxyterminal region of EL mediates its greater
ability to hydrolyze HDL (7). This suggested that there must be a specific area in the
carboxyterminal region that binds to HDL. EL is not, however, lacking in ability to
hydrolyze VLDL and LDL (5). A more accurate view of the role of the EL
carboxyterminus may be to mediate lipid binding. Boren et al. found that the interaction
between LPL and LDL occurred through binding to the triglyceride in the lipoprotein, not
through interactions with apolipoprotein B (29). The nearly complete loss in enzymatic
activity, when basic residues in the region

427

RRIRVK432 were changed to alanine,

suggests that this region may be important for lipid binding. A homologous region in
LPL, 403KIRVK407, was examined as a potential heparin-binding site (30). Similar to our
findings, when the basic residues in this region were changed to asparagines, there was a
loss of enzymatic activity. In contrast to our finding that the heparin-binding affinity of
the

427

RRIRVK432 mutant is equivalent to wild-type EL, two previous reports (30,31)

found that the

403

KIRVK407 LPL mutant eluted with a lower NaCl concentration from a

heparin sepharose column. When this region was examined within the context of a model
of the LPL dimer, however, it was found that the amino acids coordinate with a putative
heparin-binding site in the aminoterminus (32). In the EL dimer models, this region exists
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as a short β-strand that is part of a hydrophobic region near the catalytic pocket of the
opposite monomer. These results suggest that the active enzyme requires the head-to-tail
association of the two monomers. The loss of activity toward the short chain tributyrin
substrate also suggests that there are complex interactions between the two monomers
required for hydrolysis of any substrate.

The EL dimer models are consistent with having the distal regions 14KLHKPK19
and

427

RRIRVK432 in close proximity [within 25 angstroms] to each other. The resulting

positively charged surface could potentially coordinate the alignment of EL with
substrate at the lipid/water interface. In the context of an active monomer, the catalytic
serine (Ser149) is approximately 60 angstroms from the 427RRIRVK432 cluster. However,
as a head to tail homo-dimer, Ser149 is about half this distance, 30 angstroms, from
427

RRIRVK432 thus suggesting why mutations in this region may affect substrate

recognition.

The role of EL in lipoprotein metabolism and in the development of
atherosclerosis continues to be an important area of study. Based on its ability to
hydrolyze HDL and its reported association with coronary artery disease (17), EL is a
potential therapeutic target. Understanding key structural, substrate and surface binding
domains can contribute to the efforts to regulate EL pharmacologically. The findings of
this report add specifically to this effort, demonstrating that the 292-313 region of EL is
important to overall protein structure and is an important heparin-binding site, and that
the carboxyterminal region, 427RRIRVK432, is key to active conformation of the protein.
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Methods
Comparative protein structure modeling
All human EL models were generated using the molecular modeling suite
MODELLER version 8v1 (9-12) and evaluated with MODELLER versions 8v1 and 9v1.
As input for the modeling algorithm, the human EL protein sequence, NCBI protein
database accession code NP_006024.1, was aligned to the following lipases, whose
structures were obtained from the protein structure database (http://www.rscb.org/pdb/):
Homo sapiens pancreatic lipase and Sus scrofa colipase complex (Protein Data Bank
accession code 1N8S) (9), Homo sapiens pancreatic lipase and Sus scrofa colipase
complex inhibited by undecane phosphonate methyl ester (Protein Data Bank accession
code 1LPB) (10), and Equus caballus pancreatic lipase (Protein Data Bank accession
code 1HPL) (11). The presence of undecane phosphonate methyl ester in the human
pancreatic lipase crystal induced a conformational change in the lid region of 1LPB
relative to the other lipase structures. To avoid skewing the modeling by the inactive
human endothelial lipase monomer, the lid region from residues Pro235 to Ala260 of
1LPB was not used as a template. Multiple sequence alignments with the human EL
protein sequence and those of the aforementioned three protein structures were generated
by CLUSTALW (EMBL-EBI) (12) using default parameter settings (Fig. 7.2). The first
20 aminoterminal residues of human EL were not used for modeling, given that they are
cleaved in the active form. Additionally, the carboxyterminal sequence of EL,
TEDPENTSISPGRELWFRKCRDGWRMKNETSPTVELP,

has no significant homology to the other lipase structures used as templates. These
terminal 37 residues were not used in the modeling process.
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Model evaluation
The human EL models were evaluated using the Discrete Optimized Protein
Energy (DOPE) (13) algorithms of MODELLER version 9v1. Of approximately 300
models generated, the ten best human EL models exhibiting DOPE energy scores similar
to that of the crystallized pancreatic lipases were selected for further investigation. Using
MacPyMOL version 0.96 (14), the α-carbons of these EL models were structurally
aligned to those of the three template pancreatic lipase structures. The root mean square
deviation (RMSD) of each of the three conserved catalytic residues of human endothelial
lipase, Ser149, Asp73, His254, was then calculated to confirm similar acceptable
positions of these residues relative to the catalytic pocket.

Site-directed mutagenesis
Single and multiple amino acid substitutions in the EL sequence were introduced
using the QuikChange Site-Directed Mutagenesis Kit (Stratagene, La Jolla, CA). The
sequences of primers used are displayed in Table 7.1. Mutated EL in pcDNA3.1 in XL-1
Blue super-competent cells was selected on LB-ampicillin agar plates and expanded in
LB medium. Mutant plasmid was purified using a Qiagen Maxiprep kit (Valencia, CA)
and sequenced to confirm the presence of the desired mutation. Expression of wild-type
and mutant EL protein was obtained through transient transfection of 293 human
epithelial kidney cells (293 HEK) using Lipofectamine™ reagent (Invitrogen, Carlsbad,
CA). Briefly, 293 HEK cells were grown to >90% confluence in 100 mm dishes
containing Dulbecco’s modified Eagles medium (DMEM), 10% fetal bovine serum
(FBS), 50 µg/ml penicillin/streptomycin (P/S). The medium was replaced with a
transfection mixture containing 5.85 µg ELpcDNA3.1, 52.65 µl Lipofectamine™ and
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5.85 ml OPTI-MEM. After 5 hours, 5.85 ml DMEM, 20% FBS, P/S was added to each
dish. After 24 hours, the medium was replaced with 6 ml serum-free DMEM, P/S and
10U/ml heparin sulfate. After an additional 24 hours, medium was collected 30 minutes
after addition of 10 U/ml heparin sulfate. The medium was stored at -80°C until use.

Biotin-labeling of heparin
Heparin >10 kDa was biotin-labeled using the method of O’Shannessy (15). Fifty
milligrams of heparin (Sigma-Aldrich, St. Louis, MO) was dissolved in 2.5 ml sodium
acetate buffer (0.1 M sodium acetate, 0.15 M NaCl, pH 5.5) and chilled on ice. Sodium
m-periodate was added to a final concentration 10 mM, and the reaction incubated for 30
minutes in the dark. The reaction was stopped using 20 mM sodium sulfite. The heparin
solution was desalted and concentrated to 0.9 ml using Centricon-3 (Millipore, Bedford
MA). Biotin-XX-hydrazide (EMD Chemicals, Gibbstown, NJ), 100 µl of an 8 mg/ml
solution in dimethylformamide, was added and incubated 24 h at ambient temperature.
Excess biotin was removed by three concentration and re-suspension cycles using trisbuffered saline (10 mM tris-HCL, 0.15 M NaCl, pH 7.4) using Centricon-3 concentration
devices. The degree of biotin incorporation was determined by measuring the absorbance
at 500 nm of 0.9 ml avidin/HABA solution (6 µM avidin, 0.3 M HABA) [A1] and the
change in absorbance [A2] after addition of 0.1 µl biotin-labeled heparin. The percent
incorporation was then calculated: DA500 = 0.9(A1-A2); biotin (M) = DA500/3400. The
heparin concentration, assuming an average molecular weight of 20 kDa, was determined
by comparison to a standard curve of heparin using dimethyl methylene blue (16). The
molar degree of biotin incorporation = [biotin]/[heparin].
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Enzyme-linked immunosorbent assay of EL
A detailed description of the development of the endothelial lipase ELISA has
been reported previously (17). Briefly, the wells of a 96-well microtiter plate were coated
with rabbit anti-human EL antibody. Various concentrations of purified recombinant
human EL in phosphate-buffered saline, 1% BSA, were added to the wells as a standard
control. Conditioned medium from wild-type and mutant EL was diluted 1:1000 in
phosphate-buffered saline and added to the wells. Specifically bound protein was
incubated with biotin-conjugated rabbit anti-human EL antibody, followed by
streptavidin-horseradish peroxidase conjugate, and detection with o-phenylenediamine.
The reaction was stopped with 2.5M sulfuric acid and the plate read at 490 nm. A
standard curve of 490 nm absorbance versus the known concentrations of EL was
created. The concentration of EL in the conditioned medium was determined by
comparison to the standard curve multiplied by the dilution factor.

Equilibrium binding studies of EL, EL mutants to heparin
Equilibrium binding studies of EL and EL mutants to heparin were performed as
described previously (18). Briefly, biotin-heparin at 1 µg/well in phosphate-buffered
saline (PBS), was added to a streptavidin-coated microtiter plate and incubated for 2 h at
room temperature. After washing with PBS + 0.1% tween-20 (PBST), concentrations of
EL between 0 and 100 nM were added to wells in triplicate. Non-specific binding was
determined by addition of EL to blocked wells without heparin. After 2 h incubation and
subsequent washing with PBST, 100 µl of a 1 µg/ml solution of polyclonal anti-EL
antibody was added. After 2 h incubation and washing, 100 µl of a 1 µg/ml solution of
goat anti-rabbit horseradish peroxidase antibody was added. After 1 h, 100 µl of a 0.42
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mg/ml solution of ο-phenylene diamine was added. After 15 minutes, the reaction was
stopped with 100 µl of sulfuric acid. Absorbance at 490 nm was measured on a
Spectramax microtiter plate reader (Molecular Devices, Sunnyvale, CA). Specific
binding was the amount of protein bound after subtraction of binding to blocked wells.
Apparent binding affinity [KDapp] was determined using GraphPad Prism (GraphPad
Software, San Diego, CA).

Triglyceride lipase assay
Triglyceride lipase activity was measured using a glycerol-stabilized emulsion of
triolein and egg phosphatidylcholine containing glycerol-tri[9,10(n)-3H]oleate (3.3
mCi/mmol) according to a modification of the method of Nilsson-Ehle and Schotz (19).
Each assay tube contained 150 µl EL-conditioned medium, and 150 µl of a working
substrate (0.05 M Tris-HCl, 0.15 M NaCl, pH 8.0, 0.75% BSA, 3.4 mM triolein, and 250
µM phosphatidylcholine. Samples were incubated for 1 h at 37°C. Reactions were
stopped and products were extracted according to the method of Belfrage and Vaughan
(20). The liberated fatty acids contained in a 0.5 ml aliquot of the aqueous phase were
quantified by scintillation counting, using a partition coefficient of 0.4. Enzyme activity
is reported as nmol free fatty acid (FFA) liberated/h/µg protein.

Phospholipase assay
Phospholipase activity was measured using a glycerol-stabilized emulsion of
cholesterol oleate, dipalmitoylphosphatidylcholine [DPPC] and [1,2-14C]DPPC as
previously described (5). Each assay tube contained 150 µl EL-conditioned medium, 0.05
M Tris-HCl, 0.15 M NaCl, pH 8.0, 0.75% BSA, 4.6 mM cholesteryl oleate, and 245 µM
DPPC. Samples were incubated for 15 min at 37°C. The reactions were stopped and the
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products extracted by the method of Belfrage and Vaughan, with the addition of 100 µg
lysopalmitoylphosphatidylcholine [lysoPC] as carrier. The products, FFA and lysoPC, are
quantified by scintillation counting of 0.5 ml of the aqueous phase, using a partition
coefficient of 0.55 and dividing by two, to account for the lysoPC. Enzyme activity is
reported as nmol free fatty acid (FFA) liberated/h/µg protein.

Tributyrin assay
The release of fatty acid from tributyrin by EL and EL mutants was performed
essentially as described (21). Briefly, tributyrin,

14

C labeled (American Radiolabeled

Chemicals, St. Louis, MO) and unlabeled (Sigma-Aldrich, St. Louis, MO) (ratio
1:40,000), were added to a final reaction mixture of 20 mM tributyrin, 50 mM Tris-HCl,
150 mM NaCl, 2 mM CaCl2 and 2% bovine serum albumin, pH 8.5. EL wild-type and
mutant medium, 250 µl was added to separate tubes, and the reaction run for 1 hour.
Released fatty acid was extracted by the method of Belfrage and Vaughn and quantified
by scintillation counting.

Isolation of lipoprotein fractions
Human lipoproteins were isolated from pooled plasma samples from non-fasting,
normolipemic donors as follows: chylomicrons were obtained by centrifugation at
d=1.006g/ml KBr for 30 min at 20,000 rpm. VLDL (d>1.006g/ml), IDL (1.006<d<1.019
g/ml, LDL (1.019<d<1.063 g/ml), and HDL (1.063<d<1.21 g/ml) were isolated by
sequential ultracentrifugation at 39,000 rpm for 16h in a Ti70 Beckman rotor at 10°C.
Recovered fractions were dialyzed against phosphate-buffered saline and stored at 4°C.
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Lipase hydrolysis of fractionated lipoprotein lipids
Isolated VLDL and HDL were incubated with EL-conditioned media using a
modification of the method of Bamberger (22). Each reaction tube contained 1.25 mM
lipoprotein phospholipids, 40 µl conditioned medium, 20 mM Tris-HCl, 0.15 M NaCl,
pH7.4, 8 mM CaCl2 and 1% BSA in a final volume of 100 µl. Snake venom
phospholipase A2 was used as a positive control. The tubes were incubated 4h at 37°C
and the reaction stopped by addition of 25 mM EDTA. The released FFA was measured
using the NEFA C kit (Wako Pure Chemical Industries, Osaka, Japan). Enzyme activity
is reported as nmol free fatty acid (FFA) liberated/µg protein.

Table 7.1.
Primers Used for Site-Directed Mutagenesis
14 KLHKPK 19
292 RKNR 295
304 KKMRNKRNSK 313
427 RRIRVK 432

F
R
F
R
F
R
F
R

GGACGGCTGGAAGATGCCCTCCACGCCCCCGCCGCTACACAGACTGAGG
CCTCAGTCTGTGTAGCGGCGGGGGCGTGGAGGGCATCTTCCAGCCGTCC
GGGATCTGTCTGAGCTGCGCCGCCAACGCCTGTAATAGCATTGGC
GCCAATGCTATTACAGGCGTTGGCGGCGCAGCTCAGACAGATCCC
GGCTACAATGCCAACAACATGCGCAACGCCGCCAACAGCAAAATG
CATTTTGCTGTTGGCGGCGTTGCGCATGTTGTTGGCATTGTAGCC
CGGGAGCTGGCCGCCCGGGCCATCGCCGTGAAGTCTGGGGAA
TTCCCCAGACTTCACGGCGATGGCCCGGGCGGCCAGCTCCCG

Table 7.2.
Concentrations of Wild-type and EL Mutants
Protein
Wild-type
14 ALAAPA 19
292 AANA 295
304 KKMRNAANSK 313
427 AAIAVA 432

Concentration/
transfection (µg/mL)*

95.5
185
12
23
129

*Average of 2 transfections
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Table 7.3.
Lipoprotein Hydrolysis by Wild-type EL and EL Mutants
Protein

Wild-type
14 ALAAPA 19
292 AANA 295
304 KKMRNAANSK 313
427 AAIAVA 432

Tributyrin Assay*

HDL#

VLDL#

nmol butyrate/hr/
µg protein

nmol FFA/
µg protein

nmol FFA/
µg protein

0.61
0.61
0.60
0.58
0.011

+0.010
+0.028
+0.013
+0.050
+0.006

15.5
7.85
0.925
1.05
0

+
+
+
+

3.42
0.54
1.42
0.84

7.37 + 3.56
1.00 + 0.22
0
0
0

* - average of 2 experiments; # - average of 3 experiments in triplicate
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METHODS
Supplements and extensions of methods presented in chapters 2, 4, 6 and 7.
Computational design of stabilizing substitution R209P
The re-design of Arg209 of the human p53 DNA-binding domain [DBD] was
motivated by the need to further stabilize the multi-domain p53 variants in the presence
of DNA. At crystallographic concentrations in the range of 5 to 10 milligrams of protein
per milliliter, the purified stable p53 variants precipitated when mixed with dsDNA,
preventing screening of p53-DNA complexes. A visual inspection of the previously
determined p53 DBD-DNA crystal structure (Cho et al. 1994; PDB code: 1TUP) reveals
that Arg209 is exposed on the DBD surface opposite the DNA-binding residues, and that
the local positive charge, in the context of a p53 multimer, might contribute to nonspecific DNA interactions (Fig. m.1).
In order to select the optimal amino-acid substitutions that would remove the
positively charged residue, yet not disrupt the stability of the DBD, we employed a
statistical computationally assisted design strategy [SCADS] to estimate the amino-acid
probabilities at this site (Kono H. & Saven JG. 2001; Calhoun et al. 2003). SCADS is a
side chain placement algorithm based on statistical mechanics and an entropy-based
function that correlates energy levels of rotamer ensembles with amino acid identity
occupancy probabilities (explained in chapter 5). The X-ray crystal structure used for this
analysis is a stable variant of the human p53 DBD (Joerger et al. 2005; PDB code:
2BIM). Of the available DBD structures, 2BIM has the best resolution (1.98 Å) and
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shares two of the twelve stabilizing mutations with our p53 variants (V203A and
N268D), and thus served as an ideal input structure for the calculations.

In the p53 Arg209 analysis, the value of the environmental energy was
constrained to that of the input structure 2BIM, and the coordinates of the backbone
atoms were fixed (Kono H. & Saven JG. 2001). Although the protein sequence was also
fixed, rotamer sampling (via discrete residue-specific side-chain conformation libraries)
was allowed at every position within the structure. At position 209, all amino acid
identities and rotamer conformations were sampled. The results of the calculations (Fig.
2.1b) show that wild-type arginine is the most probable residue with positively charged
lysine as second most probable. The third most probable residue at position 209 is
proline.

The side-chain structure of proline constrains the backbone dihedral angle to
approximately −75°, providing relatively high conformational rigidity. Although proline
can disrupt secondary structure elements; it is commonly found as the first residue of an
α-helix and also in the edge strands of β-sheets. Indeed position 209 is located in a
connecting strand within a β-sheet (residues 204-218) of the DBD (Fig. m.2). The R209P
substitution into the stable p53 variants both increased melting temperature by an
additional 15° C (described in chapter 2, Fig. 2.1a & c), and also prevented protein
aggregation upon mixing with DNA, thus facilitating crystallographic screening of the
p53-DNA complex.
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Figure m.1

Position of Arg209 in the DNA-binding domains bound to DNA (Cho et al. 1994; PDB code:
1TUP). Surfaces of DBDs are shaded in blue, DNA is green and the two views are related by a
90° horizontal rotation. The position of the positively-charged Arg209 (red) might contribute to
non-specific DNA binding.

Figure m.2

Position of Pro209 in multi-domain p53 stable variant ST7. The same views of Fig. m.1,
presented for the crystal structure of ST7 bound to DNA. The DBD and oligomerization domains
are shown as blue cartoons, the DNA is green, and the four prolines at position 209 (one in each
DBD) are shown as red sticks and labeled accordingly.
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R209P substitution
The R209P substitution was introduced into the stable p53 multi-chain variants
ST6 (described in chapter 2) using the QuikChange XL site-directed mutagenesis kit
(Agilent Technologies, Stratagene Products Division, La Jolla, CA, USA). The primers
used were:
hp53P209_1 cgctGAGTATTTGGATGACccaAACACTTTTCGACATAGTGTG
hp53P209_2 CACACTATGTCGAAAAGTGTTtggGTCATCCAAATACTCagcg

Protein production and purification
Protein expression
Plasmids containing the stable p53 polypeptides cloned downstream of a T7
promoter with selectable tetracycline and ampicillin markers were used to transform E.
coli. BL21(DE3) cells (Stratagene, La Jolla, CA, USA). Colonies were grown at 37°C
with shaking at 220rpm in overnight LB/Amp100 starter cultures used to inoculate a final
volume of 2.4 liters of LB/Amp100 medium the next day. The cells were grown at 37°C
with shaking at 220 rpm to an OD of ~0.5-0.7. At the proper cell density, cells were
pelleted by centrifugation and resuspended in fresh LB/Tet50 medium pre-warmed to
30°C.

Protein

expression

was

induced

by

adding

IPTG

(Isopropyl

β-D-1-

thiogalactopyranoside) to a final concentration of 1 mM. Cells were incubated at 30°C for
4 to 5 hours with shaking at 220 rpm, after which the cells were pelleted, liquid medium
removed, and pellets either stored at -20°C overnight or immediately lysed and used in
the first purification steps.
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Cation exchange chromatography
Purification of the p53 variants involves a two-step process consisting of cation
exchange followed by gel filtration chromatography. The cells were lysed in buffer
consisting of 25 mM bis-tris propane (BTP) [pH 6.8, 250 mM NaCl, 5 mM DTT and
protease inhibitors], and centrifuged (Beckman Type Ti-60 fixed-angel rotor) at 50,000
rpm for 1 hour to pellet cell debris. The cell lysate was adjusted to 100mM NaCl and
passed over a cation exchange column (Sepharose SP column, Pharmacia Biotech,
Uppsala, Sweden) equilibrated with buffer I [25 mM bis-tris propane (BTP) pH 6.8, 50
mM NaCl, 5 mM DTT]. After passing the cell lysate over the column, a gradient to 100%
buffer II [25 mM bis-tris propane (BTP) pH 6.8, 1000 mM NaCl, 5 mM DTT] was started
and spanned the volume of 350 ml using a 2.5 ml/min flow rate and 5 ml fraction
volumes. Fractions containing the p53 polypeptides were pooled and concentrated at 4°C
with Vivaspin 20 MWCO 10K (Sartorius AG, Goettingen, Germany) centrifugal
concentration devices.

Gel-filtration
The concentrated fractions containing the p53 polypeptides purified by cation
exchange were loaded onto a SuperDex 200 (GE Healthcare Life Sciences) size exclusion
column equilibrated with 25 mM bis-tris propane [pH 6.8], 150 mM NaCl, 5 mM DTT
buffer at 4°C. A flow rate of 250 µl/min, and fraction sizes of 300 µl, was used to
separate the p53 polypeptides from the remaining bacterial proteins. Fractions containing
the p53 polypeptides were pooled and concentrated to 5 to 15 mg/ml using Microcon
YM-10 micro centrifugal concentration devices (Millipore, Billerica, MA, USA) at 4°C.
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The concentrated purified p53 protein was then flash-frozen in liquid nitrogen and stored
at -80°C until further use.

Purification of p53-DNA complexes
Oligonucleotide annealing
Polyacrylamide gel electrophoresis [PAGE]-purified oligonucleotides (Table m.1)
were resuspended in TE pH 7.6 [10mM Tris, 1mM EDTA] to a final concentration of 200
µM. Equimolar amounts of complementary oligonucleotides 1 and 2 were mixed in one
1.5 ml screw-cap tube for each pair, and placed into a floating tube holder. One liter of
water was brought to boil in a beaker, and the tubes containing the oligonucleotides were
placed in the beaker at water temperature of 96°C for 5 minutes. The beaker containing
the tubes of DNA was then removed from the heat and left to slowly equilibrate to room
temperature on the bench top. When the beaker water temperature reached 25°C, the
annealed oligonucleotides were removed, briefly centrifuged to collect any liquid in the
lids, and stored at 4°C.

Protein-DNA complex purification
All steps were performed either at 4°C or on ice. Purified stable ST p53 variants
were mixed in molar ratios of 4:1 protein:dsDNA (100 µl final volume) on ice in order to
form p53 tetramer-DNA complexes. The protein-DNA mix was incubated on ice for 1
hour then loaded onto a SuperDex 200 (GE Healthcare Life Sciences) size exclusion
column equilibrated with 25 mM bis-tris propane [pH 6.8], 150 mM NaCl, 5 mM DTT
buffer. The complex was passed over the column at a flow rate of 250 µl/minute and
fractions of 370 µl were collected starting 15 minutes after injection of the complex.
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Fractions containing the complex (shown by shift in molecular size and verified by SDSPAGE; Figs. m.3, m.4) were then pooled, concentrated to 5-10mg/ml with Microcon
YM-10 centrifugal concentration devices (Millipore, Billerica, MA, USA), and
immediately used in hanging-drop crystal screening at 4°C.

Figure m.3

Purification of p53-DNA complexes. Two examples of DNA bound by p53 (a) and DNA not
bound by p53 (b). p53 protein alone elutes at fraction 19, DNA alone elutes around fraction 22,
and the p53-bound DNA complex elutes at fractions 13-15. (a) Example of a p53-DNA complex.
Green boxes over DNA (26bp) indicate recognition sequences, chromatogram shows large
protein-DNA peak at fractions 13-15. SDS-PAGE stained with Coomassie blue confirms that
shifted fractions contain p53. (b) Example of an oligonucleotide too short (21bp) to interact
stably with p53 variant ST7. Unbound p53 elutes at fraction 19 (as shown in SDS-PAGE gel
below chromatogram), but does not complex with DNA, and is not enriched in fractions 13-15.
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Figure m.4

Elution profiles for p53, DNA and p53-DNA complexes. Three representative chromatograms
are presented from gel filtration procedures discussed in this methods section. Fraction collection
is always started at the same time following injection of the sample onto the Superdex 200 size
exclusion column. Purified p53 elutes at fraction 19, DNA elutes at fraction 22, and the proteinDNA complex elutes at fractions 13-15. Wavelengths: red curves are 254nm, blue curves are
280nm.
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Table m.1
Oligonucleotide pairs, sense (upper) and anti-sense (lower), used in p53-DNA crystal
screening.
Name

Length

p53tea211
p53tea212

21
21

Sequence
GGG CATG TCT GGG CATG TCT G
AGA CATG CCC AGA CATG CCC C

p53tea221
p53tea222

22
22

GGG CATG TCT GGG CATG TCT AA
AGA CATG CCC AGA CATG CCC TT

p53tea231
p53tea232

23
23

C GGG CATG TCT GGG CATG TCT C G
G AGA CATG CCC AGA CATG CCC G C

p53tea241
p53tea242

24
24

C GGG CATG TCT GGG CATG TCT C AA
G AGA CATG CCC AGA CATG CCC G TT

p53tea251
p53tea252

25
25

AC GGG CATG TCT GGG CATG TCT CA G
TG AGA CATG CCC AGA CATG CCC GT C

p53tea261
p53tea262

26
26

AC GGG CATG TCT GGG CATG TCT CA AA
TG AGA CATG CCC AGA CATG CCC GT TT

p53tea263
p53tea264

26
26

AC GGG CATG TCT GGG CATG TCT CA GA
TG AGA CATG CCC AGA CATG CCC GT TC

p53tea265
p53tea266

26
26

AC GGG CATG TCT GGG CATG TCT CA GG
TG AGA CATG CCC AGA CATG CCC GT CC

p53tea267
p53tea268

26
26

AC GGG CATG TCT GGG CATG TCT CA CC
TG AGA CATG CCC AGA CATG CCC GT GG

p53tea2609
p53tea2610

26
26

p53tea2611
p53tea2612

26
26

AC GGG CATG CTT GAG CATG TCT CA GA
TG AGA CATG CTC AAG CATG CCC GT TC

p53tea2613
p53tea2614

26
26

AC GGG CATG TAA TGG CATG TCT CA GA
TG AGA CATG CCA TTA CATG CCC GT TC

p53tea2615
p53tea2616

26
26

AC GGG CATG TCT GGG CAAG TCT CA GA
TG AGA CTTG CCC AGA CATG CCC GT TC

p53tea2617
p53tea2618

26
26

AC GGG CATG TCT GGG CACG TCT CA GA
TG AGA CGTG CCC AGA CATG CCC GT TC

p53tea271
p53tea272

27
27

AC A GGG CATG TCT GGG CATG TCT CA AA
TG AGA CATG CCC AGA CATG CCC T GT TT

.

AG AC GGG CATG TCT GGG CATG TCT CA
CT TG AGA CATG CCC AGA CATG CCC GT

.

.
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Crystal screening
All crystal screening, incubation, analysis and cryopreservation procedures were
performed in a 4°C cold-room. The conditions promoting crystal growth were probed
using crystal screening kits sampling a wide range of pH, anions, cations and polymers
(Polyethylene glycols) such as the primary biased sparse matrix Crystal Screen, Index,
PEG/Ion, SaltRX, and Natrix Screens (Hampton Research, Aliso Viejo, CA, USA) as
well as home-made screens, in addition to screening some promising conditions with
small-molecule additives; in all sampling over 1,000 different crystallographic conditions
per protein or protein-DNA sample. Additionally, various protein-precipitant ratios in the
range of 0.5:1 to 2:1 protein: precipitant were screened for most conditions. The majority
of screens were set up in 48-well greased-edge VDX plates using 1mm thick circular
coverslips to support the crystal drops, while some screens were performed in 96-well
sitting drop plates (Hampton Research). Drops were manually observed and analyzed for
the presence of crystals using a Leica stereo microscope, fitted with circular polarizers, in
a 4°C cold-room.

Colony assay
Saos 2 osteosarcoma cells (p53

-/-

) were grown to ~60% confluency and co-

transfected (FuGene, Roche Applied Science, Indianapolis, IN, USA) with plasmids
containing the Neo marker and one of three hp53 variants: WT, full length containing
mutations of crystallized variant (ST), and D248Q which abolishes DNA binding. The
cells were exposed to various concentrations (300µg, 500µg and 800µg/ml final
concentration) of G418 Geneticin (Gibco BRL Life Technologies, Inc), with medium
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changes including fresh G418 every three days, over the course of two weeks. In order to
count transformed cells (visible colonies), the cells are fixed to the 10cm plate by
removing the media and adding 3 ml 3.7% w/w formaldehyde in phosphate-buffered
saline [PBS with Ca2+ and Mg2+] and incubated at ambient room temperature for 5
minutes. The PBS/formaldehyde was then removed and 3ml of 0.05% methylene blue (in
water) was added for 10 minutes at room temperature to stain the cells. After staining,
plates were washed four times with water, left upside down to dry, and visible colonies
are counted.

Quantitative PCR
Saos 2 osteosarcoma cells (p53 -/-) grown to ~60% confluency were transfected
(FuGene, Roche Applied Science, Indianapolis, IN, USA) with plasmids containing one
of three hp53 variants: WT, full length containing mutations of crystallized variant (ST),
and D248Q which abolishes DNA binding. Total RNA was extracted (RNeasy, Qiagen,
Germantown, MD, USA) from cells harvested at various time points ranging from one to
three days after transfection and cDNA was made (PrimeScript 1st strand cDNA
synthesis, Takara Bio Inc., Otsu, Shiga, Japan) from the extracted RNA. Quantative PCR
was performed using primer sets for GAPDH (housekeeping), p53, p21, NoxA, SCOTIN,
BAX and GADD45B (Roche Lightcycler 480 Real-Time PCR system) using LightCycler
480 SYBR Green 1 Master reagents (Roche Applied Science, Indianapolis, IN, USA).
The 10 µl reactions contained 300-400ng cDNA, and PCR temperature parameters were:
95°C for 5 min (denaturation), then 40 amplification and detection cycles of 95°C for 15
sec, 60°C for 20 sec, 72°C for 20 sec, followed by a final one minute 95° C to 55° C
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melting curve analysis to confirm single-product amplification. The oligonucleotides
used in this analysis are listed below in Table m.2.

Table m.2
Oligonucleotide pairs, sense (upper) and anti-sense (lower), used for qPCR
Name

Product Size (bp)

Sequence

BAX
RTPCR_BAXh_1
RTPCR_BAXh_2

200

GCTCTGAGCAGATCATGAA
ATCATCCTCTGCAGCTCCA

Gadd45B
RTPCR_GADD45Bh_1
RTPCR_GADD45Bh_2

195

GGATTTTGCAATTTCTCC
CTCGTACACCCCCACTGT

GAPDH
RTPCR_GAPDHh_1
RTPCR_GAPDHh_2

724

TCTCTGCCCCCTCTGCTG
ACGCCTGCTTCACCACCT

Human p53
RTPCR_hp53_1
RTPCR_hp53_2

207

AGCCGCAGTCAGATCCTA
AGCAGCCTCTGGCATTCT

NoxA
RTPCR_NOXAh_1
RTPCR_NOXAh_2

248

TGGAAACGGAAGATGGAA
CCCAGTCTAATCACAGGT

p21
RTPCR_p21h_1
RTPCR_p21h_2

415

AGCTCTACCTTCCCACGG
CAGGGTATGTACATGAGG

294

TGGAGCGAGGAAAGGTGTG
GGAGGCTGAGGATAAGGGG

Scotin
RTPCR_SCOTINh_1
RTPCR_SCOTINh_2
.

.

.
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DNA binding characterization
In vitro transcription-translation
[35S]-methionine-labeled full-length human wild-type p53 and the equivalent p53
protein containing the stabilizing amino acid substitutions (ST7, Fig. 2.2, Fig. m.5) were
expressed by using a coupled in vitro transcription-translation rabbit reticulocyte lysate
system (Promega Corporation, Madison, WI, USA). Each 23 µl reaction was built by
combining all ingredients (Fig. m.5) with the final addition of 2µl of [35S]-methionine to
start the reaction. Immediately after the 1.5 hour incubation at 30°C the IVT-proteins
were used in the DNA binding gel shift assays.

DNA binding gel-shift assay
The radiolabeled in vitro translated p53 proteins were mixed at ambient room
temperature with oligonucleotides containing consensus or variant p53 DNA binding
sites (described in chapter 2, Fig. 2.5b) in reactions consisting of 1 µl IVT translated
protein, 1 µl 50 µM dsDNA, 1 µl of 10X E-Zn buffer [100 mM Tris pH 8.0, 10 mM DTT,
50% glycerol, 500 mM NaCl, 1 mM ZnOAc] and water to final volume of 10 µl, for 30
minutes. The binding reaction was then analyzed on non-denaturing acrylamide trisglycine slab gels. The vertical gels were made with 5X Tris-glycine buffer [30.3 g Tris
base, 144.1 g glycine, 20 ml 0.5 M EDTA] by mixing 31.5 ml water, 10 ml 5X Trisglycine buffer and 8.5 ml 30X acrylamide. Before sample loading, gels were pre-run at
110V for 1.5 hours in 0.5X Tris-glycine buffer. The binding reactions were directly
loaded into the gels and separated for 1 hour at 110V. After electrophoresis, the gels were
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dried for 1.5 hours, and exposed to a phosphor screen that was scanned (Personal
Molecular Imager, Bio-Rad Laboratories, Inc. Hercules, CA, USA) two days later.

Figure m.5

Representative SDS-PAGE scan of in vitro transcription-translation reactions. The luciferase
control (green), wild-type (blue) and ST7 (orange) p53 variants are labeled on the gel with
corresponding colored dots.
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Introduction
As described in chapters 6 and 7, computational homology modeling of human
endothelial lipase [hEL] was used to generate insights into the structural and functional
details of this newly characterized lipase family member (1,2). Although the specificity
of endothelial lipase towards high-density lipoprotein [HDL] has been well characterized
experimentally, there is no structural data available to describe the mechanisms
governing the propensity for hEL towards HDL hydrolysis. Experimental investigation of
this lipase variant remains challenging due to the nature of post-translational
modifications, and has rendered traditional expression systems inadequate for producing
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the levels of pure protein required for crystallographic analysis. In the absence of a
human endothelial lipase crystal structure, X-ray crystal structures from pancreatic and
lipoprotein lipases were used as guides to generate an ensemble of human endothelial
lipase models via comparative protein structure modeling for further investigation. This
appendix is divided into some of the various topics that were investigated in this
collaboration.

Model Generation
Template structures
The comparative protein structure modeling was performed using Modeller (3-6)
(verions 8 through 9). Three lipase structures were used as input for the modeling
process:
Human Pancreatic Lipase
PDB code: 1N8S
The pancreatic lipase (Homo sapiens)– colipase (Sus scrofa) complex7.
Human Pancreatic Lipase with Inhibitor
PDB code: 1LPB
The pancreatic lipase (Homo sapiens) complexed with colipase (Sus scrofa) and
inhibited by undecane phosphonate methyl ester8:
Horse Pancreatic Lipase
PDB code: 1HPL
The pancreatic lipase (Equus caballus) structure9:
Multiple sequence alignments were generated with human endothelial lipase and
the three lipase structure sequences [1N8S, 1LPB, 1HPL] using ClustalW (10) (Fig.
a1.2). From the alignments, ensembles of models (100 to 200) were created in order to
assess structural differences among the models. Using the ten best models (lowest RMSD
for backbone atoms among models and DOPE scores comparable to template structures)
as input “base” structures, 5 additional activation-lid models were generated for each
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base model. During this step, the α-helices, β-strands and β-sheets were fixed while
allowing sampling of loop regions within this context. One representative alignment of
10 models shows agreement in backbone conformation (Fig. a1.1).

Figure a1.1

Structural overlay of 10 models. The backbone atoms (n, ca, c, o) of 10 hEL models were
structurally aligned. Central core regions show a high degree of similarity among models,
whereas the solvent exposed loop regions exhibit higher positional variability.

Model selection
An atomic distance-dependant statistical potential, optimized for model
assessment and referred to as the discrete optimized protein energy method [DOPE], is
included in the Modeller suite (11). This objective function was used to find low-scoring
models representing DOPE scores close to those of the reference models (template
structure). The DOPE profiles and scores for all models, in addition to the template
structures, were calculated using MODELLER version 9v1 with a smoothing window of 15
residues. A single lipase chain in each crystal structure was used in the calculations,
disregarding co-lipases and in the case of the 1HPL dimer structure, disregarding one of
the monomers. The overall DOPE score of endothelial lipase is within 87% of the score
for 1HPL, 88% for 1N8S, and 88% for 1LPB. The residue-specific DOPE energy values
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of the models were subsequently plotted against the DOPE profiles of representative
template structures. The graphs generated from this analysis confirm that reasonable
models were generated, with energy values close to those of the template structures (Fig.
a1.3b).

Four regions in the models exhibit slightly higher DOPE values than those of the
templates (Fig. a1.3a). Amino acid numbering is for the secreted protein, after cleavage
of the 20 amino acid signal peptide. The first, consisting of human EL residues 4-51,
maps to the solvent exposed aminoterminal region of human endothelial lipase. The
second region, residues 300-320, is positioned at the junction of the amino and carboxyterminal domains of the lipase, also exposed to solvent. The third and fourth regions,
amino acids 339-347 and 427-440, respectively, lie on the solvent exposed far edge of the
carboxyterminal domain. The relative variability of these regions from model to model is
illustrated by B-factor putty in Fig. a1.3a, wider ribbons represent regions of higher
structural variability among models. In X-ray crystallography the B-factor, also known as
“temperature-factor”, is a term used to describe the degree to which the electron density
for each atom is spread out, reflecting the dynamic mobility of that atom. In this case, the
cartoon in Fig. a1.3a represents the positional variability among the models. Therefore
the higher DOPE scores found in these regions might only reflect the increased
flexibility, and not necessarily signify poorly modeled regions. The remaining regions of
the models, especially those regions surrounding the conserved catalytic triad (Ser149,
Asp173, His254) exhibit DOPE scores similar to those of the templates, demonstrating
that the models are acceptable representations of energy minimized native states.
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Figure a1.2
1N8S
1LPB
1HPL
ELhu

-----KEVCYERLG-CFSDDSPWSGITERPLHILPWSPKDVN------TRFLLYTNENP-----KEVCYERLG-CFSDDSPWSGITERPLHILPWSPKDVN------TRFLLYTNENP-----NEVCYERLG-CFSDDSPWAGIVERPLKILPWSPEKVN------TRFLLYTNENPMSNSVPLLCFWSLCYCFAAGSPVPFGPEGRLEDKLHKPKATQTEVKPSVRFNLRTSKDPE
:*: * **: .** .
* *.
.*: .:
.** * *.::*

47
47
47
20

1N8S
1LPB
1HPL
ELhu

-NNFQEVAADSSSISGSNFKTNRKTRFIIHGFIDKGE-ENWLANVCKNLFKVES-VNCIC
-NNFQEVAADSSSISGSNFKTNRKTRFIIHGFIDKGE-ENWLANVCKNLFKVES-VNCIC
-DNFQEIVADPSTIQSSNFNTGRKTRFIIHGFIDKGE-ESWLSTMCQNMFKVES-VNCIC
HEGCYLSVGHSQPLEDCSFNMTAKTFFIIHGWTMSGIFENWLHKLVSALHTREKDANVVV
:.
......:....*:
** *****: .* *.** .: . :.. *. .* :

104
104
104
100

1N8S
1LPB
1HPL
ELhu

VDWKGGSRTGYTQASQNIRIVGAEVAYFVEFLQSAFGYSPSNVHVIGHSLGAHAAGEAGR
VDWKGGSRTGYTQASQNIRIVGAEVAYFVEFLQSAFGYSPSNVHVIGHSLGAHAAGEAGR
VDWKSGSRTAYSQASQNVRIVGAEVAYLVGVLQSSFDYSPSNVHIIGHSLGSHAAGEAGR
VDWLPLAHQLYTDAVNNTRVVGHSIARMLDWLQEKDDFSLGNVHLIGYSLGAHVAGYAGN
***
:: *::* :* *:** .:* :: **. .:* .***:**:***:*.** **.

164
164
164
160

1N8S
1LPB
1HPL
ELhu

RTNGTIGRITGLDPAEPCFQGTPELVRLDPSDAKFVDVIHTDGAPIVPNLGFGMSQVVGH
RTNGTIGRITGLDPAEPCFQGTPELVRLDPSDAKFVDVIHTDGAPIVPNLGFGMSQVVGH
RTNGAVGRITGLDPAEPCFQGTPELVRLDPSDAQFVDVIHTDIAPFIPNLGFGMSQTAGH
FVKGTVGRITGLDPAGPMFEGADIHKRLSPDDADFVDVLHTYTRSFG--LSIGIQMPVGH
.:*::********* * *:*:
**.*.**.****:**
.:
*.:*:. .**

224
224
224
218

1N8S
1LPB
1HPL
ELhu

LDFFPNGGVEMPGCKKNILSQIVDIDGIWEGTRDFAACNHLRSYKYYTDSIVNPDG-FAG
LDFFPNGGVEMPGCKKNILSQIVDIDGIWEGTRDFAACNHLRSYKYYTDSIVNPDG-FAG
LDFFPNGGKEMPGCQKNVLSQIVDIDGIWQGTRDFAACNHLRSYKYYTDSILNPDG-FAG
IDIYPNGGDFQPGCGLNDVLGSIAYG----TITEVVKCEHERAVHLFVDSLVNQDKPSFA
:*::****
*** * :
: .
:.. *:* *: : :.**::* *
.

283
283
283
274

1N8S
1LPB
1HPL
ELhu

FPCASYNVFTANKCFPCPSGGCPQMGHYADRYPGKTNDVGQKFYLDTGDASNFARWRYKV
FPCASYNVFTANKCFPCPSGGCPQMGHYADRYPGKTNDVGQKFYLDTGDASNFARWRYKV
FSCASYSDFTANKCFPCSSEGCPQMGHYADRFPGRTKGVGQLFYLNTGDASNFARWRYRV
FQCTDSNRFKKGICLSCRKNRCNSIGYNAKKMRNKRN---SKMYLKTRAGMPFRVYHYQM
* *:. . *. . *:.* . * .:*: *.: .: :
. :**.* . * ::*::

343
343
343
331

1N8S
1LPB
1HPL
ELhu

SVTLSGKK----VTGHILVSLFGNKGNSKQYEIFKGT-LKPDSTHSNEFDSDVDVGDLQM
SVTLSGKK----VTGHILVSLFGNKGNSKQYEIFKGT-LKPDSTHSNEFDSDVDVGDLQM
DVTLSGKK----VTGHVLVSLFGNKGNSRQYEIFQGT-LKPDNTYSNEFDSDVEVGDLEK
KIHVFSYKNMGEIEPTFYVTLYGTNADSQTLPLEIVERIEQNATNTFLVYTEEDLGDLLK
.: : . *
:
. *:*:*.:.:*:
:
:: : * : . :: ::***

398
398
398
391

1N8S
1LPB
1HPL
ELhu

VKFIWYNN-VINPTLPRVGASKIIVETNVGKQFNFCSPETVREEVLLTLTPC-------VKFIWYNN-VINPTLPRVGASKIIVETNVGKQFNFCSPETVREEVLLTLTPC-------VKFIWYNN-VINLTLPKVGASKITVERNDGSVFNFCSEETVREDVLLTLTAC-------IQLTWEGASQSWYNLWKEFRSYLSQPRNPGRELNIRRIRVKSGETQRKLTFCTEDPENTS
::: * .
.* :
* :
* * :*:
..
:. .** *

449
449
449
451

1N8S
1LPB
1HPL
ELhu

------------------------------------------------------------------------------------ISPGRELWFRKCRDGWRMKNETSPTVELP 480

Sequence Alignment of human endothelial lipase to pancreatic lipase structures. The
sequences of three crystal structures were aligned to the hEL sequence as an initial guide for
homology modeling. Catalytic triad Ser149, Asp173, His254, Lid region, and conserved
disulfide bridges are highlighted accordingly. The 20-residue leader peptide (light grey) is
cleaved from the active hEL, and the 37 carboxyterminal residues (light grey) were not modeled
as no three-dimensional data was available for this region.
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Function
Catalytic triad residues
The catalytic triad residues, required for enzymatic function, were investigated
with attention to rotamer position in relation to the pancreatic lipase X-ray crystal
structures. These three residues appear in similar orientation and location to the guide
structures, providing evidence that the models are representative of a functional human
endothelial lipase conformation. The root mean square deviations [RMSDs] for a
representative hEL model to the human Pancreatic Lipase structure for all atoms within
each catalytic residue were calculated with at:
RMSD for S149 = 0.636 Å
RMSD for D173 = 0.312 Å
RMSD for H254 = 0.475 Å
Three disulfide bridges are also present in the models formed from six conserved
cysteine residues (Fig. a1.2). One bridge is formed by Cys232 and Cys252, located
directly on either side of the activation lid, and potentially serves to stabilize the active
site during catalytic lid displacement. Two other bridges, Cys277 to Cys288 and Cys291
to Cys296, are positioned in loops located close to hinge region connecting the Nterminal domain from C-terminal domain.
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Figure a1.3

Discrete optimized protein energy [DOPE] profile for representative hEL models.
(a) B-factor putty diagram of the EL model. Four regions of slightly higher DOPE energy
score are colored and marked with corresponding blue guide bars. The three catalytic residues:
Ser149, Asp173, and His254 are shown as red sticks. (b) DOPE profiles of template (guide)
structures are traced in yellow, orange and red. Representative model DOPE profiles are depicted
with blue and green curves. Four regions of the models that exhibit slightly higher energy values
than guide structures are highlighted with blue boxes. Locations of the three catalytic triad
residues along the amino-acid sequence are marked with black lines.
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Activation lid and substrate specificity
Reports demonstrate that triacylglyceride hydrolysis increases with increased
amphiphacity of lid residues (12-18). Likewise, biochemical experiments probing
substrate specificity showed that lid region mutations affected preferences for hydrolysis
of substrates. Furthermore, it is known that the charge state of residues on the lid greatly
affects the ability for particular lipases to recognize and properly hydrolyze its substrate
(15,18). These studies demonstrate that lid opening or closing correlates with enzyme
either activity, and that the size and geometry of the cleft under the lid and around the
catalytic center relates to substrate specificity.

The hEL activation lid sequence is 232-CGLNDVLGSIAYGTITEVVKC-252.
Conserved cysteines Cys232 and Cys252 form a disulfide bridge at the base of the
activation lid. Residues lining the catalytic pocket opposite the activation lid help to
stabilize the lid in the closed position over the active site. There is a local enrichment in
large ring residues such as tryptophan, tyrosine and histidine in the cleft under the lid
region of human endothelial lipase (Fig. a1.5a). If residues in this region were mutated to
amino acids with smaller side chains, this might destabilize the closed conformation of
the lid loop, possibly leading to a lipase with increased basal activity.
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Figure a1.4
a

b

c

Structural alignment (c) of (a) human endothelial lipase (white) with ring residues (red sticks)
and (b) horse Pancreatic Lipase lid (yellow) with ring residues (blue sticks).

Substrate specificity
The hEL models also provide a basis to investigate residues potentially involved in
conferring hEL substrate specificity. The models were structurally aligned using
MacPyMOL (version 0.96, DeLano Scientific LLC), to both horse (PDB code: 1HPL)
and human pancreatic lipase (PDB codes: 1N8S, 1LPB) crystal structures. Residues
within 8 Å of the center of the catalytic triad were then selected for analysis. Next, four
different human lipase protein sequences were aligned:
Endothelial Lipase
Lipoprotein Lipase
Hepatic Lipase
Pancreatic Lipase

gi|38174526|
gi|48146225|
gi|1695682|
gi|15679998|

Given that each lipase has different substrate selectivity, and in order to find residues that
might contribute to this substrate specificity, if a given position had identical residues
among the four lipases, it was removed from this set.
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The remaining subset then contained only those residues that vary across lipase
type (and thus could confer substrate specificity). Multi-species sequences alignments of
endothelial lipase,
Homo sapiens:
Macaca mulatta:
Rattus norvegicus:
Mus musculus:
Xenopus laevis:

gi|5174497|ref|NP_006024.1
gi|109122163|ref|XP_001090086.1
gi|60678260|ref|NP_001012759.1
gi|31543123|ref|NP_034850.2
gi|38174469|gb|AAH60756.1

revealed the residues within this subset that vary within endothelial lipase, which were
subsequently removed from this second subset. Residues showing substitutions through
evolution were assumed to be less important in contributing to substrate specificity.

The remaining residues are conserved in endothelial lipase across five species,
and are within 8 Å of the center of the catalytic triad, yet are not conserved across various
lipase types. This analysis might suggest that these particular residues confer substrate
specificity for endothelial lipase: W72, M74, T118, I146, Y148, V154, A155, P174,
G176, V198, L199, Y201, T202, L208, S209, I210, I212, D227, Q229, G233, Y243,
V250, K251, E253, E255, V258, H259, L260. Four residues in this list, Gly233, Tyr243,
Val250 and Lys251, are located in the activation lid region between the conserved
cysteines Cys232 and Cys252. This is in agreement with biochemical evidence
demonstrating that the amino-acid composition of the activation lid influences substrate
specificity.
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Calcium coordination
Calcium binding sites are common features of extracellular enzymes, such as
proteases, and coordination of calcium has a large stabilizing effect. The protease
Proteinase K from a thermophilic fungus contains two calcium binding sites, and the
other crystallized forms of lipase also coordinate one calcium atom per monomer (79,19). Calcium coordination could therefore be important to endothelial lipase stability
and function. There is a potential calcium-binding site in the human endothelial lipase
models that is in line with the crystal structure of horse pancreatic lipase. Using
MacPyMOL, the human endothelial lipase models were structurally aligned to the Equus
caballus pancreatic lipase (PDB code: 1HPL) crystal structure.

Spatial analysis of residues in the hEL models (selecting residues within 4 Å of
the calcium atom located in the 1HPL structure) revealed four residues of hEL in similar
orientation and distance that may be involved in binding calcium. The residues used in
horse pancreatic lipase to coordinate calcium are: Glu187 and Arg190, both through
interactions with their backbone carbonyl, and Asp192 and Asp195. The residues in hEL
that most probably coordinate calcium are: Ile184 (same backbone carbonyl as the horse
Glu187), Arg187 (same backbone carbonyl as horse Arg190 and conserved in all lipases),
Ser189 (same side-chain location as horse Asp192) and Asp192 (also in the same
position as horse Asp195 conserved in all lipases). Furthermore, these four endothelial
lipase residues share similar spatial distances along the sequence chain as the horse
pancreatic lipase calcium coordinating residues. The local structure is overall very similar
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among the crystal structures and the models in this region. Furthermore, the
corresponding residues are conserved across various lipases.

Figure a1.5

Calcium coordination. Human endothelial lipase (red) aligned to horse pancreatic lipase (blue).
Conserved residues that interact with calcium (green sphere) are shown as sticks and labeled
according to hEL residue index.

Mutations in population
According to the current biological data for human endothelial lipase, there are
four mutations [G26S, T111I, T298S, N396S] associated with high levels of circulating
HDL, implying the endothelial lipase has impaired enzymatic activity in these cases (20).
The N396S substitution causes a two-fold reduction in activity when compared to wildtype hEL. N396 is located very close to the glycosylation site N393, and prevention of
N393 glycosylation is likewise known to cause a two-fold reduction in enzymatic
activity. However, removal of another glycosylation site at N136A causes a 3-fold
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enhanced activity of hEL. The hEL models could provide a basis to understanding how
glycosylation might affect activity.

The four mutations were introduced, one at a time, to the wild-type sequence of
human endothelial lipase. The sequences containing the point mutations were then used
as input for the homology modeling process to generate theoretical structures containing
these mutations. Representative models of each of these mutations were then aligned to
the wild-type models. In Fig. a1.7, these alignments are graphically depicted in two
different orientations. Green arrows highlight the mutated residues in each view. The
wild-type sequences are shaded blue while the mutated endothelial lipase models are
colored red. The residue of interest is likewise represented as a “stick” versus the “line”
in the non-surface rendered monomer.

The mutations do not dramatically affect the structure (both local or global
conformation) of the lipase when compared with wild-type models. If the endothelial
lipase does function as a dimer, then all but the T111I mutations occur on the distal side
of the functional area (activation lid and catalytic triad). Hypothetically, the activation lid
opens towards the interior cavity created by the dimer. If that is indeed the case, then only
the T111I is positioned near the dimer interface. If one or more of the other mutated
residues are involved in allosteric regulation via glycosylation or other post-translational
modifications, then it fits that these residues would be positioned on the distal, solventexposed side of the dimer interface.
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Figure a1.6

a

b

Four mutations in human endothelial lipase (indicated by green arrows) associated with high
levels of circulating HDL in the bloodstream. (a) View of solvent exposed surface indicating
location of G26S (green), T298S (orange), N396S (blue), in the context of a hEL homodimer. (b)
Position of T111I (purple), located on the side of the potential dimer interface. Residues within 5
Å of the dimer interface are colored red.
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Potential dimer interface residues
The human endothelial lipase monomer model was structurally aligned to the
horse pancreatic lipase homodimer. The resulting human endothelial lipase dimer model
was then used to highlight residues on one monomer within 5 Å of the opposite
monomer. A figure from this analysis is shown in Table a1.1, with those residues near the
interface colored in red or yellow. A list of corresponding residues is also shown below.

Table a1.1

Region 1
Region 1
Region 2
Region 3
42
Q
96
G
339
R
413
Q
43
T
97
I
342
M
414
L
44
E
98
F
380
Q
415
T
46
K
99
E
381
T
416
W
47
P
100
N
403
E
417
E
61
H
124
L
418
G
62
E
125
P
420
S
63
G
128
H
421
Q
64
C
422
S
List of residues potentially involved in the hEL dimer interface
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Region 3
424
Y
452
K
453
S
454
G
455
E
456
T
457
Q
458
R
459
K
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Appendix II
p53 Supplementary Figures & Tables.

Figure a2.1

Somatic mutations in p53 – mutation affect. 24,785 total mutations. IARC TP53 mutation
database, R13 release, November 2008
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Figure a2.2

From: Millau JF, Bastien N, Drouin R. P53 transcriptional activities: a
general overview and some thoughts. Mutat Res. (2009) 681:118-33.
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Figure a2.3
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Figure a2.4

Aligned p53 DNA-binding domains. This alignment, with ST p53 sequence as the first entry,
was used to calculate relative conservation for graphs presented in Fig. 3.7. Alignment created in
ClustalW (EMBL-EBI) and colored by conservation in JalView (Waterhouse et al. 2009). Darker
blue correlates with higher conservation.

- 261 -

Table a2.1
p53 (and homologous) DNA-Binding domain sequences presented in multiple sequence
alignment (Fig a2.4)
Reference for composition-based statistics:
Schaffer, Alejandro A., L. Aravind, Thomas L. Madden,
Sergei Shavirin, John L. Spouge, Yuri I. Wolf,
Eugene V. Koonin, and Stephen F. Altschul (2001),
"Improving the accuracy of PSI-BLAST protein database searches with
composition-based statistics and other refinements", Nucleic Acids Res. 29:2994-3005.
Query= FILE_A 198
(198 letters)
Database: sprot
510,076 sequences; 179,409,349 total letters
Sequences producing significant alignments:
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40

sp|P04637|P53_HUMAN Cellular tumor antigen p53 OS=Homo sapiens G...
sp|Q95330|P53_RABIT Cellular tumor antigen p53 OS=Oryctolagus cu...
sp|P13481|P53_CERAE Cellular tumor antigen p53 OS=Cercopithecus ...
sp|P56423|P53_MACFA Cellular tumor antigen p53 OS=Macaca fascicu...
sp|P61260|P53_MACFU Cellular tumor antigen p53 OS=Macaca fuscata...
sp|P56424|P53_MACMU Cellular tumor antigen p53 OS=Macaca mulatta...
sp|Q64662|P53_SPEBE Cellular tumor antigen p53 (Fragment) OS=Spe...
sp|Q9TTA1|P53_TUPGB Cellular tumor antigen p53 OS=Tupaia glis be...
sp|O36006|P53_MARMO Cellular tumor antigen p53 OS=Marmota monax ...
sp|P10361|P53_RAT Cellular tumor antigen p53 OS=Rattus norvegicu...
sp|Q8SPZ3|P53_DELLE Cellular tumor antigen p53 OS=Delphinapterus...
sp|Q9TUB2|P53_PIG Cellular tumor antigen p53 OS=Sus scrofa GN=TP...
sp|Q00366|P53_MESAU Cellular tumor antigen p53 OS=Mesocricetus a...
sp|O09185|P53_CRIGR Cellular tumor antigen p53 OS=Cricetulus gri...
sp|P79892|P53_HORSE Cellular tumor antigen p53 (Fragment) OS=Equ...
sp|P02340|P53_MOUSE Cellular tumor antigen p53 OS=Mus musculus G...
sp|P67938|P53_BOSIN Cellular tumor antigen p53 OS=Bos indicus GN...
sp|P67939|P53_BOVIN Cellular tumor antigen p53 OS=Bos taurus GN=...
sp|P51664|P53_SHEEP Cellular tumor antigen p53 OS=Ovis aries GN=...
sp|Q9WUR6|P53_CAVPO Cellular tumor antigen p53 OS=Cavia porcellu...
sp|Q29537|P53_CANFA Cellular tumor antigen p53 OS=Canis familiar...
sp|P41685|P53_FELCA Cellular tumor antigen p53 OS=Felis catus GN...
sp|Q29480|P53_EQUAS Cellular tumor antigen p53 (Fragment) OS=Equ...
sp|P79734|P53_DANRE Cellular tumor antigen p53 OS=Danio rerio GN...
sp|Q9W678|P53_BARBU Cellular tumor antigen p53 OS=Barbus barbus ...
sp|P10360|P53_CHICK Cellular tumor antigen p53 OS=Gallus gallus ...
sp|P25035|P53_ONCMY Cellular tumor antigen p53 OS=Oncorhynchus m...
sp|O93379|P53_ICTPU Cellular tumor antigen p53 OS=Ictalurus punc...
sp|P07193|P53_XENLA Cellular tumor antigen p53 OS=Xenopus laevis...
sp|Q92143|P53_XIPMA Cellular tumor antigen p53 OS=Xiphophorus ma...
sp|O57538|P53_XIPHE Cellular tumor antigen p53 OS=Xiphophorus he...
sp|Q9JJP2|P73_MOUSE Tumor protein p73 OS=Mus musculus GN=Tp73 PE...
sp|Q9XSK8|P73_CERAE Tumor protein p73 OS=Cercopithecus aethiops ...
sp|O15350|P73_HUMAN Tumor protein p73 OS=Homo sapiens GN=TP73 PE...
sp|Q9JJP6|P63_RAT Tumor protein 63 OS=Rattus norvegicus GN=Tp63 ...
sp|Q9H3D4|P63_HUMAN Tumor protein 63 OS=Homo sapiens GN=TP63 PE=...
sp|O88898|P63_MOUSE Tumor protein 63 OS=Mus musculus GN=Tp63 PE=...
sp|Q9W679|P53_TETMU Cellular tumor antigen p53 OS=Tetraodon miur...
sp|O12946|P53_PLAFE Cellular tumor antigen p53 OS=Platichthys fl...
sp|P79820|P53_ORYLA Cellular tumor antigen p53 OS=Oryzias latipe...
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Score E
(bits) Value
370
367
361
361
361
361
361
355
355
352
350
349
348
347
343
343
342
342
338
338
338
332
285
281
278
275
275
262
259
242
241
239
238
238
236
236
236
234
227
223

e-102
e-101
2e-99
2e-99
2e-99
2e-99
2e-99
9e-98
1e-97
1e-96
4e-96
8e-96
1e-95
2e-95
4e-94
5e-94
1e-93
1e-93
1e-92
1e-92
2e-92
8e-91
1e-76
2e-75
2e-74
1e-73
2e-73
1e-69
7e-69
1e-63
2e-63
6e-63
1e-62
2e-62
8e-62
8e-62
8e-62
2e-61
3e-59
8e-58

Figure a2.5

Figure a2.6

From: Millau JF, Bastien N, Drouin R. P53 transcriptional activities: a
general overview and some thoughts. Mutat Res. (2009) 681:118-33.
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Table a2.2
p53 response element base pair step parameters. DNA structural parameters for were analyzed
using the X3DNA software package (Hassan & Calladine 1998). All displacements are measured
in Angstroms. Pictorial definitions of the step parameters are explained in Fig. a2.7. Shifted
regions are highlighted with green boxes (p53 tetramer-DNA structure) or blue boxes (model Bform DNA). Conserved C[A/T][A/T]G sequences are red.
Multidomain p53 Oligomer bound to DNA
Step
1 AC/GT
2 CG/CG
3 GG/CC
4 GG/CC
5 GC/GC
6 CA/TG
7 AT/AT
8 TG/CA
9 GT/AC
10 TC/GA
11 CT/AG
12 TG/CA
13 GG/CC
14 GG/CC
15 GC/GC
16 CA/TG
17 AT/AT
18 TG/CA
19 GT/AC
20 TC/GA
21 CT/AG
22 TC/GA
23 CA/TG

Shift
Slide
Rise
Tilt
Roll
Twist
0.44
0.30
3.17
4.89
4.61
31.53
-0.07
1.89
3.27
-1.16
5.47
27.74
-0.77
-0.00
3.51
-5.65
1.39
37.34
0.88
-0.23
3.31
3.04
2.91
37.93
-0.12
-0.72
3.25
-1.16
-0.19
31.54
0.97
0.85
3.44
5.46
5.68
44.77
0.02
-0.30
3.16
-0.80
12.48
18.36
-1.16
0.36
3.58
-2.58
4.38
42.46
-0.19
-0.94
3.28
-1.09
-0.26
33.00
-0.94
-0.39
3.35
-1.23
-2.48
34.77
-0.41
0.66
3.37
-1.03
6.60
29.60
-0.10
2.62
3.17
-1.22
-3.58
44.11
0.50
0.32
3.20
0.61
4.28
33.30
0.71
-0.22
3.48
3.85
-1.63
35.95
0.22
-0.67
3.21
1.01
-0.59
36.01
1.37
0.70
3.59
2.04
4.85
41.64
-0.26
-0.44
2.97
1.32
12.46
17.96
-1.22
0.95
3.62
-3.59
5.68
43.43
-0.22
-0.88
3.16
-2.57
1.49
33.77
-0.31
-0.18
3.40
-1.37
2.71
34.35
-0.08
-0.68
3.30
4.03
4.79
35.29
0.88
1.30
3.11
3.46
1.51
32.26
-0.08
0.57
3.50
-4.06
7.72
41.62
~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~
ave.
0.00
0.21
3.32
0.10
3.49
34.73
s.d.
0.68
0.90
0.17
3.00
4.14
7.06

B-form DNA
Step
1 AC/GT
2 CG/CG
3 GG/CC
4 GG/CC
5 GC/GC
6 CA/TG
7 AT/AT
8 TG/CA
9 GT/AC
10 TC/GA
11 CT/AG
12 TG/CA
13 GG/CC
14 GG/CC
15 GC/GC
16 CA/TG
17 AT/AT
18 TG/CA
19 GT/AC
20 TC/GA
21 CT/AG
22 TC/GA
23 CA/TG

Shift
Slide
Rise
Tilt
Roll
Twist
0.02
0.49
3.36
0.02
1.71
36.83
0.00
0.41
3.34
0.00
1.70
33.93
0.01
0.47
3.36
-0.03
1.71
35.96
0.01
0.47
3.36
-0.03
1.71
35.97
-0.00
0.54
3.38
-0.00
1.72
37.99
-0.04
0.44
3.35
0.01
1.71
35.09
0.00
0.44
3.35
0.00
1.71
35.67
0.04
0.44
3.35
-0.01
1.71
35.08
-0.02
0.49
3.36
-0.02
1.71
36.83
0.03
0.50
3.37
0.01
1.71
37.13
-0.03
0.42
3.35
0.01
1.70
34.80
0.04
0.44
3.35
-0.01
1.71
35.09
0.01
0.47
3.36
-0.03
1.71
35.96
0.01
0.47
3.36
-0.03
1.71
35.97
-0.00
0.54
3.38
-0.00
1.72
37.99
-0.04
0.44
3.35
0.01
1.71
35.09
0.00
0.44
3.35
0.00
1.71
35.67
0.04
0.44
3.35
-0.01
1.71
35.08
-0.02
0.49
3.36
-0.02
1.71
36.83
0.03
0.50
3.37
0.01
1.71
37.13
-0.03
0.42
3.35
0.01
1.70
34.80
0.03
0.50
3.37
0.01
1.72
37.13
-0.04
0.44
3.35
0.01
1.71
35.08
~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~
ave.
0.00
0.47
3.36
-0.00
1.71
35.96
s.d.
0.03
0.03
0.01
0.02
0.00
1.09
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Figure a2.7
Pictorial representation of parameters relating sequential base pair steps. The base pair
reference frame is constructed such that the x-axis points away from the (shaded) minor groove
edge. Image illustrates positive values of the designated parameters (Hassan & Calladine 1998;
Dickerson et al. 1989).
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